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Introduction 
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an introduction in oncology  
 
At the end of the 20th century in the 15 member countries of the European 
Union1 over 930.000 people died of cancer every year, and a total of 
2.500.000 cancer deaths a year occurred in the continent of Europe, excluding 
the Russian Federation2. A reduction in the number of cancer deaths can only 
be achieved in two ways: either by reducing the number of new cancers 
through primary prevention or by increasing the chances of survival and cure 
among those who develop cancer through earlier diagnosis and better 
treatment. Information on the survival of all patients after a cancer diagnosis 
is thus a key indicator of cancer control3.  
 
In 1989, the Eurocare project was set up to measure and explain international 
differences in cancer survival in Europe. The aim was to optimise the 
comparability of survival estimates and to compare diagnostic and therapeutic 
practices to help interpret international differences in survival3. The Eurocare-
3 study (the third report of the Eurocare project) reports the 5-year relative 
survival rates of 1.8 million adults who were diagnosed with cancers in 
Europe between 1990 and 1994 and followed up for at least five years up to 
the end of 1999. The 20 participating countries involved in Eurocare-3 have a 
combined population of over 400 million people. The most common 
malignancies were respectively: breast (258.000), lung (252.000), colon 
(150.000), prostate (144.000), bladder (104.000), rectum (93.000) and stomach 
cancer (90.000).  
 
Average 5-year survival rates as reported from the Eurocare-3 study vary from 
94% for lip cancer to <4% for cancer of the pancreas. Best survival (>80% 
relative 5-year survival) is found for patients with rare cancers (lip, testis, 
thyroid, melanoma of the skin and Hodgkin’s disease) accounting for 
approximately 4% of adult malignancies in Europe. Corresponding rates 
between 60% and 79% are found for the more and very common cancers 
(cervix, uterus, larynx, breast, prostate and bladder), responsible for about one 
third of European adult cancers. For one-fifth of all cancers (colorectal, 
kidney, non-Hodgkin’s lymphoma), the European average 5-year survival was 
in the range of 40% to 59%. A poorer prognosis of 20% to 39% was reported 
for the 10% of adult cancers including stomach, ovary and multiple myeloma. 
Patients with lung cancer and cancers of the pancreas, oesophagus, brain and 
liver, about a quarter of all adult cancers, had the worst prognosis of <20% 
relative 5-year survival3.  
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For most solid cancers, wide differences in survival between European 
populations were found, as also reported by Eurocare-1 and -2, despite a 
remarkable (10%) overall increase in cancer survival from 1985 to 19944. 
Among the cancers with a wide range in cancer survival rates within Europe 
are the following major cancers: lung, stomach, colon, rectum, breast and 
melanoma. The wide differences are likely to reflect differences in both stage 
at diagnosis and the availability of and access to health resources, both of 
which are amenable to intervention3.  
 
In the Netherlands, some 62.000 new cases of cancer were diagnosed in 2000. 
In the same year 38.000 patients died of the disease, accounting for 
approximately 30% of all deaths in 2000, making it the second most common 
cause of death. Out of every 1.000 men, 4.5 developed some form of cancer 
versus 4.2 out of every 1.000 women. Breast cancer was the most common 
type, followed by colorectal cancer, lung cancer and prostate cancer. Two 
thirds of all women were 60 years of age or older, whilst in the male 
population this was considerably higher, at 75%. Nine percent of all cancer 
patients were younger than 45 years5. Between 1989 and 2000 the overall 
number of malignant invasive tumours increased by about 1.000 tumours per 
year. This was due to population growth as well as to effects of the national 
breast cancer screening programme and early detection of prostate cancer6,7.  
 
 
increasing complexity of cancer care 
 
The wide and increasing range of treatment modalities and the rapid 
innovations in both curative and palliative cancer care make it more 
complicated for the different specialists to remain up-to-date with the 
available options of all specialties, which emphasises the need for 
multidisciplinary treatment in providing optimal treatment strategies for the 
individual patient. Illustrative in this respect is the shift in primary treatment 
modalities in both colorectal and breast cancer and to a more limited extent 
also in primary lung cancer treatment. In these cases surgery alone was often 
replaced by surgery in combination with radio- and/or chemotherapy. For 
example, in stage III breast cancer a decrease was found in the use of surgery 
with or without radiotherapy as primary treatment modality from 79% (1975-
1979) to 21% (1995-1997). In the same period the use of systemic treatment 
alone or in addition to surgery with or without radiotherapy increased from 
21% to 74%. In the context of this thesis, it should be remarked, that 70% of 
all stage III breast cancer patients were operated on. In rectal cancer 
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treatment the additional use of systemic therapy was remarkable in stage IV 
rectal cancers (18% in 1975-79 to 49% in 1995-97). The most evident change 
with respect to colonic cancer treatment was found for patients with stage III 
disease: between 1975 and 1979 85% of the patients were subjected to surgery 
alone and 1% was treated by surgery and systemic treatment. Between 1995 
and 1997 corresponding percentages were 50% and 47% respectively8.  
 
 
impact of the surgical oncologist 
 
Although adjuvant systemic treatment has become more important in the last 
decade, the role of surgery has not diminished. Instead, it has often become 
part of multimodality treatment. Surgery is even called to play a more 
important role, now that sophisticated detection techniques and screening 
programmes allow earlier and therefore in more instances curative treatment 
of cancer9. Moreover, a paradigm shift was encountered: by the end of the 
1980s high local recurrence rates were thought to be caused by the biology of 
the tumour. Whereas, nowadays, it is generally accepted, that surgical 
technique is the most significant factor in terms of reducing the local 
recurrence rate, at least in rectal cancers10-12. The impact of the (quality of the) 
individual surgeon on outcome in terms of local recurrence and survival rates 
in other solid tumours has been suggested in several publications.  
 
One of the first prospective randomised clinical trials evaluating the influence 
of surgical technique on morbidity, mortality, local recurrence and survival 
rates was the Dutch Gastric Cancer Trial (DCGT), comparing limited (D1) 
versus extended lymph node dissection (D2) in patients with gastric 
adenocarcinoma. Recently, the final results were reported after a follow-up of 
more than 10 years. A more extensive resection resulted in significantly higher 
morbidity and mortality rates, whereas no differences were found in overall 
survival. The extent of surgery did influence loco regional control: loco 
regional recurrence was registered in 58% of the D1-group and in 45% of the 
D2-group13.  
 
Evidence of the influence of surgical technique on local recurrence and 
overall survival rates was most clearly found in the treatment of rectal cancer 
patients. Introduction of the refined technique of total mesorectal excision 
(TME) as described by Heald12 as well as the detailed and standardised 
examination and reporting of the surgical specimen as proposed by the 
pathologist Quirke14 and the concentration of rectal cancer surgery to a 
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limited number of (sub)specialised surgeons resulted in dramatically improved 
results. Local recurrence rates varying from 40 to 50% could be reduced to 3 
to 10% depending on the radicality of resection and whether or not 
radiotherapy is applied11,15-18. 
 
The influence of the treating surgeon is not only determined by technical 
skills, which was illustrated by several British reports indicating variations in 
survival for breast cancer patients19-27. Survival advantages encountered by 
surgeons treating a greater number of patients were found to be due, in part, 
to a greater use of adjuvant treatment rather than improved surgical 
technique. 
 
These and other findings have led to increasing evidence and attention for the 
surgeon as a prognostic factor in cancer treatment outcome. With the 
development towards multidisciplinary cancer care and the growing awareness 
of the surgeon as a prognostic factor, surgical oncology has emerged as a 
subspecialty within general surgery. Surgical oncology is a subdivision of 
surgery and covers the treatment of solid tumours of the oro-
eosophagogastrointestinal tract of parenchymal and endocrine organs, and of 
skin, mesenchymal, neurogenic, bone and soft tissues. Surgical oncology also 
includes prevention, genetic counselling, specific diagnostic and staging 
procedures, rehabilitation and follow-up care. Surgical oncology is focused on 
multimodality therapy28. Basic pre-requisites for optimal surgical cancer care 
are a thorough knowledge of the disease and an excellent surgical technical 
expertise in the field of the respective organs, combined with an in-depth 
knowledge of their function9.  
 
 
research topics 
 
Ideally, the before mentioned findings concerning rectal cancer would be 
translated to the treatment of all solid cancers, but the influence of the quality 
of surgery on outcome in terms of local recurrence and survival rates is still 
unknown for several tumour sites. Although it is assumed that irradical 
surgery leads to increased local recurrence rates, it is not clear whether this 
also influences (overall) survival rates. One cannot (automatically) expect a 
similar impact of the refinement of surgical technique in any tumour site as 
found in the treatment of rectal cancers. It is therefore of importance to 
determine whether variations in quality exist and, if so revealed, to evaluate, 
for each tumour site, differences between institutions and individual surgeons 
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to determine any possible relationships between outcome and the number of 
patients treated, the degree of specialisation, training or experience.  
 
When studying the available literature reporting on local recurrence and 
survival rates one could hypothesise that data of single centres versus those of 
multi centre randomised clinical trials (MCRCTs) are usually in favour of the 
single centre settings. These differences in outcome might be due to the fact 
that single centre reports usually originate from experts, providing data ‘to be 
proud of’. Moreover most studies are performed retrospectively, allowing 
selection bias. In contrast data of MCRCTs represent a cross-section of 
unselected (prospective) results produced by an often unselected group of 
surgeons, depending on the type of trial. If this hypothesis is correct it is of 
importance to know the origin of these differences and how to minimise 
them, with the ultimate goal of improving the overall standard of surgical 
performance. Currently the quality of surgery is usually measured by local 
recurrence and survival rates, of which the audit is only possible after a period 
of time. It would be useful to develop methods for the prospective evaluation of 
surgery. In light of the lack of generally accepted and applicable tools for 
prospective quality assurance in surgical oncology and in search for the 
optimal method to improve the quality of surgical cancer care, evaluation of 
existing quality assurance projects in radio- and/or chemotherapy might be 
helpful. Moreover, one could wonder whether the methods of quality 
assurance should be adjusted to specific circumstances, in other words, 
whether different tools should be used in either single or multi centre settings.  
 
 
multi versus single centre studies 
 
It can be assumed that quality improving procedures are often restricted to 
multi centre settings, although there are examples of single centre studies in 
which a change in strategy resulted in better outcome. This is not surprising 
since the quality of surgery is considered to be of utmost importance in 
MCRCTs, because evidence-based treatment guidelines are based on the 
results of these trials. Consequently, the required funding and infrastructure 
for the implementation of a quality assurance programme are probably more 
easily acquired in case of a multi centre study. However, it should be noted 
that the majority of MCRCTs do not compare surgical techniques, but only 
require adequate surgical treatment as a prerequisite for further treatment: the 
objective of these trials is usually the added value of radio- and/or 
chemotherapy. The above mentioned hypothesis concerning the results 
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provided by MCRCTs, especially with respect to local recurrence rates, 
suggests the absence of the uniformity of surgery within MCRCTs. It is 
therefore of interest to evaluate to what extent quality assurance procedures 
have been implemented in MCRCTs.  
 
One can argue whether quality assurance procedures should be confined to 
MCRCTs, because the ultimate goal of a high standard of surgical care should 
be the optimal treatment of the individual patient. A high standard of care 
only provided by strict criteria as set within, and restricted to, the MCRCTs 
would result in an inconsistent reflection of the truth. Patients participating in 
an MCRCT would possibly receive disproportionately better treatment when 
there is unchanged quality of care outside the MCRCTs. Moreover, the added 
value of adjuvant therapies might consequently be underestimated in their 
efficacy in day to day practice. 
 
Examining the quality of surgery in a single centre is difficult when it concerns 
surgical techniques. Monitoring the quality of surgical technique in such a 
setting is complicated and often restricted to an evaluation, in most cases 
retrospective, of local recurrence and survival rates. However, the quality of 
surgical care is not solely restricted to surgical technique itself, but also covers 
optimal diagnosis and quality of pathological examination as well as 
multidisciplinary care and the proper use of adjuvant therapies. Evaluation 
and improvement of these aspects will contribute to optimal care for the 
individual patient and could, if successful, be applied to other single centres.  
 
 
breast cancer in a single centre setting 
 
To evaluate aspects of surgical care in a single centre setting the focus is best 
restricted to one tumour type. In this thesis breast cancer was chosen, because 
it is the most frequently diagnosed cancer, complete primary care is provided 
by the surgeon and the quality of diagnostics and pathology has a large impact 
on surgical treatment. Particular attention was paid to non palpable breast 
lesions since these form a specific challenge for the surgeon due to the 
increasing number of patients resulting from the mammographic screening 
programme; the fact that new methods have become available in the 
diagnostic tract in particular; and because of the surgical technical 
requirements associated with its non-palpability.  
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PRE-OPERATIVE DIAGNOSTICS - In general a high quality of pre-operative 
diagnostics is advocated to provide the correct diagnosis by imaging and by 
(pre-operative) pathological examination in the least invasive way. The 
provision of an adequate pre-operative diagnosis enables the selection of 
patients in whom more invasive procedures and in particular surgery are 
necessary. In non palpable breast cancer this feature is of particular 
importance in order to reduce the number of invasive procedures since 
approximately 50% of referred patients turn out to have benign disease29. 
Moreover, pre-operative diagnostic procedures usually form the basis for the 
assessment of the resectability of the tumour and the extent of resection. 
Advanced imaging techniques also facilitate an early diagnosis of cancer, 
allowing better outcome. It will be clear, that pre-operative diagnostics can be 
divided into pre-operative imaging (radiology and nuclear medicine) and pre-
operative pathological examination. In breast cancer care a variety of imaging 
techniques have emerged in the past decades of which is advocated that they 
allow a better detection of malignant disease as compared to conventional 
mammography. Also in the field of pre-operative pathological examination 
various minimally invasive percutaneous breast biopsy techniques were 
developed30. A high quality of diagnostic imaging techniques is also helpful in 
the staging of breast cancer in patients with a high risk of (distant) metastatic 
disease.  
 
SPECIFIC SURGICAL TECHNICAL CHALLENGES WITH RESPECT TO NON PALPABLE 
BREAST LESIONS - A high quality of surgical technique is associated with a low 
number of operations necessary to achieve a radical resection in combination 
with low morbidity and mortality, a low local recurrence rate (i.e. optimal local 
control) and high disease free and overall survival rates. When these criteria 
are translated into (non palpable) breast cancer care, the most frequently 
mentioned indicators of optimal surgical technique are the following: the 
number of operations (after adequate pre-operative localisation) required to 
achieve definitive surgical treatment (i.e. radical excision of the tumour), the 
percentage of breast conserving procedures and the local recurrence rate. 
There is no evidence that surgical technique influences overall survival in 
breast cancer patients. 
 
QUALITY OF PATHOLOGICAL EXAMINATION OF NON PALPABLE BREAST LESIONS - 
Although the local recurrence rate is only evaluable retrospectively, it is 
known that a radical resection is the most important prognostic factor for 
local recurrence. This indicates the importance of at least one aspect of 
careful pathological examination. Concerning the evaluation of the resected 
specimen, practice guidelines are available enabling the standardised 
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pathological examination of the resected specimen. The ultimate goals of a 
high quality of pathological examination are to examine tumour characteristics 
of importance for the indication of further surgical/adjuvant treatment 
(prognostic factors) and to provide feedback to the surgeon concerning the 
quality of surgical resection. 
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research questions 
 
In summary, this thesis will concentrate on the following questions: 
 
1. What is the effect of the quality of surgical oncology on treatment outcome 
for different tumour sites in terms of local recurrence, overall survival (and 
morbidity and mortality)? 
 
2. What are the causes of existing differences in the quality of surgical 
oncology? 
 
3. Which tools are available to improve and assure the quality of surgical 
oncology and what are the possible obstacles associated with their 
implementation in multi centre settings?  
 
4. How can we use the available tools most effectively with the ultimate goal 
to improve the overall quality of surgical oncology in single centre settings? 
 
 19 
outline thesis 
 
It is the aim of this study to thoroughly investigate existing differences in 
outcome of surgical oncology and their causal factors in order to develop 
procedures to improve and assure the quality of surgery. In search of the 
answers to the formulated questions with respect to what is already known 
concerning quality assurance in surgical oncology, an extensive review will be 
performed in CHAPTER 2 of the literature published between 1990 and 2000 
addressing this topic. 
 
A more detailed review will be conducted in CHAPTER 3 with respect to 
colorectal surgery, since this has been, as already mentioned, the tumour site 
in which the benefits of quality and quality assurance of surgery were proven 
most clearly. Over the past years numerous articles have been published 
evaluating all kinds of factors with a possible influence on the quality and/or 
quality assurance of surgical rectal cancer treatment. An in-depth evaluation 
of the different methods will be performed in order to take advantage of 
these experiences in other tumour sites.  
 
Quality improving procedures are often restricted to multi centre settings. To 
evaluate the current status of the use and/or implementation of quality 
assurance procedures in MCRCTs, an inventory will be made in CHAPTER 4 of 
related activities within the clinical research groups of the European 
Organisation for Research and Treatment of Cancer (EORTC). The EORTC 
consists of a wide variety of clinical research groups in the field of oncological 
care in general and can be considered as the European organisation 
conducting MCRCTs. Moreover the EORTC has employed a variety of 
initiatives to improve and assure the quality of care in related areas such as 
radiotherapy31,32 and chemotherapy33. 
 
To evaluate the opportunities of improving surgical care in a single centre 
setting, a practical but often retrospective evaluation will be carried out of 
surgical care in a teaching hospital with the final purpose to optimise the 
quality of (surgical) care for the individual patient.  
 
For this evaluation patient data will be used, primarily originating from the 
Rijnstate Hospital Arnhem, the Netherlands. This hospital established a breast 
cancer care programme in 1996 in order to optimise breast cancer care for the 
individual patient. Between January 1992 and April 2002 744 patients with 
790 non palpable breast lesions were evaluated at the outpatient department. 
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In 131 cases no surgical procedure was indicated. Of the 659 remaining cases, 
285 appeared to be benign, whereas 374 lesions contained either in situ (78) 
or invasive cancers (296). For all 790 abnormalities a total of 813 operations 
were performed, including 159 mastectomies. After a mean follow-up of 46 
months (0-123 months) 22 local recurrences were found and 24 patients 
developed distant metastases. 
 
In order to enable the analysis of the quality of surgical care the following 
aspects will be evaluated. 
 
PRE-OPERATIVE DIAGNOSTICS - The increase in non palpable lesions and the 
fact that generally approximately 50% of referred patients turn out to have 
benign disease29 have resulted in the development of various minimally 
invasive percutaneous breast biopsy techniques30. In case of mammographic 
abnormalities these techniques are meant to minimise the number of patients 
subjected to surgical excisional biopsy and to minimise the number of 
operations in case of malignant disease. A specific diagnostic and surgical 
challenge is formed by lesions not visible on mammography and/or 
ultrasonography. Ten percent of breast cancers are not visible by 
conventional diagnostic methods at any time and in another 20% further 
diagnostic procedures are indicated because of indeterminate 
mammographies34. The latter group consists primarily of patients subjected to 
previous breast surgery or patients with dense breasts. Both Tc-99m-sestamibi 
scintimammography34-38 and magnetic resonance imaging (MRI)39-41 have 
emerged as adjuncts to mammography in these patients. The additional value 
of both will be analysed in CHAPTER 5. 
 
With the increasing quality of MRI and its more frequent application in the 
analysis of non palpable breast lesions, there are a (currently small) number of 
patients in whom the lesion is only visible on MRI. These patients might 
benefit from the MRI-localised surgical excisional biopsy procedures. 
Experience with this technique is limited and not much is known of its added 
value. The quality and clinical utility will therefore be evaluated in CHAPTER 6. 
 
A pre-operative diagnosis is provided wherever possible. In some situations, 
however, patients are operated on without a (reliable) pre-operative diagnosis. 
In these cases per-operative pathological analysis (frozen section analysis) 
could be valuable in order to limit the number of additional operations. The 
clinical utility of this procedure will be determined in CHAPTER 7. 
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SURGERY - Complete excision of a non palpable lesion remains a specific 
challenge to the surgeon, even if a pre-operative diagnosis is available and the 
lesion has been localised properly. It is advocated that breast conserving 
surgery/wide local excision for non palpable breast cancer should be confined 
to specialist breast surgeons42. In a teaching hospital this type of operation 
should consequently be reserved to qualified breast surgeons as opposed to 
surgical residents in training. CHAPTER 8 will address the differences between a 
university versus a non university teaching hospital. Particular attention in this 
study will be paid to the influence of the type of primary surgeon, i.e. fully 
qualified surgeon versus surgical resident-in-training to assess the validity of 
the advocates for specialisation. 
 
PATHOLOGY - The quality of surgical excision is examined by the pathologist. 
One of the most important prognostic factors is the margin of resection43-52. 
In case of tumour-positive margins, re-excision is consequently always 
performed, although in about half of the cases no residual tumour is present 
in the re-excisional specimen. In CHAPTER 9 an analysis of tumour 
characteristics will be made, to identify some common attributes that may 
make classification of such characteristics of assistance in decision-making on 
the extent of re-operation. 
 
MULTIDISCIPLINARY CARE - The surgeon plays a role in the decision on 
adjuvant treatment, at least as a member of the multidisciplinary team 
providing medical care. In ‘high-risk’ patients the type of treatment depends, 
to a certain extent, on the staging of the disease. Staging is currently 
performed by means of X-ray of the thorax, ultrasonography of the liver and 
bone-scanning. FDG-PET, however, might be more successful than these 
conventional methods in the detection of (distant) metastases and/or in the 
detection of local recurrences. This will be subject of study in CHAPTER 10.  
 
The general discussion in CHAPTER 11 will put the results of the different 
studies in perspective.  
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abstract 
 
INTRODUCTION – In recent years increasing attention is being paid to the 
quality of cancer care. Standardised treatment has been proven to benefit the 
patient. For radio- and chemotherapy several criteria could be defined to 
guarantee a standard of quality and to enable quality assurance procedures to 
be initiated. In surgery, no such criteria are available for various reasons. It 
was the aim of this study to review the literature concerning existing methods 
of quality assurance in surgical oncology and to determine a relationship 
between surgery-related factors and the variability in outcomes in the 
treatment of solid cancers.  
 
METHODS - Medline databases were searched for publications released between 
1990 and 2001 regarding quality assurance in surgical oncology and evidence 
of surgeon variability in treatment outcomes. 
 
RESULTS - Wide variations in outcome were found in virtually all tumour 
types. Clear evidence was found for the influence of the quality of the surgical 
procedure on the prognosis and quality of life of cancer patients. The annual 
volume of procedures plays a role in the outcome of complex procedures in 
particular, such as oesophagectomies, pancreatectomies and the treatment of 
non-small cell lung cancer. Moreover, a minimum number of new yearly cases 
would benefit breast cancer patients, which seems to be related to the 
appropriate use of adjuvant therapies rather than to the quality of surgery. In 
the treatment of other solid tumours, local recurrence and survival rates are 
clearly influenced by the quality of surgery, depending on adequate training 
and individual surgical skill.  
 
CONCLUSION - These findings emphasise the need for strict quality control 
procedures in surgical oncology and might imply a considerable change in 
cancer treatment strategies, because the routine use of adjuvant therapies 
could be questioned. Factors of importance for improving outcomes and 
enabling quality assurance in surgical oncology are training, the use of 
standardised surgical techniques, multidisciplinary treatment, quality of 
radiology and pathology, registration and a regular audit of results. 
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introduction 
 
In recent years increasing attention has been paid to the quality of cancer care. 
The importance of multidisciplinary treatment is now obvious and a 
multidisciplinary approach to cancer research and management is the future 
for patients1. The benefits of multidisciplinary treatment are related primarily 
to the access and use of standardised and up-to-date therapy. Similarly 
patients participating in clinical trials generally experience a survival advantage 
over non-participating patients, which is due (in part) to standardised 
treatment2,3. For radiotherapy4-12 and chemotherapy13-16 several criteria could 
be defined to guarantee a standard of quality and to enable quality assurance 
procedures to be initiated. 
 
In surgery, however, no quality assurance guidelines are yet available. One of 
the reasons for this is the absence of quantifiable parameters in surgery. 
Moreover, the impact of primary surgical treatment is often underestimated 
especially when post-operative adjuvant treatments are evaluated.  
 
For many years most treatment failures were considered to be caused by the 
biological behaviour of the tumour rather than by inadequate local therapy17. 
However, several studies have shown18-22 that an improvement in the quality 
of surgical procedures has had much more influence on local recurrence rates 
than the use of adjuvant radiotherapy. Differences in the quality of surgery 
seem to be the main cause of wide variations in the outcome of local 
treatment for most solid malignancies. This is of importance not only in day-
to-day practice, but in clinical trials in particular, where the effect of adjuvant 
therapy may consequently be wrongly interpreted. Such an ambiguous 
situation is visible for example in the trial testing the efficacy of radiotherapy 
following total mastectomy as reported by Overgaard23. Mean local recurrence 
rates of 9% (irradiated patients) versus 32% (non-irradiated group) were 
observed, which are both considered to be rather high. The authors clearly 
identified important variations in the extent of surgery. Both the management 
of the axilla and the mastectomy procedure seemed to have been 
inappropriate, since more than half of the recurrences appeared on the chest 
wall. It was concluded, that with current surgical methods of treatment, 
radiotherapy seemed to be required for adequate loco-regional control. This 
has resulted in the standard application of radiotherapy following 
mastectomy. By using the word current in this example, the authors have 
already suggested that with improved surgical therapy, radiotherapy might not 
be necessary in most cases.  
 28 chapter 2 
Therefore it seems appropriate in clinical trials in particular to develop tools 
to improve the quality of surgical interventions. In contrast to chemotherapy 
and radiotherapy, the quality of surgery appears to be difficult to examine. 
The surgical procedure consists of a multi-step procedure, depending on the 
individual surgeon. Whereas varying rates in local control might be clear 
parameters of quality, these are related to long-term effects and are not the 
most relevant indicators in prospective quality control programmes. Several 
attempts to track the performance of the surgeon have been undertaken, 
varying from efforts to standardise surgery and pathology reports to training 
courses and live audits in the operating theatre.  
 
Within the European Organisation for Research and Treatment of Cancer 
(EORTC) quality assurance has been an area of interest for many years24. In 
the fields of chemotherapy13-16 and radiotherapy6,12,25-41, several quality 
assurance projects have been successfully implemented. Based on the success 
of a previous quality assurance programme in surgical oncology42, the 
importance of surgery in local control and the evidence that outcome may be 
related to the quality of treatment, the EORTC decided that, although 
difficult, some type of uniformity in the quality of surgery should be 
guaranteed in order to provide reliable and proper results in surgical and 
adjuvant trials. 
 
As guidelines on this topic are not yet available, the Quality Assurance 
Committee of the EORTC intended to review the literature concerning 
existing tools to audit the performance of the surgeon. However, as it was 
expected that information on this topic would be scarce, the review was 
extended to the identification of evidence of surgeon variability in the 
treatment of solid tumours. The ultimate goal was to identify indicators of 
surgical performance relevant for quality assurance in surgical oncology and in 
clinical trials in particular. 
 
 
methods 
 
Medline databases were searched for publications released between 1990 and 
2001 on quality assurance in surgical oncology and evidence of surgeon 
variability in treatment outcomes. The terms used for the research were: 
quality (assurance/control/method), (practice) guidelines, local recurrence 
(rate), learning curve, (overall) survival (rate), variability, surgery, surgeon, 
physician, hospital, specialisation, volume, morbidity and mortality. These 
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terms were combined with individual cancer terms (specific site-related quality 
indicators such as anastomotic leak rates). The bibliography of each article 
was reviewed for other potentially relevant papers. 
 
Although the number of publications has increased recently, the available 
literature on methods of quality assurance in surgical oncology was, as 
expected, scarce. Similarly the number of publications concerning variability 
in surgical performance has increased in recent years. Altogether 202 articles 
were selected for this review. The main selection criteria were number of 
patients of more than 50 and publications in English between 1990 and 2001. 
The selected publications were categorised according to levels of evidence. 
The categories used were as follows (in rank order starting with the most 
important): systematic review, multi centre randomised clinical trial 
(MCRCT), single centre randomised clinical trial (SCRCT), multi centre 
prospective observational study (MCPO), single centre prospective 
observational study (SCPO), population-based study (PB), multi centre 
(retrospective) observational study (MCO) and single centre (retrospective) 
observational study (SCO). In all tables publications are listed in this order.  
 
In the following sections evidence of variability in outcome related to surgery 
in oncology will be reviewed. Efforts have been undertaken to identify the 
causes for these differences by evaluating the effect of either the hospital or 
the surgeon. The most common parameters of evaluation of the hospital are 
‘volume’ and ‘type of hospital’. The yearly volume represents the number of 
cases treated on an annual basis related to a tumour site. Different types of 
hospitals are cancer centres, teaching and district hospitals. The performance 
of individual surgeons was frequently rated according to case load (number of 
cases treated) per year or the completion of a specialised training. 
Furthermore, specific technical aspects in oncological surgery and the 
adherence to these principles have been evaluated for their possible influence 
on outcome. These sections will be followed by the review of published data 
concerning projects related to quality assurance in surgical oncology.  
 
 
results 
 
rectal cancer 
 
DIFFERENCES IN LOCAL CONTROL AND SURVIVAL - In table 1 the selected 
publications reporting on local recurrence and long-term survival rates after  
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treatment for rectal cancer are listed. To prevent the possible influence of 
adjuvant treatment, only series in which surgery was the only treatment 
performed are shown. 
 
McCall reviewed 51 publications43 in which adjuvant therapies were not used. 
10.465 rectal cancer patients treated between 1982 and 1992 were studied. 
The median value for loco-regional recurrence rates (LRR) was 18.5% with a 
range of 3% to 50%. In publications after 1991 overall LRR varied from 1% 
to 30%. LRRs in MCRCTs were high (26% to 30% after surgery alone)44-46 
when compared to single centre series 1% to 14%47-52. Lowest figures for 
LRR were found in single centre prospective observational studies (SCPOs), 
varying from 1% to 5%47-50, with one exception of 23%53, in which total 
mesorectal excision (TME) was routinely applied. TME was first described by 
Heald et al.18,54 and is increasingly used in Europe as a standardised surgical 
procedure in the treatment of rectal cancers55. 
 
Overall survival (OS) after surgery alone varied from 41% to 85% (table 1). 
MCRCTs reported 5-year OS-rates between 41% and 50% for all patients 
including patients with non-curatively resected cancers. The remaining studies 
showed survival rates after curative resections which appeared to range from 
50% to 85%. Despite the promising figures regarding LRRs, hardly any results 
were reported concerning survival rates after TME. This seems mainly due to 
the fact that follow-up is too short to draw clear conclusions56. Overall 
survival rates show an inverse correlation with local recurrence rates18,21,57-59.  
 
The reported curative resection rates varied from 40% to 88% of which the 
opposites correspond with OS-rates of 66%44 and 41%46 respectively. It 
became clear, that the surgeons’ opinions were not reliable as a predictive 
value with regard to local control and overall survival59,60. 
 
FACTORS INFLUENCING LOCAL CONTROL AND SURVIVAL - An explanation for 
better local control and improved survival after the (routine) performance of 
TME compared to conventional surgery is described by several 
authors18,49,51,57. Evidence of tumour involvement of the circumferential (or 
lateral) margins proved to be a more important indicator for local 
control18,19,47,49,51,53,54,70-73 and/or survival18,49,51,74,75 than the extent of distal 
tumour-free margins. The routine resection of distal margins of 5 cm to 10 
cm has been replaced by 2-cm margins, following pathological studies 
performed by Quirke70 and Wolmark76 in the 1980s. These studies failed to 
show microscopic intramural longitudinal spread for distances greater than 12 
mm distally. In addition several studies have shown that distal tumour-free 
 33 
margins of 1 cm (or less) are as effective provided TME is properly 
performed50,77. This might enable a reduction in the rate of abdominoperineal 
resections (APRs) performed. Furthermore, tumour spill or perforation seem 
to negatively influence local control78-82 and survival59,81,82. 
 
HOSPITAL AND SURGEON RELATED FACTORS - Fifteen publications reported on 
the possible influence of hospital characteristics58,59,80,83-94 on outcome in 
colorectal cancer surgery, twelve on surgeon characteristics22,58,64,65,78,83-85,89-
91,95. Although wide variation exists (table 2), it appears that outcomes in rectal 
cancer surgery are related more to surgeons’ technique than to volume or 
specialisation. 
 
TRAINING AND QUALITY ASSURANCE - The importance of surgical skill was 
clearly shown by the results of a training programme initiated by the 
Stockholm Colorectal Cancer Study Group22. Workshops and television-
based demonstrations in the fields of surgery and pathology were used to 
teach the principles of TME. The results of these patients were compared 
with the results of patients who had been included in previous randomised 
clinical trials by the same institutions. A decrease of more than 50% in the 
proportion of abdominoperineal resections and local recurrence were 
obtained and an increase in survival was observed. Operative mortality (OM), 
complications and anastomotic leak rate (ALR) remained unchanged. 
 
An even more intensive quality assurance programme has been performed in 
the Netherlands96. The surgical procedure and pathological examination were 
standardised. In addition to instruction videos and training courses, the first 
five operations had to be supervised by a TME-trained consultant surgeon. A 
pathology panel was set up to guarantee pathology quality control. Short-term 
results of this initiative have been promising in terms of the rate of 
abdominoperineal resections and involved lateral margins with no increase in 
morbidity or mortality56,96. Two-year results that were published recently97 
revealed that short-term radiotherapy in addition to TME reduces the risk of 
local recurrence. 
 
It can be concluded that TME as described by Heald18,54 has yielded much 
better results than the performance of conventional surgery in terms of local 
control and survival. These results have been reproduced in multi centre 
clinical trials, which confirm the feasibility and efficacy of standardised 
surgery. The same applies for the standardised pathological examination as 
described by Quirke and Dixon70.  
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breast cancer 
 
DIFFERENCES IN LOCAL RECURRENCE - In a meta-analysis (table 3) of 
randomised controlled trials begun after 1985, the Early Breast Cancer 
Trialists’ Collaborative Group (EBCTCG) concluded that LRRs after 
mastectomy were similar to those after breast conserving surgery followed by 
radiotherapy (BCS+RT)108. Moreover LRR appeared to be independent of the 
extent of surgery. Mean LRR after surgery alone was found to be 19.6% 
compared with 6.7% if radiotherapy was additionally used. No differences in 
10-year OS were found, which is in line with other publications. LRRs are 
listed according to the type of surgery and the possible use of additional 
radiotherapy. From this table it can be extrapolated that LRRs are generally 
higher in MCRCTs109-112 when compared with single centre reports113-118. 
Furthermore, the results from the Milan studies113-115 have shown the 
influence of the extent of surgery on local control. In this situation the 
performance of a single centre study has an advantage over a multi centre one 
because the uniformity of surgery is much more reliable. Furthermore, in two 
multi centre studies119,120 the implementation of ‘strict’ quality control has 
contributed to a low LRR. This illustrates the impact of surgery on local 
control. In both studies surgical quality control consisted primarily of a review 
of operative and surgical pathology reports regarding margins of resection and 
a minimal number of removed lymph nodes. Of additional interest are the 
reports by Christiaens providing information on differences in surgical 
procedures among surgeons who presumably performed the same type of 
operation121,122, which emphasises the need for the development of guidelines 
concerning surgery and its documentation123.  
 
ADEQUACY OF AXILLARY LYMPH NODE EXCISION AND SENTINEL LYMPH NODE 
BIOPSY - Since the status of the regional nodal basin remains the single most 
important independent variable of predicting prognosis124, the performance of 
axillary lymph node dissection (ALND) seems highly important. However, for 
several reasons, controversy now rages over the current role of ALND in the 
management of operable breast cancer125. This controversy is reflected in 
varying rates of axillary clearance or lymph node sampling100,103,104,126-131 as 
shown in table 4. Rates vary between 8% and 86%. Initiatives to improve the 
rate and quality of axillary clearance have been undertaken in the UK North 
Thames (East) Health Region129,131 and in the St. Vincent’s Hospital in 
Dublin126. In the former, regional clinical guidelines were developed and 
feedback was given to the specialist surgeons, resulting in an increase of 
axillary surgery from 46% to 76%129. In the latter, 100 axillary dissections 
were independently audited by a second surgeon for completeness of 
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dissection126. Any further excised tissue was labelled as level IV. The 
incidence of the level IV node retrieval decreased from 47% in the first 60 
cases to 20% in the remaining 40.  
 
Sentinel lymph node biopsy has become a promising alternative to ALND. 
Several reports125,139-142 have proven its predictive value, which may omit 
axillary clearance with its concomitant morbidity. The implementation of 
sentinel lymph node biopsy has shown a learning curve. Since the successful 
implementation requires a multidisciplinary team approach between surgeons, 
radiologists, pathologists and nuclear medicine personnel, strict quality 
control procedures should be applied before SLNB can be used as a regular 
procedure125. Multi centre randomised clinical trials by the EORTC and the 
Medical Research Council are currently running. In these trials strict quality 
control procedures have been defined. 
 
DIFFERENCES IN OVERALL SURVIVAL - Table 5 shows reports, mainly of British 
origin, concerning variations in survival. The survival advantages encountered 
by surgeons treating a greater number of cases were found to be due, in part, 
to a greater use of adjuvant treatment rather than improved surgical 
technique99-107. It is therefore advocated that breast cancer patients should be 
treated by surgeons caring for 30 or more new breast cancer patients per year 
in a multidisciplinary setting which facilitates the access to adjuvant 
treatment99,107.  
 
oesophagus 
 
Most publications (table 6) concerning variability among surgeons and 
hospitals are focused on 30-day (i.e. operation-related) mortality. Overall, 
higher volume was linked with lower mortality. However, no influence of 
volume on overall survival has been found. Patients selected for 
oesophagectomy had a slightly better prognosis than those who were not157. 
Until proven otherwise, the best chance of curing this neoplasm includes an 
operation that encompasses removal of the entire tumour and draining lymph 
nodes with adequate proximal and distal margins158. The reported mortality 
for oesophagogastrectomy in recently reported series varies from 2% to 10%. 
Acceptable 30-day mortality is approximately 5%. Anastomotic leak rates vary 
from 5% to 10% in the majority of reported series with an average of 7%, 
although some series report leak rates of less than 2%. The most important 
predictors of survival are the presence or absence of residual tumour after 
resection152, the degree of wall penetration159 and the ratio of invaded to 
removed lymph nodes147,152,159.  
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Five-year survival based on surgical techniques is reported from 21% to 31% 
with one exception of 50% 5-year survival for stage IIa disease as reported by 
Skinner159. Therefore, completeness of local resection and extent and/or 
completeness of LND seem important parameters to audit the quality of 
surgery. 
 
lung cancer 
 
Within Europe 1-year relative survival rates for lung cancer are reported to 
vary between 24% and 40%160 (table 7). The influence of surgical treatment 
was not studied in this publication. The role of surgery in the treatment of 
small cell lung cancer is considered to be limited161 and only beneficial in a 
selected (5%) group of patients with small peripheral tumours. 
 
Table 7: Lung cancer 
 
Reference Type 
study 
Number of 
patients 
OM 
 
LRR OS Comment 
Deslauriers162 Review   + + - Completeness of resection is known prognostic 
factor 
- Overall LRR is higher after limited resection 
than after lobectomy (current standard) without 
the expected advantages 
Deslauriers166 MCPO 
 
783 +   - Morbidity and mortality figures prospectively 
documented. NSD OM between types of 
resection, however SD in morbidity rates 
Bach163 PB 2.118 +  + - Operation-related mortality and morbidity are 
related to hospital volume. 5-year OS was 
higher for patients operated on in high-volume 
hospitals 
Janssen-
Heijnen160 
PB 
 
173.448   + - Geographic variation in survival in Europe is 
large for which the most likely explanation is 
the variation in access to specialised care. 24-
40% relative 1-year survival 
Silvestri167 PB 
 
1.583 +   - OM lower when surgery is performed by 
thoracic surgeons when compared with results 
of general surgeons: 3.0 vs 5.3% 
Begg154 PB 
 
5.013 
different 
tumour sites 
+   - 30-day-mortality in relation to procedure 
volume No link between procedure volume and 
30-day mortality of pneumonectomies 
Romano164 PB 
 
12.439 +   - OM community-based hospitals California 
Predictors of OM: extent of resection and 
hospital volume 
Lacasse168 MCO 
 
399   + - Positive surgical resection margins did not 
predict early recurrence or death 
- Prognostic factors for LRR were tumour size 
and nodal status 
Damhuis165 MCO 
 
7.899 +   - Post-operative OM: 3.1%, 20% resection rate 
Extent of surgery (i.e. treatment choice) one of 
the major determinants of operative risk 
Snijder169 SCO 
 
834  + + - The presence of mucosal or peri-bronchial 
residual disease, but not carcinoma in situ, at 
the bronchial resection margin in patients with 
stage I NSCLC has an adverse effect on survival 
 
LRR = Local Recurrence Rate; NSCLC = Non Small Cell Lung Cancer; NSD = No Significant Difference; OM = Operative Mortality; 
OS = Overall Survival 
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However, in the treatment of non-small cell lung cancer surgery remains the 
mainstay of treatment162. 
 
Recently Bach163 examined the influence of hospital procedure volume on 5-
year survival in a population-based study. A positive association was present 
with 44% survival rates for patients operated on in high-volume hospitals  
(> 67 annual procedures) compared with 33% when treated in low-volume 
hospitals (< 8 annual procedures). Similar differences were found regarding 
post-operative complications (20% versus 44%) and 30-day mortality (3% 
versus 6%). Four additional publications were found evaluating factors of 
influence on 30-day mortality. The extent of resection was found to be the 
strongest determinant of in-hospital mortality164,165.  
 
In a population-based series154 a non-significant trend was found between 
procedure volume and 30-day mortality of pneumonectomies. The influence 
of the individual surgeon was only addressed by Silvestri167 who compared 
OM between general and thoracic surgeons. Results were in favour of the 
thoracic surgeons of whom 70% performed more than 10 resections per year, 
whereas 75% of general surgeons performed fewer than 10. Deslauriers162 
reviewed the literature concerning surgical therapy of early non-small cell lung 
cancer and found that anatomic lobectomy should remain the “gold standard” 
of surgical resection. A more limited resection resulted in a three-fold increase 
in local recurrences, an increase in risk of death and did not provide the 
expected advantages such as lower OM or late functional advantages. The 
influence of the surgical resection margin on overall survival is 
controversial168,169, although completeness of resection is a known prognostic 
factor for local recurrence162. 
 
Of importance for prospective assessment of the quality of surgery is the 
prospective multi centre observational study performed by the Lung Cancer 
Study Group166 determining the prevalence of morbidity and mortality 
associated with resection of lung cancer. Operative mortality was found to be 
3.8% and 27% had a major complication. Although nodal status is one of the 
most important prognostic factors, no publications were found evaluating the 
adequacy of resection.  
 
sarcoma 
 
osteosarcoma - In the treatment of osteosarcomas the importance of 
adequate surgery has become clear in a number of publications170-176 (table 8) 
all providing evidence of the influence of the surgical margin status on the 
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risk of local recurrence. Limb saving surgery is as safe as amputation in the 
treatment of similar tumours, provided that an adequate margin of resection 
could be achieved. Overall LRR varied between 2.3% and 8%, but in the 
Rizzolli studies inadequate resections resulted in local recurrences of 21.9% 
versus 4.7% if the margins were free of tumour172. Grimer171 evaluated the 
data of three specialised centres with different surgical treatment approaches. 
Interestingly no differences in overall survival could be found between the 
centres, although LRRs varied between 2.5% and 13.3%, which appeared to 
be related to the resection margins of surgery. The prognostic effect of local 
recurrence on survival was analysed using data of two MCRCTs of the 
European Osteosarcoma Intergroup170. Although a strong relationship was 
found with three techniques of multivariate analysis, it is not possible to 
conclude whether local recurrence causes poor outcome or is just a surrogate 
indicator of poor outcome.  
 
Table 8: Osteosarcoma 
 
Reference Type 
study 
Number of 
patients 
Influence of  
surgery on LRR 
Influence of  
surgery on OS 
Comment 
Weeden170 
 
MCRCT 
 
559 
 
+  
LSS > amputation 
see comment - LRR higher in patients after LSS 
- Local recurrence is an indicator of 
poorer survival  
Grimer171 MCRCT/
MCO 
202 
 
+ - - LRR differences are related to the 
margins of surgery that were 
achieved 
Bacci172 SCPO 570  + margins not mentioned - LRR not influenced by type of surgery 
but adequacy of surgical margins 
does influence LRR 
Bacci173 SCPO 540  + margins - - LRR not influenced by type of surgery 
but adequacy of surgical margins 
does influence LRR 
- LSS only if it is possible to achieve 
adequate surgical margins 
- If pathology examination shows 
inadequate surgical margins an 
immediate amputation should be 
considered  
Picci201 SCPO 514  + margins not mentioned - For only 2/23 cases of LR no clear 
explanation for LR was found 
- In the remaining cases the quality of 
margins, site of biopsy as well as 
complications related to the biopsy 
procedure were directly related to LR 
Picci174 SCPO 400 + margins  - Surgical margins strong prognostic 
factor for LR 
Lindner175 SCO  136  + margins - Surgical margins important 
prognostic factor 
Sluga176 SCO 131 - type - type - NSD in local and systemic tumour 
control between ablative and sparing 
surgery, provided that wide or radical 
tumour resection can be achieved 
 
LR = Local Recurrence; LRR = Local Recurrence Rate; LSS = Limb Saving Surgery; NSD = No Significant Difference; OS = Overall Survival 
 
SOFT TISSUE SARCOMA - Similar to the findings in osteosarcomas, the margin 
of resection is of importance in soft tissue sarcomas with respect to the 
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occurrence of local recurrence177-191 (table 9). In 1991 Barr177 reviewed the 
literature with respect to the influence of local recurrence on survival and 
concluded that a survival deficit due to local recurrence could not be 
excluded. Ever since, most publications have found a strong relationship 
between either adequacy of resection179,180,182,192-195 or the occurrence of local 
recurrence180,185,189,196-198 and survival. Others, however, advocate that local 
recurrence is only weakly associated with the development of metastases183,184 
or may only be an expression of the aggressiveness of the tumour184. One 
single centre observational study concluded that negative margins did not 
measurably improve survival187. Surgical treatment is preferably and most 
commonly performed in specialist centres199. Two publications199,200 studied 
the influence of the time of referral (before or after surgery) on outcome, of 
which the results are contradictory. 
 
gastric cancer 
 
The influence of surgery on outcomes in gastric cancer was recently reviewed 
by Hartgrink203 (table 10). Surgery is the only possible curative treatment for 
gastric cancer and fortunately results have improved throughout the years 
with respect to survival, morbidity and operative mortality203-206. However, 
between western207 countries and Japan205 a wide variation is still found 
concerning survival (5-year OS 19% versus 50% respectively) and operative 
mortality (7.2% versus 2%). Although other factors play a role, differences in 
surgical techniques are at least in part responsible for better outcomes. The 
more aggressive Japanese approach including extended lymph node 
dissections are claimed to be the main causal factor for differences in 
outcomes. Consequently, efforts have been made to introduce D2-dissections 
in western countries too, which has resulted in a variability in outcomes, most 
likely because of the different definitions of the extent of resection208-210. In 
addition, two multi centre randomised clinical trials examined the possible 
benefit of D2-dissections, the Dutch Gastric Cancer Trial (DGCT) and the 
British Medical Research Council Gastric Cancer Surgical Trial (MRC). Both 
trials showed the same trend of higher 30-day-mortality and morbidity related 
to extended dissection with no clear survival benefit. Overall survival was 
approximately 10% higher regardless of the extent of lymph node dissection 
in the DGCT211,212(45% D1 and 47% D2) versus the MRC213,214 (35% D1 and 
33% D2), which may be due to quality control.  
 
Of interest for this review are the methods of quality control used in the 
DGCT215, which were absent in the MRC-trial. Japanese standards for the 
D1- and D2-dissections were used216 and a Japanese surgeon was invited to 
 49 
instruct the participating Dutch referent surgeons. All D2-dissections were 
supervised by referent surgeons, whereas nearly all D1-dissections were 
attended by the study coordinator. In addition, the number and location of 
lymph nodes detected at pathological examination were related to the 
guidelines of the protocol. Violation of the protocol was specified as 
contamination and non-compliance. Contamination included all cases in 
which lymph nodes were harvested from stations that were not supposed to 
be present according to the protocol. If lymph nodes were not retrieved from 
stations that should have been harvested, this was called non-compliance. 
Contamination occurred in 6% of D1-dissections, whereas non-compliance 
occurred in 51% of the D2-dissections. Factors influencing contamination 
and non-compliance were studied by Bunt217 and consisted primarily of 
station-specific factors as well as non-familiarity with the Japanese standards 
at the start of the trial. It has become clear from this example that, although 
detailed guidelines were available, variability among surgeons continues to 
exist, which emphasises the need for strict quality control in surgical trials. 
Furthermore, several publications have provided evidence that surgical 
complications are influenced by the extent of the operation212,214,218. 
 
Roukos204, Siewert219, Wanebo210, Thorban220, Hallissey221 and Songun222 
examined the prognostic value of microscopic resection line involvement, 
which was found to decrease survival significantly.  
 
The influence of the individual surgeon on outcomes is not yet clear. A 
retrospective study by McCulloch228 and results of the German Gastric 
Cancer Study229 showed differences in outcomes according to the experience 
of the surgeon, whereas no serious heterogeneity was found among surgeons 
participating in the DGCT212,224. Therefore it seems that results are related 
more to proper training and supervision than to individual surgical skill224. 
Moreover, hospital experience and/or volume seem to be of significant 
influence on morbidity and post-operative mortality154,225-228,230.  
 
pancreatic cancer 
 
As resections for pancreatic cancer are high-risk procedures, a number of 
reports have been published (table 11) concerning a possible relationship 
between 30-day mortality and/or morbidity and hospital volume154,231-240 or 
surgeons’ case load235,238,241,242. Although a variety of cut-off points was used 
to categorise high and low-volume institutions and the quality of some 
publications is questionable243, there appears to be a relationship between 
hospital volume or experience and operative mortality and morbidity. Up-to
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date percentages for operative mortality are 1% to 5% for single institutional 
series versus 8% to 10% for multi centre or population-based series with 
complication rates varying from 20% to 40%241. Surgeon case volume does 
not appear to influence 30-day mortality independently, but other surgeon-
related characteristics, such as specialised training, have not yet been 
examined241. Resection-line involvement is one of the most important 
predictive factors244-250 for overall survival and is obviously of relevance in the 
audit of the quality of pancreatic surgery. 
 
head and neck cancer 
 
The available literature regarding the influence of the quality of surgery on 
treatment outcomes in head and neck cancer is limited (table 12). This might 
be explained by the rarity of these tumours and the fact that most of these 
patients are treated by superspecialists.  
 
Table 12: Head and neck cancer 
 
Reference Type 
study 
Number of 
patients 
OM 
 
LRR OS Site/Tumour 
type 
Comment 
Jacobs251 MCRCT 684    Squamous 
cell cancer 
- Development of surgical QC mechanisms in 
MCRCTs 
- QC primarily based on review of the submitted 
operative and pathology reports  
- 77% compliance rate with the written surgical 
protocol 
Wanebo193 MCPO 214   + Soft tissue 
sarcoma 
- 5-year DFS 56%, OS 70% 
- Adequacy of resection (margins free of 
tumour) was a major determinant of survival 
Kraus182 SCPO 60   + + Soft tissue 
sarcoma 
- Positive margins prognostic factor for local 
control and OS 
Gillgren255 PB 469   + Melanoma - Prospective data during 18 year period:  
10-year OS 68% for male patients vs 87% for 
female patients 
- The surgical resection margin seemed to be of 
no importance to outcome 
Sosa256 PB 5.860  +   Thyroid 
(B+M) 
- High-volume surgeons (> 100 cases during 6 
years) had the lowest complication rate: 5.1% 
vs 8.6% in the low-volume group (1-9 cases) 
Tran253 SCO 164  + + Soft tissue 
sarcoma 
- Surgical margin status prognostic factor for 
local control and survival 
Cook252 SCO 478  + + Squamous 
cell cancer 
- The presence of positive resection margins 
was associated with decreased 5-year OS, 
time to tumour recurrence and survival with 
nodal recurrence 
- Every effort should be made to obtain negative 
resection margins 
Farhood254 SCO 176  + + Soft tissue 
sarcoma 
- OS 2-year 75%, 5-year 55%, 10-year 46% 
- A significantly increased risk of treatment 
failure was associated with positive margins 
and local recurrence 
 
B+M = Benign + Malignant; DFS = Disease Free Survival; LRR = Local Recurrence Rate; OM = Operative Mortality; OS = Overall Survival; QC = Quality 
Control 
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The available publications concern different types of cancers: squamous cell 
cancer251,252, soft tissue sarcomas182,193,253,254, melanomas255 and thyroid 
resections256. The findings suggest similarities with the same tumour types in 
other sites: margin status is a prognostic factor in soft tissue sarcomas but not 
in melanomas.  
 
Jacobs251 reported on the results of a quality control mechanism developed 
for the Head and Neck Intergroup. Quality control was based mainly on a 
comparison of the operative note and the surgical pathology report 
concerning TNM-staging. Wide variation was found between staging by the 
review committee and the operating surgeon but appeared to be a 
consequence of the recognised differences between clinical and pathologic 
staging. In addition, compliance with the surgical parameters of the protocol 
was 77%. The primary area of surgical variation from the protocol was related 
to the management of the neck: either performance of a dissection or sacrifice 
of the accessory nerve.  
 
 
discussion 
 
The surgeon has now been recognised as an important factor in treatment 
outcomes. In the past, the quality of surgery was taken for granted or not 
considered to make any difference in treatment outcomes. It has become clear 
from this review that the annual volume of procedures in particular plays an 
important role in the outcome of complex procedures, such as 
oesophagectomies, pancreatectomies and the treatment of non-small cell lung 
cancer. Moreover, a minimum number of new yearly cases would benefit 
breast cancer patients, which seems to be related to the appropriate use of 
adjuvant therapies rather than to the quality of surgery. In the treatment of 
other solid tumours local recurrences and survival are clearly influenced by 
the quality of surgery depending on adequate training and individual surgical 
skill.  
 
Consequently, the additional value of adjuvant therapies should be re-
evaluated, because a wide variation in the quality of surgery must have been 
present when evaluating the efficacy of these therapies in the past. Whereas 
quality assurance in the administration of chemotherapy was initiated and 
funded primarily by the pharmaceutical industry, these aspects in surgery have 
been absent for a long time because of a lack of funding.  
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As well as the lack of funding, the optimal approach to develop a useful 
quality control system in surgical oncology has been unclear. From this review 
some conclusions can be drawn regarding the development of such a system. 
Factors of importance for improving outcomes and enabling quality assurance 
are training, the use of standardised surgical techniques, multidisciplinary 
treatment, quality of radiology and pathology, registration and a regular audit 
of results. The benefit of adequate training in combination with the use of 
standardised surgical techniques was demonstrated in the surgical treatment 
of rectal cancer and could serve as an example for improving outcomes in 
other tumour sites.  
 
Moreover, the quality of radiology and pathological examination are essential 
factors in order to improve and audit the quality of surgery. Pre-operative 
diagnostics usually form the basis of the assessment of the operability of the 
tumour and the extent of resection. The quality of the reporting of pathology 
can contribute significantly to the audit of the performed operation and is 
obviously essential for appropriate staging of the tumour. The use of 
checklists could add to the standardised examination of the specimen by the 
pathologist. More interaction between the surgeon and the pathologist might 
facilitate an increase in quality in both areas but this would require a change in 
attitude. The pathologist should provide feedback to the surgeon more openly 
when the resection is inadequately performed according to the pathological 
examination. The surgeon should require the pathologist to report the 
essential parameters currently in use and give feedback when information is 
missing or inadequately reported. 
 
Obviously, this approach would benefit from a multidisciplinary treatment, 
when these aspects could be discussed in a joint meeting with surgeon, 
radiologist and pathologist. Moreover a multidisciplinary team should consist 
of the oncologist and radiotherapist in order to apply up-to-date and 
appropriate treatment.  
 
Registration of all aspects of cancer care is essential in order to monitor the 
quality of treatment. Concerning surgery, the most important items should be 
the operation-related morbidity, mortality, adequacy of resection, local 
recurrences and overall survival. National cancer registries would probably be 
the most relevant means to acquire all treatment-related information. A 
regular audit of the data could (with feedback to hospitals and individual 
surgeons) make one aware of existing differences and would probably have a 
major impact on the quality of treatment. Illustrative is the fact that studies 
reporting on the wide variety in outcomes in the United Kingdom in breast 
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and colorectal care have had major consequences. The current ‘policy 
framework for commissioning cancer services’ (www.doh.gov.uk) or Calman-
Hine Cancer Plan designed by the National Health Service has been the most 
radical answer in an effort to reduce the extent of variations. As a result clear 
guidelines have been developed concerning chemotherapy and radiotherapy. 
Interestingly, surgical guidelines are still absent.  
 
In addition, the Eurocare studies have shown wide geographical variations in 
outcomes259-261. The reliability of the results has sometimes been questioned 
due to the fact that several European countries do not have (reliable) national 
cancer registries262,263. It should be the task of the European Union to enforce 
each member state to set up such registries because they can provide valuable 
information on (geographical) differences and therefore form the basis of a 
European strategy for monitoring, audit and change of cancer care. 
 
So far surgical quality assurance programmes have been restricted to multi 
centre clinical trials. Within the European Organisation for Research and 
Treatment of Cancer (EORTC) several efforts have been undertaken by the 
individual clinical research groups during the past decades. Furthermore, for a 
long time the presence of multidisciplinary treatment within the hospitals has 
been a requirement to participation in EORTC-trials. At present a structural 
approach is being designed in order to obtain reliable methods for quality 
assurance in surgical oncology. One of the difficulties encountered is that 
several means of quality control are feasible within a particular country, but 
are much more difficult to accomplish within Europe as a whole. For example 
the necessary logistics for the supervision of operations by a limited number 
of (super-)specialised surgeons are quite difficult to accomplish. Because of 
the complicated nature of such a programme, it is still only considered to be 
in the research setting rather than being put into common practice as yet. In 
an effort to encourage its development, the EORTC has appointed a medical 
research fellow to be dedicated to this project for the next few years. 
 
Surgery is still the most important treatment variable in most solid cancers 
and its impact has been emphasised in the past decades. Surgical quality 
assurance programmes are currently at an early stage of development, in 
contrast with chemotherapy and radiotherapy where quality control 
mechanisms have been available, at least in clinical trials, for a long time. 
However, the difficulty of auditing a multi-step procedure has not been the 
only restricting cause of the lack of quality control. More important clarifying 
factors were the belief that treatment failures were considered to be caused by 
the biological behaviour of the tumour rather than by the quality of surgical 
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treatment and also a lack of funding. The latter is still the most restricting 
factor in improving surgical performance. In addition, the European Union 
has consistently contributed financially to the improvement of quality 
(control) in radio- and chemotherapy. Now it is clear that a better control of 
the quality of surgical procedures in oncology is possible and may have a 
major impact on outcomes of cancer patients. Here is an opportunity for the 
European Union, national politics and insurers to contribute significantly to 
an increase in the quality of cancer care. 
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abstract 
 
INTRODUCTION - Increasing evidence of both the importance of surgery and 
the role of the individual surgeon in outcomes of surgical oncology has been 
published in the past decade. A review of the available literature concerning 
these topics in the treatment of colorectal cancers was intended to give an 
insight in the causal factors for the observed differences between hospitals 
and surgeons. Not only oncological outcomes such as local recurrence rates 
and overall survival rates were to be considered, but operation-related 
morbidity and mortality as well. The final goal of the review was to identify 
quality indicators in surgical oncology which could be relevant for the 
implementation of quality assurance programmes.  
 
METHODS – Medline databases were searched for publications released 
between 1990 and 2001 regarding quality assurance in surgical oncology and 
evidence of surgeon variability in treatment outcomes of colorectal cancers. 
 
RESULTS - Although a wide variability was found in all aspects related to 
surgery, literature concerning relevant indicators for a prospective audit of the 
quality of surgery was scarce. A few successful quality assurance programmes 
have been described with major consequences for the prognosis and quality 
of life of colorectal cancer patients. As a result the additional value of 
adjuvant radiotherapy after standardised surgery has been questioned and is 
currently the subject of several clinical trials within Europe.  
 
CONCLUSION – Wide variations were found in treatment outcomes regarding 
colorectal cancers due to the quality of surgical technique. The 
implementation of a standardised surgical technique has resulted in a major 
decrease in local recurrence rates. Moreover it has been feasible to guarantee 
the performance of standardised surgery by the use of a quality assurance 
programme. 
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introduction 
 
In recent years increasing attention has been paid to the quality of cancer care. 
The importance of multidisciplinary treatment is now obvious and a 
multidisciplinary approach to cancer research and management is the future 
for patients1. The benefits of multidisciplinary treatment are primarily related 
to the access and use of standardised and up-to-date therapy. Similarly 
patients participating in clinical trials generally experience a survival advantage 
over non-participating patients, which is due (in part) to standardised 
treatment2,3. For radiotherapy4-12 and chemotherapy13-16 several criteria could 
be defined to guarantee a certain level of quality and to enable quality 
assurance procedures. In surgery however, no quality assurance guidelines are 
yet available. One of the reasons for this is the absence of quantifiable 
parameters in surgery. Moreover, the impact of primary surgical treatment is 
often underestimated especially when post-operative adjuvant treatments are 
evaluated.  
 
For many years most treatment failures were considered to be caused by the 
biological behaviour of the tumour rather than by inadequate local therapy17. 
However, several studies have shown18-22 that an improvement in the quality 
of surgical procedures has had much more influence on local recurrence rates 
than the use of adjuvant radiotherapy. Differences in the quality of surgery are 
the main cause of wide variations in the outcome of local treatment for most 
solid malignancies. This is not only of importance in day-to-day practice, but 
in clinical trials in particular, where the effect of adjuvant therapy can 
consequently be wrongly interpreted. 
 
Such an ambiguous situation is for example visible in the trial testing the 
efficacy of radiotherapy following total mastectomy as reported by 
Overgaard23. Mean local recurrence rates of 9% (irradiated patients) versus 
32% (non-irradiated group) were observed, which are both considered to be 
rather high. The authors clearly identified important variations in the extent of 
surgery. Both the management of the axilla and the mastectomy procedure 
seemed to have been inappropriate, since more than half of the recurrences 
appeared on the chest wall. It was concluded that with the current surgical 
methods of treatment, radiotherapy seemed to be required for adequate loco-
regional control. This has resulted in the standard application of radiotherapy 
following mastectomy. By using the word current in this example, the authors 
already suggested that with improved surgical therapy, radiotherapy might not 
be necessary in all cases.  
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Therefore it seems appropriate to develop tools to improve the quality of 
surgical interventions in clinical trials in particular. In contrast with 
chemotherapy and radiotherapy, the quality of surgery appears to be difficult 
to examine. The surgical procedure consists of a multi-step procedure 
depending on the individual surgeon. Whereas varying rates in local control 
might be clear parameters of quality, these are related to long-term effects and 
are not the most relevant indicators in prospective quality control 
programmes. Several attempts to track the performance of the surgeon on a 
short-term basis have been undertaken, varying from efforts to standardise 
surgery and pathology reports to training courses and life audits in the 
operating theatre.  
 
Within the European Organisation for Research and Treatment of Cancer 
(EORTC) quality assurance has been an area of interest for many years24. In 
the fields of chemotherapy13-16 and radiotherapy6,12,25-41 several quality 
assurance projects have been successfully implemented. On the basis of the 
success of a previous quality assurance programme in surgical oncology42, the 
importance of surgery in local control and the evidence that outcome may be 
related to the quality of treatment, the EORTC decided, that although 
difficult, some type of uniformity in the quality of surgery should be 
guaranteed in order to provide reliable and proper results in surgical and 
adjuvant trials. 
 
As guidelines on this topic are not yet available, the Quality Assurance 
Committee of the EORTC intended to review the literature concerning 
existing tools to audit the performance of the surgeon. However, as it was 
expected that the available information on this topic would be scarce, the 
review was extended to the identification of evidence of surgeon variability in 
the treatment of solid tumours. 
 
In recent years, a relationship between the quality of surgery and outcome 
parameters has been demonstrated most clearly in colorectal cancer surgery. 
Therefore this type of malignancy was chosen as the first topic in a series of 
publications addressing the importance of surgical performance. Areas of 
interest were not only outcome measures in terms of local control and 
survival, but morbidity, mortality and quality of life as well. The ultimate goal 
was to identify indicators of surgical performance relevant for quality 
assurance in surgical oncology and in clinical trials in particular. 
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methods 
 
Medline and Cancerlit databases were searched concerning publications on 
quality assurance in surgical oncology and evidence of surgeon variability in 
treatment outcomes of colorectal cancers between 1990 and 2001. Search 
terms: quality, surgery, (practice) guidelines, learning curve, quality assurance, 
quality control, methods, variability, surgeon, physician, hospital, 
specialisation, volume, morbidity and mortality. These terms were combined 
with individual specific quality indicators such as anastomotic leak rates. The 
bibliography of each article was reviewed for other potentially relevant papers. 
 
Although the number of publications has increased recently, the available 
literature on quality assurance (methods) was, as expected, scarce. Similarly 
the number of publications concerning surgeon variability increased during 
recent years. In order to give a clear idea about the consequences of such 
variability between surgeons, this review was restricted to publications 
concerning colorectal cancer surgery. Altogether 194 articles were selected for 
this review. The main selection criteria were number of patients of more than 
50 and publication in English between 1990 and 2001. After exclusion of 
reports comparing laparoscopy with conventional surgery and publications 
already cited in review articles or vice versa, 122 reports remained. The 
selected publications were categorised according to level of evidence. The 
categories used were as follows (in rank order starting with the most 
important): systematic review (review), multi centre randomised clinical trial 
(MCRCT), single centre randomised clinical trial (SCRCT), multi centre 
prospective observational study (MCPO), single centre prospective 
observational study (SCPO), population-based study (PB), multi centre 
(retrospective) observational study (MCO) and single centre (retrospective) 
observational study (SCO). In all tables publications are listed in this order.  
 
In the following sections evidence of variability in outcome related to surgery 
in colorectal cancer will be reviewed. Efforts have been undertaken to identify 
the causes for these differences by evaluating the effect of either the hospital 
or the surgeon. The most common parameters of evaluation of the hospital 
are ‘volume’ and ‘type of hospital’. The yearly volume represents the number 
of cases treated on an annual basis related to a tumour site. Different types of 
hospitals are cancer centres, teaching and district hospitals. The performance 
of individual surgeons was frequently rated according to case load (number of 
cases treated) per year or the completion of a specialised training. 
Furthermore, specific technical aspects in oncological surgery and the 
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adherence to these principles have been evaluated for their possible influence 
on outcome. These sections will be followed by the review of published data 
concerning projects related to quality assurance in surgical oncology. 
 
 
results 
 
To evaluate the quality of colorectal cancer surgery several parameters are 
generally considered, which will be described in this section. Long-term 
oncological outcome is judged in terms of local control and survival. 
Furthermore, colorectal surgery is associated with long-term morbidity of 
which the most important are a permanent stoma and sexual and/or urinary 
dysfunctions. Indicators of morbidity are therefore the rate of 
abdominoperineal resections (% APR) and the incidence of sexual and urinary 
dysfunctions due to autonomic nerve damage. The most relevant parameters 
to evaluate the quality of surgery on a short-term basis are 30-day mortality 
(OM) and the anastomotic leak rate (ALR). In the next sections, the observed 
variation in each of these parameters will be reviewed.  
 
differences in local control and survival 
 
In table 1 the selected publications reporting on local recurrence and long-
term survival rates after treatment for colorectal cancer are listed. Of specific 
interest is the existing variation caused by the surgical procedure. To prevent 
the possible influence of adjuvant treatment, only series in which surgery was 
the only treatment performed are shown. Local recurrence rates refer to rates 
after (potentially) curative surgery unless otherwise stated. The reported data 
of multi centre clinical randomised trials (MCRCTs) for surgery alone are 
indicated in bold. The routine use of total mesorectal excision  
 
(TME) is stated separately. TME was first described by Heald18,64 and is 
increasingly used as a standardised surgical procedure in the treatment of 
rectal cancers in Europe65. 
 
In colorectal surgery wide variations have been reported concerning local 
recurrence rates (LRR) and overall survival (OS). However, it is remarkable 
that all reports only described local recurrence rates for patients with rectal 
cancer. This suggests that local recurrence is not as common in colon cancer 
as in rectal cancer. It might therefore be appropriate not to generalise the 
results for colon and rectal cancer treatment. No data regarding duration of 
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follow-up are shown in the table, but virtually all authors reported LRRs after 
a minimum follow-up of 2 years after surgery in which the majority of pelvic 
recurrences are reported to occur66,67. 
 
McCall reviewed 51 publications43 in which adjuvant therapies were not used. 
Altogether 10.465 rectal cancer patients treated between 1982 and 1992 were 
studied. The median value for loco-regional recurrence rates was 18.5% with a 
range of 3% to 50%. Nine papers reported local recurrence rates of 10% or 
less.  
 
Regarding publications published after 1991, reported variations in LRR 
appeared to be reduced compared to the data of McCall et al.43. Overall LRR 
varied from 1% to 30% in the selected publications. When MCRCTs are 
compared, LRR varied from 26% to 30%44-46 after surgery alone. In these 
studies LRRs for all patients were included and not only the ones after 
curative resections. The corresponding range of curative resection rates was 
found to be 40% to 88%. Lowest figures for LRR were found in single centre 
prospective observational studies (SCPOs), varying from 1% to 5%50,52,54,55 
with one exception of 23%53. All SCPOs routinely applied TME in contrast 
with virtually all other reports. Interestingly, MacFarlane54 showed a LRR of 
5.2% in a high-risk group containing Dukes B2 and C patients. In 
retrospective single centre series (SCOs) a LRR range of 3.5% to 14%60,62 was 
found.  
 
Overall survival after surgery alone varied from 41% to 85%. MCRCTs 
reported OS-rates for all patients, including patients with non-curatively 
resected cancers. 5-year OS-rates between 41% and 50% were found, similar 
to data reported by Adam53(48%). The remaining studies showed survival 
rates after curative resections which appeared to be 50% to 85% in rectal 
cancer patients and 56% to 76% in colon cancer patients. Remarkably, best 
results were achieved in Dukes B2 patients with 85%54 survival after a median 
follow-up of almost eight years. Despite the promising figures regarding 
LRRs, hardly any results were reported concerning survival rates after TME. 
This seems mainly due to the fact that follow-up is too short to draw clear 
conclusions68. Overall survival rates show an inverse correlation with local 
recurrence rates18,21,47,69,70. 
 
The rate of curative resections is included in table 1 in order to detect a 
supposed correlation between curative resections and lower local recurrence 
rates and increased survival. In the majority of publications a curative 
resection was defined according to the definition of the operating surgeon  
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with respect to the probability of residual tumour left after the operation. 
Furthermore, the extent of margin clearance (either distal or circumferential) 
played a role in the surgical opinion regarding the performance of a curative 
or palliative procedure. The reported curative resection rates varied from 40% 
to 88%, of which the opposites correspond with OS-rates of 66%44 and 
41%46 respectively. It became clear that the surgeons’ opinion was not reliable 
as a predictive value with regard to local control and overall survival47,71.  
 
factors influencing local control and survival 
 
MARGINS OF RESECTION - An explanation for better local control and improved 
survival after the (routine) performance of TME compared with conventional 
surgery is described by several authors18,54,60,69. Evidence of tumour 
involvement of the circumferential (or lateral) margins proved to be a more 
important indicator for local control18,19,50,53,54,60,64,72-75 and/or 
survival18,54,60,76,77 than the extent of distal tumour free margins. The routine 
resection of distal margins of 5 cm to 10 cm has been replaced by 2-cm 
margins following histo-pathological studies performed by Quirke72 and 
Wolmark78 in the 1980s. These studies failed to show microscopic intramural 
longitudinal spread for distances greater than 12 mm distally. In addition, 
several studies showed that distal tumour-free margins of 1 cm (or less) are as 
effective, provided TME is properly performed55,79. This might enable a 
reduction in the rate of abdominoperineal resections performed. 
 
TUMOUR SPILL - The inadvertent perforation or incision into rectal carcinoma 
during surgery may lead to massive dissemination of tumour cells in the 
operative area. The publications addressing this topic are listed in table 2. 
Tumour spill or perforation seem to negatively influence local control80-84 and 
survival47,83,84. 
 
EXTENT OF LYMPHADENECTOMY - The optimal extent of lymphadenectomy is 
still controversial. The TNM classification requires at least 12 tumour-free 
lymph nodes in order to qualify a tumour reliably as node negative. Although 
extended lymphadenectomy is advantageous in reducing local recurrence and 
improving survival, it has disadvantages such as urinary and sexual 
dysfunction. In Japan it is widely used under certain circumstances85 whereas 
in Europe similar results have been reported with TME alone20. 
 
CYTOCIDAL WASHOUT - The reduction of LRR by routine cytocidal washout 
remains unclear. In their review on factors of influence on local recurrence, 
McCall et al43 concluded that the pooled local recurrence rates with the use of 
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a cytocidal agent were only 1% to 2% less than pooled LRR for the groups as 
a whole. More recent studies addressing this topic were not available. 
 
long-term morbidity 
 
Indicators for long-term morbidity as a means to audit the quality of the 
performed (colo)rectal surgery are the percentage of abdominoperineal 
resections (% APR) and sexual and urinary dysfunctions, as was previously 
mentioned. In table 1 an overall variation in APR-rate was found of 6% to 
58%, of which the higher rates originated from MCRCTs and population-
based studies in particular. In the Lothian and Borders Large Bowel Cancer 
Project48 an average APR-rate of 29% was found with a range of 0% to 60% 
depending on the individual surgeon. Five of 84 surgeons were responsible 
for the surgical treatment of 50% of the rectal cancer patients. An analysis 
comparing the APR-rate when treated by one of these five surgeons or by one 
of the remaining failed to show clear differences. The performance of TME 
was associated with lower rates of APR with the exception of one report53. 
This report was the same as that in which local control and survival after 
TME were poorer than in the remaining TME studies. 
 
Havenga et al.86 reviewed the literature since 1980 on urinary and sexual 
dysfunction after surgery for rectal cancer. Six publications were described 
regarding urinary function after conventional surgery. Neurogenic bladder 
was encountered in 9.6% of 187 patients reported. The majority of 
dysfunctions had been objectively verified to be caused by detrusor 
denervation as a result of damage to the sacral splanchnic nerves.  
 
Nineteen studies reported on the incidence of male sexual function after 
conventional surgery for rectal cancer. Complete erectile dysfunction averaged 
25% and appeared to be higher following abdominoperineal resections (34%) 
when compared with low anterior resections (20%). Respective percentages 
for loss of ejaculations were 16% (average), 19% (APR) and 33% (LAR). The 
seven studies reporting on female sexual dysfunction reported decreased 
libido (24%), dyspareunia (38%) and diminished or no orgasm (28%).  
 
Evaluation of reports concerning the extent of autonomic nerve preservation 
revealed that bladder and sexual dysfunction can be avoided by identifying 
and preserving the pelvic autonomic nerves. With the use of TME, this does 
not seem to compromise local control and survival21,87.  
 
 
 86 chapter 3 
short-term complications 
 
Short-term complications comprise 30-day mortality-rate (OM) and 
anastomotic leak rate (ALR). The latter is usually defined as the percentage of 
symptomatic anastomotic leaks. The results of the selected publications are 
shown in table 3. Articles reporting data of patients of whom more than 5% 
had been subjected to pre-operative chemo- or radiotherapy were excluded to 
avoid potential bias. The same applies for studies concerning the efficacy of a 
specific type of anastomosis. 
 
ANASTOMOTIC LEAK RATE (ALR) - In 1980 Fielding88 already suggested that the 
surgeon was probably the most important single factor influencing 
anastomotic integrity. In his prospective analysis of 1466 colorectal cancer 
patients operated on by 84 surgeons, the ALR varied from 0.5% to 30%, 
which could not be explained by differences in case mix. McArdle56 reported 
a range of ALRs between surgeons of 0% and 25% after curative colorectal 
resections. More recent data are available from the Lothian and Borders Large 
Bowel Cancer Project48, a prospective multi centre study in which a mean 
ALR was reported of 8.9% for rectal cancers. When operations for rectal 
cancer were analysed for the 84 individual surgeons, the ALR ranged from 
0% to 75%. Five consultant surgeons were responsible for the surgical 
treatment of 50% of rectal cancer patients. These patients were not more 
likely to receive an anastomosis, but when an anastomosis was performed it 
was less likely to leak. 
 
Of the seven studies evaluating ALR in colorectal cancer patients, only three 
supplied data according to tumour location. In these three studies48,51,58 
anastomoses were endangered more often in rectal than in colon cancer 
patients. 
 
ALR after the performance of TME19,49,52,55,60,74,89,92,93,95,103 tends to be higher 
(10% to 14%, range 1% to 14%) than after the performance of conventional 
surgery46,48,49,51,56,58,60-63,90,94,100,101 (generally below 10%). This can be explained, 
in part, by the fact that the percentage of low anastomoses is generally higher 
with the use of this technique. Several studies90,93,100,101,104,105 have provided 
evidence of a higher risk of anastomotic leakage in low anastomoses, although 
the definition of low varies from 5 cm to 8 cm from the anal verge. Therefore 
most authors52,55,90,92,93,95,100,105 advocate the use of a protective stoma in this 
group of patients. In only one publication the routine use of such a stoma is 
questioned after rectal resections with an anastomosis below the perineal 
flection63. 
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THIRTY-DAY MORTALITY - Operative mortality or 30-day mortality rates (OM) 
vary between 0.5% and 16.3% but are generally below 10%. A higher OM is 
found after emergency procedures58 or non-curative resections55-57, with 
increasing age57 and following anastomotic leaks49,52,62,63,74,88,90,95,100,101,103. 
Evidence of intersurgeon variability in OM was supplied by data from the 
Lothian and Borders Large Bowel Cancer Project48. After resection of 
colorectal cancers an average OM-rate of 16.3% was reported with a range of 
8% to 30%. After curative resection OM varied between surgeons from 0% 
to 20% with an average of 6.2%. 
 
hospital and surgeon related factors 
 
As a result of the existing differences, several authors have attempted to 
identify criteria for optimal results. In other areas, such as oesophageal106-108 
and pancreatic cancer surgery109,110, a clear correlation was found between 
hospital and/or surgeon volume and outcome111,112. For rare cancers, for 
example sarcomas, the benefit of specialised care has been advocated113. Table 
4 contains the results of studies examining a possible similar relationship in 
(colo)rectal cancer surgical treatment. Operation-related mortality, local 
recurrence rates and overall survival were considered to be of specific 
importance.  
 
Among the most frequently cited publications concerning intersurgeon 
variability are the data of the prospective studies reported by Phillips81 and 
McArdle56,57. Variations in local recurrences were similar and ranged from 0% 
to 21%. Kapiteijn82 found an average local recurrence rate of 22.5% with an 
interinstitutional variation of 9% to 36% between 12 hospitals. Hermanek70,114 
observed loco-regional recurrences in 22% of patients, which varied from 
10% to 37% among seven departments of surgery with a particular interest in 
colorectal surgery. Intersurgeon variability varied between 4% and 55% with 
an average of 20%56,57,70. 5-year survival rates averaged 60% related to the 
individual surgeon (range 46% to 79%) and 58% depending on the institution 
(range 54% to 62%). Consequently a highly significant correlation between 
local recurrence rate and 5-year survival was detected. On the contrary, 
experts in Europe and the United States have reported recurrence rates of 3% 
to 8% 18,19,60,74,76.  
 
Thirteen publications reported on a possible influence of hospital 
characteristics on outcome in colorectal cancer surgery, seventeen on surgeon 
characteristics. 
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In Sweden 1399 patients were included in two prospective randomised trials, 
conducted by the Stockholm Rectal Cancer Study Group116 (the purpose of 
the trials was to evaluate the benefits of pre-operative radiotherapy). The risk 
of local recurrence and death from rectal cancer appeared to be lower when 
patients were operated on by specialists qualified for at least 10 years or 
working in university hospitals. However, the risk of death in some 
community hospitals was similar to those in university hospitals.  
 
Hermanek117 and Kessler90 both reported on the prospective observational 
study of the German Study Group Colo-Rectal Carcinoma (SGCRC) 
concerning surgical mortality. As previously mentioned, these patients were 
operated on in surgical departments with a special interest in colorectal 
surgery. No significant differences were found between either hospital or 
surgeon volume. Neither was a relationship observed regarding volume and 
local recurrence or overall survival.  
 
In five of the remaining eight studies no relationship was found between 
hospital volume82,118,119 or type118,121,122 and outcome. Kee120 on the contrary 
reported a slightly worse survival in hospitals with higher case loads. 
 
Information regarding the influence of the individual surgeon on outcome 
was reported in a Canadian study80. 683 patients with rectal cancer were 
treated by 52 different surgeons. Five of the surgeons were trained in 
colorectal surgery and performed 16% of the operations. 47% of the 
procedures were performed by surgeons who had each operated fewer than 
21 resections during the 8-year study period. Multivariate analysis showed that 
the risk of local recurrence and disease specific survival were negatively 
influenced both by surgeons not trained in colorectal surgery and operating 
less than 21 operations during the study period. These results suggest that 
both specialisation and surgeon volume are independent factors determining 
outcome.  
 
The benefit of specialisation was confirmed by Rosen99 concerning operative 
mortality. Furthermore, outcome seemed to be improved by the 
concentration of care to a colorectal team123. In contrast, data from the 
SGCRC47 proved that similar 5-year survival rates can be obtained by both 
low and high-volume surgeons, provided that they were appointed to a 
surgical department specialised in colorectal surgery. A low-volume surgeon 
was defined as one performing less than 10 radical resections during a 28-
month period, whereas high-volume surgeons performed 15 or more. The 
findings reported by Harmon97 were slightly different. It was found, that low 
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and medium-volume surgeons performed better when operating in higher-
volume hospitals. The best results were obtained by high and medium-volume 
surgeons operating in high-volume hospitals. Apparently, outcomes in 
colorectal surgery are related more to surgeons’ technique than to volume or 
specialisation.  
 
training and quality assurance 
 
The importance of surgical skill was clearly shown by the results of a training 
programme, initiated by the Stockholm Colorectal Cancer Study Group22. 
Workshops and television-based demonstrations in the fields of surgery and 
pathology were used to teach the principles of total mesorectal excision 
(TME). The outcomes of these patients were compared with the results of 
patients who had been included in previous randomised clinical trials 
performed by the same institutions. A decrease in the proportion of 
abdominoperineal resections and local recurrences of more than 50% were 
obtained and an increase in survival was observed. Operative mortality, 
complications and anastomotic leak rate remained unchanged.  
 
In the Netherlands an even more intensive quality assurance programme has 
been performed89. The surgical procedure and pathological examination were 
standardised. In addition to instruction videos and training courses, the first 
five operations had to be supervised by a TME-trained consultant surgeon. A 
pathology panel was formed to guarantee pathology quality control. Although 
long-term results are still awaited, short-term results of this initiative have 
been promising in terms of the rate of abdominoperineal resections and 
involved lateral margins with no increase in morbidity or mortality68,89.  
 
It can be concluded that TME as described by Heald18,64 has yielded much 
better results than the performance of conventional surgery in terms of local 
control and survival. These results have been reproducible in multi centre 
clinical trials (at least on a short-term basis), which confirms the feasibility and 
efficacy of standardised surgery. The same applies for the standardised 
pathological examination as described by Quirke and Dixon72.  
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discussion 
 
The results described have shown wide variations in outcomes of surgical 
treatment in all its aspects. Not only do differences in local recurrences exist, 
they also influence overall survival, as a clear correlation between these 
outcome parameters was shown. Moreover, it has been demonstrated that the 
individual surgeon was a possible causal factor of this variability. Interestingly, 
the number of publications and the level of evidence of the articles addressing 
this topic has increased in recent years. Although both the type and volume of 
the hospital play a role in outcomes after surgery for colorectal cancer, the 
surgeon appears to be the most important determinant. With regard to the 
individual surgeon, personal skills and specialisation to a lesser extent, seem to 
influence outcomes more than case load, although a minimum of annual 
procedures should be required. The importance of surgical skill in preventing 
local recurrences and consequently improving survival, can, for example, be 
illustrated by the variety in tumour spill/perforation and the percentage of 
tumour positive resection margins. The same applies for differences in 
operation related mortality and morbidity. The required annual number, 
however, cannot be defined on the basis of the reviewed publications. 
 
In rectal cancer surgery, two multi centre clinical trials/multi centre 
observational studies22,89 have provided evidence that with the use of 
standardised techniques and extensive quality assurance programmes, a 
considerable improvement in oncological outcomes and a decrease in 
morbidity and mortality can be accomplished. The implementation of quality 
assurance programmes in addition to standardised surgery is one of the key 
factors in improving the quality of cancer care if a repetition of the past is to 
be avoided. An example of the existence of differences between surgeons 
who presumably performed the same operation was described in breast 
cancer by Christiaens124. 
 
Moreover, the quality of radiology and pathological examination are essential 
factors in order to audit the quality of surgery. Pre-operative diagnostics 
usually form the basis of the assessment of the operability of the tumour and 
the extent of resection. The quality of the reporting of pathology can 
contribute significantly to the audit of the performed operation and is 
obviously essential for appropriate staging of the tumour. More interaction 
between the surgeon and the pathologist might facilitate an increase in quality 
in both areas but this would require a change in attitude. The pathologist 
should provide feedback to the surgeon more openly when the resection is 
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inadequately performed according to the pathological examination. The 
surgeon should require the pathologist to report the essential parameters 
currently in use and give feedback when information is missing or reported 
inadequately. 
 
In order to achieve an overall change in strategy, several aspects should be 
considered. First of all, adequate registration of all treatment-related data is 
necessary. National cancer registries would probably be the most relevant 
means to acquire this information. A regular audit of the data could (with 
feedback to hospitals and individual surgeons) make one aware of existing 
differences and would probably have major impact on the quality of 
treatment. Studies reporting on the wide variety in outcomes in the UK in 
breast and colorectal care have had major consequences. The current ‘policy 
framework for commissioning cancer services’ or Calman-Hine Cancer Plan, 
designed by the National Health Service has been the most radical answer in 
an effort to reduce the extent of variations. Clear guidelines are available 
regarding chemotherapy and radiotherapy, however the ones concerning 
surgery are considered to be rather limited.  
 
The Eurocare studies have furthermore shown wide geographical variations in 
outcomes125,126. The reliability of the results has sometimes been questioned 
due to the fact that several European countries do not have (reliable) national 
cancer registries127,128. It might be the task of the European Union to enforce 
each member state to set up such registries, because they can provide valuable 
information on (geographical) differences and therefore form the basis of a 
European strategy for monitoring, audit and change of cancer care. 
 
The importance of multidisciplinary treatment cannot be overemphasised, 
although publications addressing this topic are limited. A review written by 
Rougier and Neoptolemos1 was the only one found concerning colorectal 
cancer treatment and advocated a multidisciplinary approach in advanced 
stages in particular. The benefits of specialised care are not only related to 
knowledge in the specialists’ own field, but to the knowledge of related areas 
as well: the surgeon should be aware of the indications for radiotherapy or 
chemotherapy and vice versa. Dahlberg et al.123 for example described a 
strong reduction in local recurrence rates (47% to 13%) as a result of the 
more systemic use of radiotherapy following the concentration of care to a 
colorectal unit.  
 
So far surgical quality assurance programmes have been restricted to multi 
centre clinical trials. Within the European Organisation for Research and 
 98 chapter 3 
Treatment of Cancer (EORTC) several efforts have been undertaken by the 
individual clinical research groups during the past decades. At present a 
structural approach is being designed in order to obtain reliable methods for 
quality assurance in surgical oncology. One of the difficulties encountered is 
that several means of quality control are well feasible within a country, but are 
much more difficult to accomplish within Europe as a whole. For example 
the necessary logistics for the supervision of operations by a limited number 
of specialty-trained surgeons are quite difficult to accomplish. Because of the 
complicated nature of such a programme, it is still considered to be in the 
research setting rather than being put into practice yet. In an effort to 
encourage its development, the EORTC has appointed a medical research 
fellow dedicated to this project for the coming years. 
 
With the improvement of surgical treatment, the (routine) use of adjuvant 
therapy could be questioned68. This might imply a considerable change in 
cancer treatment strategies because common practice is generally based upon 
the results of MCRCTs. Similar efforts should be undertaken to improve 
general surgical oncological practice, otherwise the results of MCRCTs can no 
longer be representative for common practice. The conclusions of MCRCTs 
would then be useless.  
 
Surgery is still the most important treatment modality in colorectal cancer and 
it’s impact has been emphasised in the past decades. Surgical quality assurance 
programmes are currently at an early stage of development, in contrast with 
chemotherapy and radiotherapy where quality control mechanisms have been 
available, at least in clinical trials, for a long time. The difficulty of auditing a 
multi-step procedure has however not been the only restricting cause of the 
lack of quality control. More important clarifying factors were the belief that 
treatment failures were considered to be caused by the biological behaviour of 
the tumour rather than by the quality of surgical treatment and a lack of 
funding. The latter is still the restricting factor in improving surgical 
performance. Whereas the development of chemotherapy quality control 
measures was funded indirectly by the industry, no such financial sources are 
available for surgery. In addition, the European Union has consistently 
contributed to the improvement of quality (control) in radio- and 
chemotherapy. Now it is clear that a better control of the quality of surgical 
procedures in oncology is possible and may have a major impact on outcomes 
of cancer patients. Here is an opportunity for the European Union, national 
politics and insurers to significantly contribute to an increase in the quality of 
cancer care. 
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abstract 
 
INTRODUCTION - The European Organisation for Research and Treatment of 
Cancer (EORTC) has a long history in the development of quality assurance, 
in particular in radio- and chemotherapy. Quality assurance in surgical 
oncology is considered to be more complicated, because it is a multi-step 
procedure depending on the individual. Because of the growing importance of 
the quality of surgical intervention in the multi-modality treatment approach 
of most cancers, the EORTC recently decided to investigate the current status 
of quality assurance programmes, both within and outside, of the EORTC. 
 
METHODS - Between the end of 2000 and February 2001, all subcommittee 
chairmen and Data Center teams of ten EORTC clinical research groups 
which are active in the field of quality assurance in surgical oncology were 
interviewed. In addition clinical trial protocols, case report forms and 
publications by the EORTC groups related to this field were considered as 
possible sources of information.  
 
RESULTS – An increasing awareness of the importance of quality assurance in 
surgical oncology was encountered in all of the EORTC clinical research 
groups. This can be concluded from the implementation of quality assurance 
questionnaires, a trend to a more detailed description and documentation of 
the surgical procedures and increasing efforts to use some kind of quality 
assurance in surgery-related trials.  
 
CONCLUSION - Several methods have been used or are currently under 
investigation to ensure the quality of surgery within clinical trials. These 
include the review of reported data, standardisation of surgery and pathology 
forms, training sessions and site-visits. However, there has been no attempt to 
harmonise these initiatives across the different medical specialties. The 
EORTC will have to address this problem within its short-term scientific 
strategy. 
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introduction 
 
Within the European Organisation for Research and Treatment of Cancer 
(EORTC) quality assurance has been an area of interest for many years1. In 
the 1980s the EORTC received several grants from the European 
Community to perform quality control projects at different levels. As part of 
this programme, the Radiotherapy Group (RTG) started to investigate the 
quality and homogeneity of the radiotherapy delivered by institutions 
participating in trials of this group2-7. Various techniques were used for this 
purpose including dummy run, equipment checks and in vivo and in vitro 
dosimetry and an immediate review of first randomised patients8-20. The 
programme has demonstrated that the establishment of a quality assurance 
programme in radiotherapy was feasible and could contribute to uniform the 
important aspects of radiotherapy treatment of the participating institutions. 
 
In addition, the quality assurance committee (QAC) initiated projects 
regarding quality assurance in chemotherapy and reporting of data in clinical 
trials21-24. Considerable variation was found between centres in the 
organisation of chemotherapy administration. However, more striking 
differences were noted between the type and quality of hospital files regarding 
the (lack of) systemic recording of treatment related data. As a consequence 
stricter guidelines concerning the calculation of doses of chemotherapy have 
been defined. Furthermore a systemic therapy checklist was developed to 
facilitate the reporting of the sequence, timing and doses of chemotherapy 
and treatment related toxicity as well. The use of the EORTC systemic 
checklist markedly increased the quality and quantity of treatment data 
reported in the patient’s file25.  
 
In the field of surgery, a quality control programme was implemented by the 
Melanoma Group with regard to isolated limb perfusion as adjuvant 
treatment in melanomas located on the extremities26. The performance of site 
visits resulted in a decrease of surgery-related protocol violations from 28% to 
11%, which showed the feasibility of surgical quality control. 
  
More recently, the importance of the quality of surgery and its influence on 
outcome has been shown more clearly. The quality of local surgical therapy 
for solid tumours influences local control to a large extent. For many years, 
most treatment failures were considered to be caused by the biological 
behaviour of the tumour rather than by an inadequate local therapy. However, 
several studies have shown27-31 that an improvement in the surgical procedure 
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had much more influence on local recurrence rates than the use of adjuvant 
radiotherapy. The role of surgery has been questioned in adjuvant trials, 
which are very common within the EORTC. If the quality of surgery varies 
between the participating centres and individual surgeons, then how reliable is 
the effect of adjuvant treatment. Such ambiguous situation is for example 
visible in the trial on the effect of radiotherapy following total mastectomy as 
reported by Overgaard32. Mean local recurrence rates of 9% (irradiated 
patients) versus 32% (non-irradiated group) were observed, which are both 
considered to be rather high. The authors clearly identified important 
variations in the extent of surgery. Both the management of the axilla and the 
mastectomy seemed to have been inappropriate, since more than half of the 
recurrences were on the chest wall. It was concluded, that with the current 
surgical methods of treatment, radiotherapy seemed to be required for 
adequate loco-regional control. This has resulted in the standard application 
of radiotherapy following mastectomy.  
 
Although it is known that a wide variation may exist in the quality of surgery, 
it seems virtually impossible to objectively assess the quality of surgery, in 
contrast to the objectively measurable treatment variables in chemo- and 
radiotherapy. The success of an operation depends on the sequence of 
numerous manual actions and technical factors in which the individual 
surgeon is the only determinant. Because the evaluation of the surgical 
procedure is so complex, the quality of surgery is usually assessed by surrogate 
indicators related to outcome. Frequently used outcome parameters are either 
short-term morbidity and mortality or long-term local control and survival.  
 
On the basis of the success of the previous quality assurance programme, the 
importance of surgery in local control and the evidence that outcome may be 
related to the quality of treatment, the EORTC decided that, although 
difficult, some type of uniformity in the quality of surgery should be 
guaranteed in order to provide reliable and proper results in surgical and 
adjuvant trials. As guidelines on this topic are not yet available, the QAC of 
the EORTC started with an inventory of the available experience and future 
plans within the groups. The ultimate goal was to try to identify quality 
criteria, which could be used for all groups within the EORTC. 
 
Quality assurance activities within the groups are handled by different 
subcommittees in collaboration with representatives of Data Center staff. 
Therefore, a description will be given of the presence of these subcommittees 
within the EORTC groups and their respective responsibilities. This section 
wille be followed by the evaluation of current practices regarding protocol 
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descriptions and documentation on the case report forms (CRFs), preceding 
specific projects on quality assurance in surgical oncology (QASO).  
 
 
methods 
 
Between the end of 2000 and February 2001, all subcommittee chairmen and 
Data Center teams of ten EORTC clinical research groups which are active in 
the field of quality assurance in surgical oncology were interviewed (table 1). 
Ten clinical research groups are active in fields related to specific tumour 
sites, including the Radiotherapy Group (RTG). The RTG was included in the 
project because radiotherapy also focuses on local control. Moreover, most of 
the patients treated by radiotherapy have been operated on as well. Therefore 
both the quality of radiotherapy and surgery are of importance for the 
evaluation of the efficacy of treatment. 
 
The aim of the interviews was to acquire information on general strategies 
and specific projects within the groups in the field of quality assurance in 
surgical oncology.  
 
All 61 protocols of the abovementioned groups were evaluated to select the 
studies in which local control was considered to be of importance. As the 
quality of surgery mainly influences local recurrence rates, only trials reporting 
on local recurrence, disease-free or progression-free survival were examined 
together with trials in which an ‘adequate’ resection was specifically required 
(appendix). The majority of these protocols were open during the last 
evaluation (January 2001). In addition, two Gastrointestinal Tract Cancer 
Group (GITCG) trials, which had been closed to entry in 1998, were 
examined, because the number of open trials was too limited to allow a 
proper evaluation. In other groups (Breast Cancer Group, Genito-Urinary 
Tract Cancer Group and Lung Cancer Group) trials to be opened soon were 
included for the same reason. Altogether, 23 protocols were selected for 
further evaluation concerning parameters in the fields of surgery, pathology 
and radiology. Publications and reports by the individual EORTC groups on 
projects related to quality assurance in surgery and pathology were also 
evaluated and reported.  
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results 
 
EORTC groups’ subcommittees 
 
Table 1 shows the presence within a group of formal subcommittees for 
quality assurance, surgery and pathology. In general, the quality assurance 
subcommittee is responsible for the admission and audit of the group 
members, the surgery subcommittee for the description of the surgical 
procedures in the protocol and the pathology subcommittee is either active in 
the quality of pathology (reporting) and/or pathology review and marker 
studies. Altogether their activities are essential to enable quality assurance in 
surgical oncology. 
 
QUALITY ASSURANCE SUBCOMMITTEES (QASC) - In 1998 minimal requirements 
for quality assurance within the EORTC groups were defined by the EORTC 
Quality Assurance Committee (QAC). These requirements consisted of the 
nomination of a responsible investigator for quality assurance matters of the 
group, the creation of a QASC with the purposes of reviewing membership 
and checking the compliance with the regulations of the group. Furthermore 
the subcommittee should identify, discuss and address specific quality 
assurance problems which may be ‘disease or modality’ oriented and suggest 
possible perspectives of research programmes. The QASC should provide a 
yearly report of its activities to the quality assurance unit of the Data Center. 
The presence of a quality assurance subcommittee in various EORTC groups 
is outlined in table 1.  
 
Table 1: Presence of subcommittees 
 
Group name 
 
Quality 
Assurance 
Subcommittee 
Surgery 
Subcommittee 
Pathology 
Subcommittee 
BCG (Breast Cancer Group) + + + 
EOI (European Osteosarcoma Intergroup) - + + 
GITCG (Gastrointestinal Tract Cancer Group) + + + 
GUTCG (Genito-Urinary Tract Cancer Group) + - + 
GCG (Gynecological Cancer Group) + + + 
HNCG (Head and Neck Cancer Group) + + + 
LCG (Lung Cancer Group) + + + 
MG (Melanoma Group) - + + 
RTG (Radiotherapy Group) + - - 
STBSG (Soft Tissue and Bone Sarcoma Group) - + + 
 
+ = present; - = not present  
 
In seven out of ten groups, a QASC is present and active. The Head and 
Neck group appointed a Quality Assurance Co-ordinator in stead of a 
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committee, because of the limited size of the group. In the Melanoma Group, 
no quality assurance committee is present; however, quality assurance 
activities have been undertaken by the Board of the Group in collaboration 
with the Data Center team. There is no QASC in the EOI and the STBSG, 
which are both small groups and mainly consist of specialised institutions. 
The STBSG does, however, site-visit at each applying institution.  
  
The tasks of the QASCs usually include the audit of membership and the 
initiation of quality assurance programmes which are either disease- or 
modality-specific. Table 2 shows the current tasks of the different QASCs. 
 
Table 2: Tasks of the quality assurance subcommittees 
 
Group name Audit membership 
 
Compliance with 
regulations 
QASO 
BCG + + - 
GITCG + + + 
GUTCG + + - 
GCG + + + 
HNCG + - - 
LCG + + - 
RTG + + - 
 
+ = present; - = not present ; QASO = Quality Assurance in Surgical Oncology 
 
All of the seven groups that have a QASC are active regarding the audit of 
membership and the evaluation of the compliance of the group members with 
the regulations of the group. The latter is generally implemented through 
some type of quality control of the data collected in clinical trials. Concerning 
surgery, solely the GITCG and the GCG have discussed structural projects in 
quality assurance within this subcommittee. In the other groups, quality 
assurance programmes related to specific treatment modalities are not 
handled by the QASC. It is the responsibility of the surgery subcommittee or 
the study co-ordinator of specific protocols. In the RTG, the QASC has 
defined minimum criteria for radiotherapy departments to participate in 
EORTC trials. 
 
In most groups, a quality assurance questionnaire has been developed 
separately for the selection of new group members. However, the number of 
questions concerning surgery varies. Table 3 shows whether information, 
considered to be of importance for quality assurance is collected by the 
questionnaires within the different groups. 
 
A majority of the questionnaires require information related to the general 
structure and management of the hospital. This information includes the type 
of hospital and the number of patients treated per year. The presence of a 
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‘joint clinic’ or multidisciplinary consultations is checked in about half of the 
questionnaires. The information collected on hospital facilities like radiology, 
pathology and nuclear medicine is scarce. 
 
Table 3: Quality Assurance Questionnaires 
 
Department of Surgery  Group nam
e 
Q
uestionnaire 
H
ospital type 
V
olum
e 
Facilities 
radiology 
N
uclear 
M
edicine 
P
athology 
M
D
C
 
T
otal 
volum
e 
V
olum
e 
specific 
area 
N
o staff 
m
em
bers 
S
peciali-
sation 
BCG + + + + + + + - + + + 
EOI - - - - - - - - - - - 
GITCG + + + - - +/-(1) + - + + + 
GUTCG + - + + + - - + - + - 
GCG + + + - - - - - + + - 
HNCG + + + + - + + - + + + 
LCG + + + + - - + - + + - 
MG + + - - - - + - + + + 
RTG + + + - - - + - - - - 
STBSG - - - - - - - - - - - 
 
+ = present; - = not present; MDC= multidisciplinary consultation/’joint clinics’; (1) surgeon is asked if he asks consent from the local pathologist for trials 
and if the pathologists systematically reports the number of removed and positive lymph nodes. 
 
The situation concerning the information related to volume of activities and 
staff members in the department of surgery and the hospital in general, can be 
summarised as follows. In six groups this information should be provided 
either by the applying institution or by the applying department (GITCG, GCG, 
HNCG, LCG, MG, and RTG). As a result, the questionnaire will provide 
heterogeneous information. In some cases it will be related to the overall 
hospital characteristics. In other cases it will provide parameters related to a 
certain department (LCG). As a consequence, only the name of the 
responsible surgeon will be known, if the surgical department is not applying, 
because the questionnaire does not require information of the surgical 
department specifically except for the name of a representative. Concerning 
the GCG and RTG the applying department will obviously be known. The 
GITCG and the HNCG have added a paragraph collecting information about 
the numbers of patients treated yearly and the number of staff members. The 
MG has restricted the required information on volume to the number of 
melanoma patients treated during the last two years and does not require any 
information about staff members.  
 
Some groups have written a Standard Operating Procedure (SOP) on the 
membership requirements and/or on the functioning of the QASC (BCG, 
GITCG, and RTG). This document is of importance for objective admission 
of new members and objective audit of the performance of group members.  
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The initiation of programmes concerning quality assurance in surgical 
oncology (QASO) will be discussed later. 
 
SURGERY SUBCOMMITTEES - Table 1 shows the presence of a surgery 
subcommittee for the individual groups. In all groups, except for the GUTCG 
either a surgery committee or a loco-regional control subcommittee 
(STBSG/BCG) is present. Although there is no surgery subcommittee in the 
GUTCG, this group has been active concerning QASO. Subcommittees per 
tumour type have initiated QASO programmes in their fields. 
 
The main task of the surgery subcommittees is to design and develop surgical 
trials or trials related to loco-regional therapy. Some subcommittees also write 
the surgical part of the protocols and/or are responsible for the development 
of a QASO programme. 
 
PATHOLOGY SUBCOMMITTEES - A pathology subcommittee is present in all 
groups except for the RTG (table 1). The majority of the pathology 
subcommittees are focused on pathology review, either systematic (EOI and 
STBSG) but more often incidental (remaining groups). This procedure will 
ensure the quality of staging, but obviously cannot evaluate the quality of 
surgery. Only several blocks of the specimen will be available to the reference 
pathologist, which will not allow a correct evaluation of resection margins 
and/or the number of resected lymph nodes. Other fields of interest are 
translational research and standardising pathology reporting. The latter 
initiative is undertaken through a detailed description of the information to be 
reported as well as through specific data collected in the CRFs (EOI, HNCG, 
LCG and STBSG).  
 
evaluation of clinical trial protocols 
 
The 23 selected protocols and case report forms (CRFs) have been evaluated 
with respect to parameters of interest in the fields of surgery and pathology, 
which is shown in the appendix. Table 4 shows the overall ‘score’ for these 
parameters within the different clinical research groups. A particular 
attribution has been paid to the extent of the descriptions of surgical and 
pathological procedures in the protocol and the way the adherence to these 
guidelines was checked in the CRFs. The extent of the descriptions has been 
categorised into: no description (-), limited guidelines (+/-), general guidelines 
(+), detailed description (++) and precise description (+++).  
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The minimum criteria to evaluate the surgical intervention include the type of 
surgical procedure, the extent of local surgery and the extent of the 
lymphadenectomy. The margins of resection and the number of (resected and 
involved) lymph nodes were considered as minimum criteria for the reporting 
of the pathological examination. Consequently, a minus in the table means, 
that this information was not collected on the CRFs, a +/- indicates that the 
criteria were partially met, a + means that these items were collected. More 
detailed CRFs were rewarded with an increasing number of pluses. Other 
parameters checked included the collection of the original surgery and/or 
pathology reports and pathology review. 
 
Table 4: Evaluation of trials  
 
Surgery Pathology Radiology Group nam
e 
N
um
ber of 
selected trials 
P
rotocol 
C
R
F 
P
rotocol 
C
R
F 
C
ollection original 
reports surgery 
and pathology 
P
athology review
 
P
rotocol 
C
R
F 
Q
A
S
O
 
BCG 3 + + +/- + - - + + +/- 
EOI 1 + ++ + + - + + ++ - 
GITCG 4 ++ ++ +/- + - - - +/- +/- 
GUTCG 3 + ++ + ++ +/-PA +/- + +/- - 
GCG 4 + + +/- +/- +/-Surg/PA +/- + +/- +/- 
HNCG 1 + +++ + +++ - - + + + 
LCG 2 +++ +++ +/- +/- +Surg/PA - + + + 
MG 1 ++ + +/- ++ +PA + + + - 
RTG 3  +/- + +/- + +/-PA +/- + +/- - 
STBSG 1 ++ ++ ++ + +PA + + + - 
 
- = not present; +/- = partially present; + = meets minimum criteria; ++ = detailed; +++ = precise; QASO = Quality Assurance in Surgical Oncology;  
CRF = Case Report Form; PA = Pathology; Surg = Surgery. The appendix contains the results of the evaluation of the separate protocols 
 
The quality of pre-operative imaging is also very important in many tumours. 
Although it is impossible to check the quality of pre-operative imaging, it was 
checked whether the protocol contained an adequate description of 
radiological evaluations required and whether this was checked on the CRF. 
 
By evaluating the different protocols, it has become clear, that the majority of 
the groups do not have a general strategy on the description and reporting of 
surgery and pathology. For example, some groups had well-designed 
descriptions and documentation in one trial, but in other trials, hardly any 
attention was paid to the same topics. During the years, however, the 
attention to the extent of the description and the reporting has increased. 
 
Most groups meet the minimum criteria for the description of the surgical 
procedure in the protocol. It may, however, be necessary to state that these 
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minimum criteria are general guidelines only. Therefore they might not be 
sufficient for a proper quality control of the operative procedure.  
 
Guidelines on the reporting of pathology are generally less detailed than the 
surgical guidelines, although the minimum criteria mentioned before are 
usually checked on the CRFs. About half of the groups collect original 
(pathology and/or surgery) reports and compare them with the data 
submitted on the CRFs. This is performed either systematically (LCG) or in 
specific protocols (GUTCG, GCG, MG, RTG and STBSG). Although 
precise results are not yet known, it has become clear that the audit of data 
consistency in these fields is as important as in any other field. 
 
Concerning programmes on quality assurance, it was remarkable, that hardly 
any of the groups described the quality assurance procedures in the section 
‘quality assurance’, which is a standard section of the protocols. These 
procedures were specified within the sections concerning surgery. The +/- 
sign in the table (in the QASO-column) indicates that QASO-programmes are 
designed for specific protocols and not on a structural basis. In the GITCG, 
GCG and HNCG-protocols with a quality assurance programme, and in 
some of the GUTCG protocols, a drawing of the extent of resection should 
be kept in the clinical record. 
 
Currently, required pre-operative radiological examinations are outlined in all 
protocols (with an exception of some trials of the GITCG). The performance 
of mandatory radiological examinations is virtually always checked. The 
results of recommended follow-up evaluations are usually not requested on 
the CRFs. 
 
projects in quality assurance in surgical oncology  
 
This section describes the efforts of the groups in the field of quality 
assurance in surgical oncology. Table 5 shows the projects in the different 
groups. This table gives an overview of the publications and subjects of 
ongoing projects per group. 
 
BREAST CANCER GROUP (BCG) - In 1991, the group published its first manual 
for clinical research in breast cancer in an effort to standardise as many 
aspects of diagnosis and treatment as possible33. The manual has been 
updated several times, with the most recent version published in 200034. 
Although this resulted in standardised descriptions of the surgical procedures, 
this could not immediately be translated into a standardised documentation of  
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Table 5: Projects in the field of quality assurance in surgical oncology 
 
Group 
name 
Title article/project Name first 
author 
Journal name Year 
publication 
BCG 
 
- Manual for clinical research in breast cancer BCG n.a.  1991 (1st)–
2000 (last) 
 - Quality assurance of surgery in clinical trials Fentiman European Journal of 
Cancer 
1994 
 - Documentation of the surgical procedure: a 
tool for quality assessment for breast 
conservative treatment 
Christiaens Anticancer Research 1996 
 - More detailed documentation of the operative 
procedures in breast conserving treatment: 
what good will it do to us? 
Christiaens European Journal of 
Surgical Oncology 
1996 
 - Comparison of the surgical procedures for 
BCT of early breast cancer in seven EORTC 
centres 
Christiaens European Journal of 
Cancer 
1996 
 - CRFs as a tool for quality assurance: 
consistency with guidelines in the protocols 
Christiaens Not yet published 2001 
 - Long-term results of a randomised trial 
comparing breast conserving therapy with 
mastectomy: EORTC no 10801 trial 
Van Dongen Journal of the 
National Cancer 
Institute 
2000 
 - Quality assurance of the sentinel node 
procedure in breast cancer 
BCG n.a. ongoing 
project 
 - Analysis of old trials investigating the 
possible relationship between local tumour 
control and survival 
BCG n.a. future 
project 
EOI - Effect of local recurrence on survival in 
resected osteosarcoma 
Weeden European Journal of 
Cancer 
2001 
 - Surgical outcomes in osteosarcoma Grimer Journal of Bone and 
Joint Surgery British 
Volume 
2002 
GITCG - Manual for diagnosis and treatment of 
gastrointestinal cancer 
Wils n.a. 1993 
 - Prognostic factors in resectable gastric 
cancer: results of EORTC study no 40813 on 
FAM adjuvant chemotherapy 
Lise Annals of Surgical 
Oncology 
1995 
 - Final results of a phase III clinical trial of 
adjuvant chemotherapy in resectable gastric 
cancer 
Lise Journal of Clinical 
Oncology 
1995 
 - Total mesorectal excision with or without 
preoperative radiotherapy in primary rectal 
cancer: no 40971 
GITCG Not yet published n.a. 
 - Adjuvant chemotherapy in resectable gastric 
cancer: no 40905 
GITCG Not yet published n.a. 
GUTCG - Treatment of superficial bladder tumours: 
achievements and needs 
Kurth European Urology 2000 
 - Quality control of radical prostatectomy: a 
feasibility study 
Van Poppel European Journal of 
Cancer 
2001 
 - Variability in the recurrence at first follow-up 
cystoscopy after TUR in stage TaT1 
transitional cell carcinoma of the bladder: a 
combined analysis of seven EORTC centres 
Brausi European Urology 2002 
 - How is radical nephrectomy performed over 
Europe: analysis of differences 
Kirkali Not yet published 2001 
GCG - Quality control in multicentric clinical trials Favalli European Journal of 
Cancer 
2000 
 - No 55971 GCG n.a. ongoing 
HNCG - No 24954 HNCG n.a. ongoing 
 - Standardising surgery and pathology case 
report forms 
Surgery and 
Pathology 
Subcommittee 
n.a. ongoing/ 
future 
LCG - No 08941 LCG n.a.  ongoing 
 - No 08981 LCG n.a.  ongoing 
 119 
Group 
name 
Title article/project Name first 
author 
Journal name Year 
publication 
 - Standardising forms for registration LCG n.a. ongoing 
MG - Surgical quality control in an international 
randomised clinical trial 
Schraffoordt 
Koops 
European Journal of 
Surgical Oncology 
1992 
 - Quality assurance of the sentinel node 
procedure 
MG n.a.  ongoing 
RTG - Interinstitutional differences in the boost 
versus no boost trial 
Bartelink Not yet published 2001 
STBSG - Quality Control in Surgery RTG n.a. ongoing 
 
n.a. = not applicable 
 
the procedure actually performed35. With the aim of developing a standard 
surgical report for breast conserving therapy, the surgical procedure was 
translated into a series of steps that could be quantitatively documented35. 
Between 1993 and 1994, a comparison was made of the surgical procedures 
for breast conserving treatment in seven EORTC centres. Even though the 
participating centres were involved in a single trial and had previously 
developed regular contacts about the practical aspects of treatment, many 
differences were detected. The need for a stricter set of guidelines was 
stressed, especially in conducting clinical trials36-38. Consequently, the 
standardised report was used in one of the EORTC-trial35. Unfortunately, this 
trial was closed prematurely because of insufficient accrual of patients. 
 
In 2000 the long-term results of the 10801 trial39 (comparing breast-
conserving therapy with mastectomy) in which patients had been entered 
between 1980 and 1986 were published. As part of the analysis, differences 
were calculated concerning local recurrences among the participating centres. 
These variations ranged from 10.5% to 36% after breast conserving therapy 
and from 4.6% to 21.3% after mastectomy. 
 
Recently, the group opened the AMAROS-trial (protocol no 10981: after 
mapping of the axilla: radiotherapy or surgery), which contains an extensive 
programme on quality assurance of the sentinel node procedure. In order to 
participate in the study surgeons should follow a training course and complete 
the learning phase for this procedure. Strict quality control guidelines are 
defined and they will be checked by review of the documented procedures 
and site visits. Quality assurance procedures for the related specialties have 
also been developed. One of the future plans is the analysis of old trials to 
investigate the possible relationship between local tumour control and 
survival40.  
 
EUROPEAN OSTEOSARCOMA INTERGROUP (EOI) - The effect of local recurrence 
on survival in resected osteosarcoma was recently highlighted in a paper of 
the group41. The remarks made in this paper on the consistency of the data, 
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were of interest for our study. The trial data suggested that 64 (11%) of the 
570 patients had a local recurrence. After verification of these data using the 
definition of local recurrence in the protocol, the reported local recurrences 
appeared to be unjustified in 19 of the 64 patients (29.7%).  
 
In a second study, the influence of surgical therapy on outcome was 
evaluated. Additional data on surgical methods and outcomes of 202 patients 
were collected. These patients had been treated by three centres, attributing 
the majority of patients in the trial. Between the centres a variation in local 
recurrence rates was found ranging from 2.5% to 13.3%. A clear relationship 
was found between the extent of surgery and local recurrence rates. The 
centre with the low local recurrence rate had a very high (51%) rate of 
amputation compared with the other centres (15% and 17%). Interestingly, 
the survival curves for patients having an amputation at all three centres were 
virtually the same.  
 
GASTROINTESTINAL TRACT CANCER GROUP (GITCG) - Similar to the BCG, the 
GITCG published a Manual for diagnosis and treatment of gastrointestinal 
tract cancer in 199342.  
 
In the years 1994-1995, the group performed a retrospective study on the 
‘adequacy’ of surgery for gastric cancer as a prognostic factor in resectable 
gastric cancer, with the use of the surgery and pathology data of trial no 
4081343,44. The adequacy of surgery was judged on the extent of regional 
lymphadenectomy in relation to tumour site. Among the 309 patients 
analysed, it was found that adequate surgery had been achieved in only about 
33% of the cases. Moreover, this study demonstrated that in Europe in the 
early 1990s approximately ten different surgical approaches were used for the 
treatment of gastric cancer. It was evident that the institutions with the 
highest number of registered patients, and therefore with a wider experience 
of gastric cancer, tended to follow the guidelines suggested for adequate 
surgery more uniformly than those with fewer patients. The comparison made 
between the data in the surgical and pathology forms was useful in assessing 
the quality of surgery. This was used to define the criteria for surgery in 
protocol no 40905. Moreover, it enabled a selection of the participating 
institutions. A commitment statement on the performance of the specified 
surgical procedure by the investigators was required, before participation was 
accepted.  
 
Furthermore, the group participated in the Dutch TME study (EORTC no 
40971), in which a QASO programme was implemented. However, only 42 
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EORTC patients could be included. The low accrual by the EORTC was 
mainly due to the quality assurance requirements. Logistical aspects, related to 
supervision of operations by a limited numer of specialised surgeons, formed 
the main restricting factors. Conditions, which are very feasible within one 
country, appeared to be much more difficult to easily implement across 
different European countries.  
 
The attention of the group to the importance of the quality of surgery is 
further emphasised by the organisation of a symposium in April 2001 called 
‘The Surgeon as a Prognostic Factor’.  
 
GENITO-URINARY TRACT CANCER GROUP (GUTCG) - Differences in local 
recurrence rates for superficial bladder cancer at 3 months after complete 
resection have been analysed recently45. The data of 2655 patients of 18 
different institutions treated between 1975 and 1986 were analysed. The study 
revealed wide variations in local recurrence rates between the institutions: 0% 
to 36% for single tumours and 7% to 75% for multiple tumours. The 
variation between institutions remained unexplained and is currently subject 
of further investigation. 
 
The group also performed a feasibility study on the quality control in radical 
prostatectomies46. Detailed information on the surgical procedure was 
collected by means of questionnaires (232 patients treated in 23 institutions). 
The mean values for each parameter were very different in the various 
centres. However, the outcomes in terms of tumour control and incontinence 
could not be related to the number of radical prostatectomies performed. The 
authors concluded that quality control of radical prostatectomies is feasible on 
the basis of very few parameters that can recognise centres that perform 
better or worse than a proposed average. 
 
A current project of the group is a prospective survey on the performance of 
radical nephrectomy in renal cell carcinoma. By means of questionnaires it is 
attempted to document the technique(s) of radical nephrectomy in Europe 
and to investigate the feasibility of quality control measures in this procedure. 
Preliminary results of 136 patients operated on by 37 urologists will be 
presented at the European Association of Urology (EAU) in April 200147. 
From these results it was found that although clear differences in surgical 
approach and management do exist, one cannot conclude from these data 
that one urologist is doing better than another. 
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GYNECOLOGICAL CANCER GROUP (GCG) - The results of the project of the GCG 
on quality control were published in 200024. Although this study revealed 
interesting information on data consistency and quality assurance in 
chemotherapy, it did not address any aspect of quality assurance in surgery. In 
the presently open trial no 55971 (Neo-adjuvant chemotherapy in advanced 
ovarian cancer followed by interval debulking surgery versus primary 
debulking surgery followed by chemotherapy) it was stated that the operations 
should be performed by senior surgeons only. Detailed guidelines on the 
surgical procedure and reporting are provided by the protocol. Hospital 
reports of surgery and pathology are collected and a site-visit programme has 
been undertaken.  
 
HEAD AND NECK CANCER GROUP (HNCG) - The HNCG has a quality control 
programme in its larynx preservation trial no 24954 (Phase III study on larynx 
preservation comparing induction chemotherapy and radiotherapy versus 
alternating chemo-radiotherapy in resectable hypopharynx and larynx 
cancers). In this trial, the operability must be assessed by a head and neck 
surgeon. A precise sketch of the local and nodal extension must be kept in the 
clinical record. The protocol provides general guidelines concerning the 
extent of surgery and the levels of lymph nodes that should be resected. 
Essential elements on the reporting of pathology are clearly described. All 
recommendations are checked on the CRFs. Quality control will pay attention 
to the radicality of the operation and the completeness and proper 
examination of the lymphadenectomy. This information will be evaluated on 
the basis of the data provided on the CRFs.  
 
This group is also currently working on a project aiming at the design of 
standard operative and pathology reports. Moreover, they have recommended 
the use of specific guidelines on the reporting of the pathological 
examination. These are used by approximately 80% of the pathologists when 
patients are entered into the trial. In common practice the guidelines are 
generally not used. This is considered as a problem because patients are 
randomised after the diagnosis is confirmed by pathological examination. To 
encourage the participation of the pathologists of the member institutions and 
the use of the proposed guidelines in common practice, the group invited the 
pathologists of the largest institutions to discuss that face to face during a 
group meeting. 
 
LUNG CANCER GROUP (LCG) - The LCG has focused its attention on adequately 
documenting the performed surgery (procedure and complications) and 
pathology. This was implemented in the currently open trial in which surgery 
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is an important part of the treatment (no 08941, Surgery versus radiotherapy 
in patients with stage IIIa non-small cell lung carcinoma (NSCLC) after a 
response to induction chemotherapy). The protocol contains a detailed 
description of the required surgical procedure and a drawing indicating the 
exact location of the described regional lymph nodes. Detailed CRFs are 
compared with the original (hospital) forms for consistency. The same 
method of quality control is planned for a trial that will be opened soon (no 
08981-phase II-trial, which evaluates the effect of surgical treatment of stage 
IIb NSCLC after induction chemotherapy). 
 
MELANOMA GROUP (MG) - The MG has been a pioneer in the field of quality 
assurance of the surgical procedure. In the isolated limb perfusion trial (no 
18332, opened in 1984) a quality assurance programme was performed. With 
general meetings and site-visits, the percentage of protocol violations could be 
reduced from 28% to 11%26. Currently, the Melanoma Group is defining 
standard guidelines and CRFs for quality control in sentinel lymph node 
dissections.  
 
RADIOTHERAPY GROUP (RTG) - The RTG usually performs its trials in 
collaboration with one of the disease oriented groups. It therefore does not 
have a general strategy regarding the quality (control) of surgery.  
 
SOFT TISSUE AND BONE SARCOMA GROUP (STBSG) - The group recently designed 
standard reports on all aspects related to the quality of surgery. This includes 
the pre-operative examination and treatment, detailed documentation of the 
performed surgery (and post-operative complications) and adequate reporting 
of the histological examination.  
 
 
Within the groups several ideas concerning the methods of quality assurance 
in surgical oncology are currently under discussion. Site-visits is one of the 
methods mentioned most frequently. Although this is expected to be the 
most effective way to check the quality of the operative procedure, the groups 
do not have the financial funding to put this into practice. Video-taping 
would be less costly, but it would still require a lot of time to audit and is less 
effective. Training sessions could be helpful especially in technically complex 
procedures or for the implementation of new techniques. Similar sessions 
were also mentioned to be of importance for pathologists in order to 
encourage the accuracy of their reporting.  
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A method of quality control, already implemented in some groups, is the 
design of specific guidelines for the descriptions of surgery in the protocol 
and standard items on the CRFs. The GUTCG and GCG are now discussing 
this procedure as well. An idea brought up by the EOI was to design a case 
study and to require each surgeons’ view on adequate treatment. This would 
enable a discussion on the adequacy of treatment in similar cases. 
Furthermore it was mentioned that since objective criteria to assess the quality 
of surgery are not yet available, adequate reporting of the performed 
procedures should be the first step in the process. 
 
 
discussion 
 
It has become clear that there is an increasing awareness of the importance of 
quality assurance in surgical oncology in all of the EORTC clinical research 
groups. This can be concluded from the implementation of quality assurance 
questionnaires, a trend to a more detailed description and documentation of 
the surgical procedures and increasing efforts to use some kind of quality 
assurance in surgery-related trials. Despite successful projects in the past by 
individual groups and promising ongoing and future initiatives, the 
implementation of quality assurance in surgical oncology requires a more 
structural approach. This was emphasised by the EORTC Scientific Strategy 
Meeting in 19991 and during the EORTC site-visit by the National Cancer 
Institute (NCI) in 2000.  
 
The NCI is facing the same dilemma in the US and has changed its strategy 
accordingly. The bottom-up approach has been replaced by a top-down 
approach. In the bottom-up strategy the groups decide on the initiation of a 
quality assurance programme and are responsible for the funding of the 
programme. Using the top-down approach, the importance of quality control 
is acknowledged by the top and the implementation of quality assurance 
programmes is encouraged by providing funding for the development of 
projects. This has resulted, in recent years, in initiatives in the fields of breast 
cancer48, colorectal cancer and melanomas, with a variable rate of success. 
Similarly, the EORTC quality assurance committee (QAC) could play an 
important role in order to implement a structured strategy concerning quality 
assurance in surgical oncology. One aspect should be to encourage the use of 
a more uniform quality assurance questionnaire, especially regarding 
information on the surgical departments. Furthermore it would be 
recommendable to define guidelines on the descriptions of required 
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procedures and reporting in the protocols concerning radiology, surgery and 
pathology. Although the Protocol Review Committee (PRC) currently 
requires detailed descriptions, no clear guidelines are yet available. More 
attention to the performance and quality of pre-operative diagnostics would 
also be appropriate, because these very often form the basis in the assessment 
of the operability of the tumour and the extent of resection. Moreover, 
guidelines on the reporting of pathology should be provided since these could 
contribute substantially to the audit of the performed operation. Adequate 
reporting and collection of data could be implemented by defining minimum 
criteria for the CRFs. The consistency of these data should be checked by 
collection of the hospital/original reports and comparing them with the data 
collected on the CRFs. The efficacy and necessity of this kind of evaluation 
was clearly shown in the Dutch TME-study49, a multi centre randomised 
clinical trial applying pre-defined standards of surgery, radiotherapy and 
pathology in rectal cancer.  
 
However, even if guidelines and adequate documentation are provided, it will 
remain a difficult task to audit the (quality of the) performed surgery. There 
are some major restricting factors in the quality assurance of surgery: the 
methods of quality control and the funding of potentially successful 
initiatives. Both factors are of importance when comparing strategies in 
quality assurance between either radiotherapy or chemotherapy and surgery. 
Whereas the performance of a radiotherapist and a medical oncologist are 
quantifiable and therefore objectively measurable, the performance of the 
surgeon consists of a multi-step procedure, which is dependent on the 
individual. Documentation of the surgical procedure is only representative for 
the actual performance to a limited extent, considering the fact, that it is 
impossible to document each single step. Therefore, the most effective, but 
costly solution remains a personal audit of the surgeon in the operating 
theatre. The logistic difficulties of the implementation of this kind of quality 
control in Europe should not be underestimated. This has been illustrated by 
the low accrual of the EORTC in the TME-study: the feasibility of a national 
system cannot be translated in a pan-European success automatically.  
 
Apart from the variability in the quality of operations themselves, the quality 
of surgery is related to the quality of pre- and post-operative staging (i.e. 
quality of radiology and pathology), as was mentioned before. These 
disciplines should therefore be included in quality assurance programmes 
focused on surgical oncology. A joint approach of the responsible specialists 
would be useful in the development of quality assurance criteria in surgical 
oncology. The need for further discussion amongst specialists of new 
 126 chapter 4 
methods to be applied specifically to this area has been expressed by the 
subcommittee chairmen. The best opportunity for this meeting would 
probably be at the next conference organised by the European School of 
Surgical Oncology (ESSO) which will take place in 2002.  
 
Concerning funding, the situation is also different in chemotherapy compared 
to surgery. In chemotherapy, trials are frequently financed by the 
pharmaceutical industry, which obviously does not apply to surgery. This in 
combination with the complexity of surgical quality control on its own 
emphasises the need for a structural top-down approach. The EORTC Board 
has recently decided to encourage a structural development in quality 
assurance in surgical oncology. As part of this programme, a research fellow 
will be appointed for several years. However, the tasks of such a fellow will 
only enable adequate co-ordination and development of methods of quality 
control. To put these systems into practice, additional funding will be 
essential. In the past the EORTC quality assurance programmes in 
radiotherapy and chemotherapy have been funded in part by grants from the 
European Union (EU). As the impact of the quality of surgical oncology is 
now generally acknowledged, it would be appropriate for the EU to support 
such programmes as well. 
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appendix 
 
Evaluation of trials 
 
Surgery Pathology Radiology 
G
roup nam
e 
S
elected trial 
no 
P
rotocol 
C
R
F
2 
P
rotocol 
C
R
F
2 
O
riginal 
reports 
surgery and 
pathology 
P
athology 
review
 Protocol 
C
R
F
2 
Q
A
S
O
1 
BCG 10963 -3 - -3 + - - + + - 
 10974 ++ -4 -3 -4 - - + -4 - 
 10981 +++5 ++ ++ ++ - - ++ ++ +  
EOI 80931 +6 ++ + -7 - + + ++8 - 
GITCG 409059 +++ +++ +++ +++ - - -10 - +/-11 
 409119 -3 +/- -3 +/- - - -10 - - 
 40954 ++ +++ ++ ++ - - + + - 
 40983 ++12 ++ - +/- - - + +/- - 
GUTCG 30904 + ++ + ++13 PA + + +/- +/-11 
 30955 + + + ++13 - - + - +/-11 
 30994 + -4 - -4 - - + -4 - 
GCG 55874 -3 + +/- +/- PA + + + - 
 55971 +++ +++ - +/- Surg+PA - + + +/-11 
 55981 + + + + - - + +/- - 
 55991 +/- +/- +/- +/- - + + - - 
HNCG 24954 + +++ +/-14 +++ - - + + + 
LCG 08941 +++ +++ +/- +/- Surg+PA - + + +/-11 
 08981 +++ -4 +/- -4 Surg+PA - + -4 + 
MG 18991 ++ + +/- ++13 PA + + + - 
RTG 22911 + + ++ + PA + + + - 
 22921 +/- ++ +/- +++ - - + + - 
 22922 -3 + +/- +/-15 - - + - - 
STBSG 62931 ++ ++ ++ -16 PA + + + - 
 
- = not present; +/- = partially present; + = meets minimum criteria; ++ = detailed; +++ = precise; PA = pathology; Surg = surgery. 
1 = quality assurance in surgical oncology; 2 = case report form; 3 = no paragraph on pathology and/or surgery, requirements can only be found in the 
eligibility/stratification criteria; 4 = not yet available; 5 = very detailed on sentinel node procedure, minimum criteria on local treatment; 6 = short 
description, but more detailed information can be obtained; 7 = only margin status is required, however, pathology-review will be performed; 8 = CRF info 
and collection of hard copies; 9 = closed in 1998; 10 = no preoperative requirements, but recommended follow-up evaluations; 11 = no official quality 
assurance programme, but drawings, etc to check the extent of surgery; 12 = aimed at resection of liver metastases. No description of surgery for the 
primary tumour, on CRF minimum criteria present, except for margin status; 13 = no information on number or ratio of lymph nodes; 14 = to be found in the 
quality assurance paragraph; 15 = margin status not requested; 16 = original pathology report is used in stead of a CRF 
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abstract 
 
INTRODUCTION - The aim of the study was to determine the clinical usefulness 
of scintimammography as a complementary method in patients with equivocal 
mammographies. Patients were divided into four subgroups to evaluate the 
value of scintimammography according to the indication for further analysis: 
dense breasts on mammography, previous breast surgery, discrepancies 
between physical examination and mammography and discrepancies between 
mammography and diagnostic biopsy procedures. Moreover a comparison 
was performed between scintimammography and magnetic resonance imaging 
(MRI) in all patients in whom both diagnostic methods were used.  
 
PATIENTS AND METHODS - One-hundred-and-seventy-five scintimammo-
graphies were performed in 161 female patients. Each patient had a physical 
examination and mammography prior to the scintimammography procedure. 
Thirty-two patients also underwent MRI. Imaging results were either 
confirmed by pathological examination (n =106) or patients were subjected to 
a follow-up programme (n = 69).  
 
RESULTS - Malignant lesions were found in 19% of all cases. Sensitivity, 
specifity, positive predictive value and negative predictive value for all patients 
were 50%, 92%, 61% and 88% for mammography; 71%, 85%, 53% and 92% 
for scintimammography and 90%, 73%, 60% and 94% for MRI. Analysis of 
subgroups revealed best results for scintimammography in patients with dense 
breasts (sensitivity increased from 33% to 100%, although specificity 
decreased from 98% to 88% compared to that of mammography). In 
combination with mammography both scintimammography and MRI are 
helpful adjuncts in distinguishing benign from malignant disease in patients 
with indeterminate mammographies. Most favourable sensitivity is found for 
MRI (90% vs 71%), whereas scintimammography shows better specificity 
rates (85% vs 73%).  
 
CONCLUSION - Currently, a tendency is found towards the more frequent use 
of MRI instead of scintimammography. However, it would be interesting to 
investigate the role of scintimammography as an additional clinical tool in 
patients with a positive MRI because of the high sensitivity and relatively low 
specificity of MRI since it is a non-invasive, cheaper investigation and is 
better available than invasive MRI-guided biopsy to investigate the found 
lesion. 
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introduction 
 
Mammography, used as a screening method, has been demonstrated as a 
significant benefit for the survival of breast cancer patients older than 50 
years1. In younger patients this benefit is limited2 due to a more difficult 
interpretation of mammography. Factors that complicate the mammographic 
diagnosis of breast cancer are dense glandular tissue3, previous breast surgery, 
breast implants and radiation therapy4. Further investigations are therefore 
often required in women belonging to these groups.  
 
In the past decade both scintimammography and magnetic resonance imaging 
(MRI) have been found to be useful diagnostic tools in patients with 
indeterminate mammographies. The value of scintimammography was proven 
by three prospective multi centre studies5-8. Scintimammography is helpful in 
dense breasts in particular7 and in the diagnosis of primary breast lesions with 
a diameter of more than 1 cm. MRI has shown its merits as a diagnostic tool 
in the same group of patients9-11. Literature comparing both techniques is 
limited but provides higher sensitivity but lower specificity rates for MRI9-15. 
 
It was the purpose of this study to determine the value of 
scintimammography in several subgroups of patients according to the 
indication for further analysis. If both scintimammography and MRI were 
performed in the same patients, the additional diagnostic methods were 
compared.  
 
 
patients and methods 
 
PATIENTS - Data of 161 consecutive patients with 57 palpable and 118 non 
palpable lesions, who underwent 175 Tc-99m sestamibi scans between 1999 
and 2002 were retrospectively reviewed. The mean and median age of the 
patients was 49 years (range 15 to 80 years). Each patient had a physical 
examination and a bidirectional mammography prior to the 
scintimammography procedure.  
 
In 32 patients additional MRI was obtained during the same period. The 
number of MRIs increased and the number of scintimammographies 
decreased since 1999: in 1999 7% of patients were subjected to MRI 
compared to 75% in 2002. The results of diagnostic imaging were confirmed 
by pathological examination in 106 patients. The remaining 69 patients were 
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subjected to a follow-up programme with a mean period of 28 months. 
During follow-up neither invasive nor in situ cancers were diagnosed in this 
group. The lesions found were therefore considered as benign.  
 
Patients were subdivided according to the indications for 
scintimammography: dense breasts on mammography (DB), previous surgery 
(PS), discrepancies between physical examination and mammography (PE) or 
discongruencies between mammography and diagnositic pathologic 
examinations (MAM). Data are shown in table 1. The following inclusion 
criteria were used: 
• Dense breasts if patients had dense glandular breast tissue, which leads to a 
difficult interpretation of conventional mammographies5.  
• Previous surgery could have been carried out ipsilateral, contralateral or on 
both sides, including breast conserving therapy, breast reduction or 
reconstructive surgery.  
• Abnormal physical examination was the reason for scintimammography in 
a group of patients with nipple discharge, a retracted nipple, pain, mastitis 
(especially in the elderly) or palpable abnormalities in the breast or axilla 
with no abnormalities on mammography. 
• The mammography group encompassed primarily patients with non 
palpable abnormalities in which pathological evaluation was non 
suspicious, inconclusive or impossible.  
 
Table 1: Results subgroup analysis  
 
 DB PE MAM PS Total 
Median age (range) 40 (15-63) 48 (29-79) 56 (47-68) 55 (31-80) 49 (15-80) 
Malignant (n=) 3 7 9 15 34 
Benign (n=) 59 24 15 43 141 
Total (n=) 62 31 24 58 175 
Sensitivity Xm  33%  57%  89% 27%  50% 
Sensitivity SSM  100%  86% 56% 67% 71% 
Specificity Xm  98% 92% 73% 91% 92% 
Specificity SSM  88% 63% 100% 88% 85% 
 
DB = Dense Breasts; PE = Physical Examination; MAM = Equivocal Radiology; PS = Previous Breast Surgery; Xm = Mammography;  
SSM = Scintimammography 
 
MAMMOGRAPHY - Mammographies were obtained in oblique and cranio-caudal 
directions and were classified according to the BI-RADS lexicon. 
Mammographies classified as BI-RADS four (suspicious abnormality) and five 
(highly suggestive for malignancy) were considered as positive for malignancy.  
 
SCINTIMAMMOGRAPHY - The radionuclide imaging was performed 5-10 minutes 
after intravenous injection of 740 MBq Tc-99m sestamibi. The patient was 
examined successively anterior, right and left lateral and lying on both sides. 
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Scintimammographies with focal or patchy diffuse uptake in at least one 
planar image of the breast were reported as positive for malignancy. Diffuse 
uptake without focal accumulation and homogenous uptake of tracer in both 
breasts was classified as negative.  
 
MAGNETIC RESONANCE IMAGING (MRI) - MRI was performed on a 0.5-T- (n=27) 
and a 1.5-T- (n=5) clinical MR system. A phased-array bilateral breast coil was 
utilised with patients placed in prone position. Intravenous contrast material 
(0.1 mmol gadolinium per kilogram body weight) was administered in all 
patients and a dynamic study was obtained in a minority of patients. Based on 
the morphological characteristics and patterns of enhancement, the lesions 
were classified according to the BI-RADS-MRI lexicon. BI-RADS four 
(suspicious abnormality) and five (highly suggestive for malignancy) were 
considered as positive for malignancy. 
 
Analysis of the scintimammographies was based on the existing written 
reports. Mammographies and MRI examinations were classified by three 
radiologists without knowledge of further results.  
 
PATHOLOGY - Pathology was obtained if indicated on the basis of clinical 
evaluation and/or additional imaging. Pathological examinations varied from 
fine needle aspiration, large core needle biopsy and surgical biopsy to 
mastectomy. All invasive and/or in situ cancers were classified as 
malignancies. 
 
 
results 
 
Of the 175 lesions, 34 appeared to be malignant (19%), whereas 141 lesions 
were benign. Table 2 shows the results of mammography and 
scintimammography. The corresponding number of malignancies is given in 
brackets. 
 
Seventeen of 28 mammographies that were described as positive for 
malignancy gave the correct diagnosis (61%), compared to 24 of 45 positive 
scintimammographies (53%). If both mammography and scintimammography 
were positive, the malignancy rate was 81% (13/16), if both were negative 112 
of 118 (95%) lesions were benign. Consequently, in case of a false negative 
mammography, scintimammography was able to detect 11 additional 
malignancies in a group of 29 (40%). However, four out of 12 (33%) lesions 
were malignant in case of a suspicious lesion on mammography in 
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combination with a non suspicious scintimammography. In the six patients 
with malignant disease, in whom both mammography and 
scintimammography were non suspicious, ductal carcinoma in situ (DCIS) 
was found in three and invasive ductal carcinoma in the remaining three 
patients. 
 
Table 2: Outcome of mammography and scintimammography 
 
 Xm positive Xm negative Total 
SSM positive 16(13) 29(11) 45(24) 
SSM negative 12(4) 118(6) 130(10) 
Total 28(17) 147(17) 175(34) 
 
Xm = Mammography; SSM = Scintimammography; in brackets: number of malignancies 
 
SUBGROUPANALYSIS - Previously defined subgroups consisted of the following 
numbers of patients: dense breasts (DB) in 62 cases, physical examination 
(PE) in 31, equivocal radiology (MAM) in 24 and previous breast surgery (PS) 
in 58. In table 1 the median age and absolute numbers of malignant and 
benign lesions are given for each subgroup as well as sensitivity and specificity 
rates for mammography and scintimammography per subgroup. Best results 
for scintimammography were found in patients with dense breasts with an 
increase in sensitivity from 33% to 100%, although specificity decreased from 
98% to 88% as compared to mammography.  
 
MRI VERSUS SCINTIMAMMOGRAPHY - MRI was performed in 32 patients. 
Results of MRI as compared to scintimammography for the overall group are 
shown in table 3. Of the 15 positive examinations, 9 could histologically be 
confirmed. However, in case of a negative MRI, 16 of 17 findings were 
benign. In all four patients with MRIs suggestive for malignant disease in 
combination with negative scintimammographies, either fibrocystic breast 
tissue, a scar lesion or adenosis were found. Only one of 14 patients with both 
non suspicious MRIs and scintimammographies appeared to have malignant 
disease, which was an invasive lobular carcinoma. Further evaluation 
combining mammographic, scintimammographic and MRI results did not 
reveal additional information. 
 
Sensitivity, specificity, positive predictive value and negative predictive value 
were calculated (table 4). Both scintimammography and MRI resulted in 
better overall results than mammography. Comparing MRI and 
scintimammography, most favourable sensitivity was found using MRI (90% 
versus 71%), highest specificity using scintimammography (85% versus 73%). 
Table 5 shows more detailed results of pathological evaluation. 
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Table 3: Outcome of scintimammography and MRI 
 
 SSM positive SSM negative Total 
MRI positive 11(9) 4(-) 15(9) 
MRI negative 3(-) 14(1) 17(1) 
Total 14(9) 18(1) 32(10) 
 
SSM = Scintimammography; MRI = Magnetic Resonance Imaging; in brackets: malignancies 
 
Table 4: Results of SSM, MRI and X-ray mammography 
 
 Xm SSM MRI 
Sensitivity 50% 71% 90% 
Specificity 92% 85% 73% 
PPV 61% 53% 60% 
NPV 88% 92% 94% 
 
PPV = Positive Predictive Value; NPV = Negative Predictive Value; Xm = Mammography; SSM = Scintimammography; MRI = Magnetic Resonance 
Imaging 
 
Table 5: Results of pathological evaluation 
 
Benign n = Malignant n = 
Fibrosis/Fibro adenoma 38 DCIS 3 
Fibrocystic change 8 IDC 23 
-itis 9 ILC 8 
Lipoma 2   
Other 4   
Normal breast tissue 11   
No pathological evaluation 69   
Total 141  34 
 
DCIS = Ductal Carcinoma In Situ; IDC = Invasive Ductal Cancer; ILC = Invasive Lobular Cancer 
 
 
discussion 
 
Scintimammography and MRI are generally accepted as adjuncts to 
mammography and physical examination in the diagnosis of breast cancer.  
 
Previous studies primarily address the utility of scintimammography related to 
dense breasts5,7, the size of the tumour6,16 or its accuracy concerning palpable 
and non palpable lesions6,17. From these reports it is known, that the results of 
scintimammography are independent of breast density7, the technique is more 
accurate in case of palpable lesions17 and diagnostic accuracy may be 
influenced by the size of the lesions (which also applies for MRI)11,15. In the 
present study with a different approach, based on the clinical dilemmas as 
encountered in our hospital, the subgroup of patients with dense breasts also 
benefited most of scintimammography. 
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In the review and meta-analysis of the clinical value of scintimammography 
by Liberman, evaluating the data of 5340 patients5-7, an overall sensitivity and 
specificity of 85.2% and 86.6% were estimated18. In multi centre trials 
sensitivity varied from 71% to 93%, specificity from 69% to 87%, positive 
predictive values from 58% to 75% and negative predictive values from 81% 
to 98%5-8. Our results show a relatively low sensitivity (71%) and positive 
predictive value (53%), probably because of patient selection based on 
equivocal mammographies. Like and comparing with literature our negative 
predictive value (92%) was good and our specificity relatively high (85%).  
 
Reviewing the literature on the accuracy of MRI for breast malignancies is 
much more difficult because of the great variety of used MR systems (varying 
from low to high field), scan protocols, perfusion criteria and reporting 
systems. However, a sensitivity of more than 90% and a highly variable 
specificity (ranging from 19% to 97%) can be concluded for 1.5-T-MRIs for a 
mixture of palpable and non palpable lesions and a random mix of different 
tumour types19-30. Diagnostic performance of MRI is still improving with the 
use of (ultra) high field magnets, detailed architectural assessment, time-signal 
intensity curves of contrast enhancement and probably diffusion-weighted 
techniques. In the present retrospective study with also different MR 
techniques used, the results were comparable with literature. In the clinical 
setting our overall sensitivity of MRI (90%) was higher than that of 
scintimammography (71%). However, because of the high sensitivity of 
scintimammography in the subgroup of dense breasts (100%), this is probably 
still an indication for scintimammography.  
 
The ultimate goal of additional (non-invasive) diagnostic procedures is to 
minimise the number of invasive and/or surgical procedures. The high 
negative predictive value of scintimammography might add up to a more 
expectant policy. Although in combination with a suspicious mammography 
one should be aware of a possible malignancy. In the current group of 
patients a wait-and-see policy was advocated in 69 of the 175 patients based 
on the results of scintimammography. In none of them an invasive or in situ 
cancer was diagnosed. In other words, 39% of the patients benefited from 
this approach.  
 
In addition no malignancy was found in patients with a positive MRI and 
negative SSM. Several authors have reported similar results9-11 due to strong 
and early enhancement patterns as reported for rapidly growing 
fibroadenomas, highly proliferative dysplasia, abscesses and fibrocystic 
changes20,21,31.  
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Although scintimammography has shown promising results as an adjunt to 
mammography, a tendency towards the more frequent use of MRI is currently 
encountered. Most plausible explanations are that the results of 
scintimammography are strongly depending on the size of the tumour and are 
less reliable in non palpable tumours9-11. Moreover, MRI can be 
recommended in the pre-operative planning for assessment of tumour 
invasion of the chest wall and of the pectoralis muscle, which may alter the 
surgeons’ approach to therapy11. 
 
However, because the high sensitivity and relatively low specificity of MRI it 
would be interesting to investigate the role of scintimammography as an 
additional clinical tool in patients with a positive MRI since 
scintimammography is a non-invasive, cheaper investigation and is better 
available than invasive MRI-guided biopsy to investigate the found lesion. 
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abstract 
 
INTRODUCTION - With the increasing use of magnetic resonance imaging (MRI) 
in combination with its high sensitivity and lower specificity, the treating 
physician is more frequently confronted with non palpable breast lesions only 
visible on MRI. In these cases it is often difficult to obtain adequate material 
for pathological examination. One of the methods to do so is excisional 
biopsy after MRI-guided wire localisation. It was the aim of this study to 
examine the feasibility and added value of this method in the analysis of 
otherwise occult breast lesions.  
 
PATIENTS AND METHODS - Data of all 35 patients, referred to the University 
Medical Centre Nijmegen between 1999 and 2004, subjected to excisional 
biopsy after MRI-guided wire localisation were reviewed.  
 
RESULTS - MRI detected 36 suspicious lesions requiring a localisation 
procedure. In all cases the procedure was successfully completed and no 
complications were reported. Of the excised lesions 27 appeared to be benign 
and 10 were malignant. In 25 patients pre-operative histological examination 
was carried out, which was obtained either by ultrasound-guided biopsy 
(n=14) or by MRI-guided biopsy (n=11). However, pathologic examination 
was described as ‘inconclusive’ or ‘no atypia’ in all cases. After MRI-guided 
excisional biopsy eight of these patients appeared to have malignant disease 
(32%). In five patients (14%) the lesion was missed during surgical excision in 
spite of accurate wire localisation, requiring MRI-guided re-excision in one 
patient. In the remaining four patients an additional invasive procedure was 
omitted since the lesion remained unchanged during follow-up MRIs.  
 
CONCLUSION - Excisional biopsy after MRI-guided wire localisation is a 
promising tool in the evaluation of suspicious breast lesions only visible on 
MRI. It has proven to be a reliable and useful method and is therefore of 
additional value in surgical practice. The expected increase of otherwise occult 
lesions, justifies further evaluation and development of the technique as well 
as a wider availability.  
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introduction 
 
Contrast enhanced magnetic resonance imaging (MRI) has become a useful 
diagnostic tool in the detection of breast cancers. It has proven to be able to 
detect cancers in patients in whom conventional diagnostic methods do not 
suffice1,2. Its high sensitivity (94% to 100%)3 is an advantage, although 
specificity remains moderate (37% to 100%)3. Promising results have been 
reported in the evaluation of the extent of breast cancer, e.g. to evaluate 
multicentricity or multifocality4, in differentiation between a scar and a 
carcinoma5, evaluation of tumour recurrence or chest wall involvement, 
identification of the primary site in patients with occult breast cancer6 and to 
monitor chemotherapy response7.  
 
Moreover, MRI is able to detect lesions not visible on other imaging 
modalities in 10% to 39% of the cases8-10. In screening high-risk women MRI 
has proven to detect more lesions compared to mammography11,3,12. A lesion, 
only visible on MRI, poses the dilemma of obtaining material for histological 
examination. A first approach to these lesions is often attempted using 
ultrasound. This procedure was successfully performed in every enhancing 
lesion or region on MRI as described by Obdeijn6. However, not every 
enhancing lesion on MRI will be detected with sonography, partly because 
enhancing lesions do not represent pathology and partly because not all solid 
lesions are shown with sonography6. In such cases MRI-based guidance 
systems are needed to guide needle biopsy or allow localisation of the lesion.  
 
Several approaches have been described of which the most frequently used is 
localisation in the prone position by means of a compression device that 
immobilises the breast to prevent tissue shift during MRI-guided wire 
localisation12,13. In general, excisional surgery after MRI-guided wire 
localisation is advocated unless percutaneous MRI-guided vacuum biopsy is 
available in case of lesions of 10 mms or smaller13. Since the use of MRI is 
still increasing in combination with the described high sensitivity and 
moderate specificity, the number of lesions that can only be visualised by MRI 
will also increase resulting in the more frequent dilemma of obtaining 
adequate histological material. Pre-operative MRI-guided localisation devices 
are still scarcely available and literature concerning its reliability is 
limited5,8,12,14,15. In this report the feasibility and added value of MRI-guided 
wire-localised excisional breast biopsies will therefore be evaluated.  
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patients and methods 
 
PATIENTS - From September 1999 till June 2004 all 35 patients in whom MRI-
guided excisional biopsies were performed were included in this study. All 
women also underwent mammography and ultrasound prior to MRI 
localisation of the lesion for either screening11, follow-up or additional 
imaging purposes. MRI investigations were performed on a 1.5-T-clinical MR 
system (Siemens, Erlangen, Germany: Magnetom Vision, Sonata or 
Symphony) using a standard dynamic breast MRI protocol16. 
 
Mammographic examinations were performed using a General Electric DMR 
mammographer. Each patient underwent mammograms in the oblique and 
cranio-caudal direction. Ultrasound was carried out with a Toshiba SSA 380 
using a 10 MHz transducer by an experienced breast radiologist. Preferably, 
patients were subjected to either ultrasound-guided histological needle biopsy 
or MRI-guided histological needle biopsy instead of the more invasive MRI-
guided excisional biopsy. 
 
EVALUATION OF IMAGING METHODS - From both the mammography and 
ultrasound examinations the written reports were used for data collection. 
Lesion detection and whether biopsies were taken was scored. 
 
All MRI examinations were retrospectively evaluated by an experienced breast 
radiologist on a dedicated breast MRI work station (MT Jade, Mevis, 
Germany) scoring tumour location, size, morphology, delineation, internal 
enhancement morphology and enhancement kinetics. Morphology was 
classified as being a rounded, lobulated, irregular or ductal enhancing pattern. 
Lesion delineation was described as sharp, vague or with spiculae. Internal 
morphology of a lesion was classified as homogeneous, inhomogeneous, rim 
enhancement or with non enhancing septations. Lesion enhancement kinetics 
were evaluated according to the criteria described by Kuhl et al.17. In 
conclusion the lesion was scored according to the BI-RADS-MRI lexicon18. 
 
MRI LOCALISATION METHODS - For MRI-guided localisation of the lesions two 
methods were used. In both methods the patient is positioned prone with the 
‘target’ breast fixated in the breast coil. Gadolinium containing contrast 
medium is used to visualise the lesion and the double hook wire can only be 
introduced from the lateral side. The most frequently applied method in this 
study uses (from 1999 until June 2003, 28 cases) a prototype coil where the 
lesion is targeted related to a single marker that is placed on the laterally 
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placed compression grid that consists of horizontal bars. The localisation wire 
is placed using a ‘free-hand’ method. In the second method used (from July 
2003, 9 cases) the position of the lesion is related to five markers in the 
laterally positioned grid. A needle guide is used for accurate wire placement19. 
The position of the wire was acquired from the written report from the 
radiologist. 
 
Figure 1 shows a transversal image of the left breast with the enhancing lesion 
(a) and with the localisation wire in situ (b). 
 
 
 
(a) 
 
 
(b) 
 
SURGICAL PROCEDURE - In all cases surgery was performed under general 
anesthesia on the same day. Excisional biopsy after MRI-guided needle 
localisation was usually performed from a peri-areolair incision towards the 
palpable end of the wire. It was always attempted to remove the lesion with a 
surgical margin of at least 1 cm. Since enhancement cannot be reproduced on 
the specimen, a reliable countercheck by specimen MRI is not possible5. 
Neither was specimen X-ray performed, because of the fact that the lesions 
had not been visible on mammography. In case of an in situ or invasive breast 
cancer, additional surgery was performed according to the current guidelines.  
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PATHOLOGY - All material was routinely evaluated by the pathologist. Specific 
attention was paid to the correspondence of the aspect of the lesion on MRI 
and the consistency of the excised tissue with MRI characteristics. Lesion 
characteristics are shown in table 1.  
 
Table 1: MRI lesion characteristics 
 
Lesions detected  n=36 
Mean tumour size (mm)  15 (range 5 to 42) 
Tumour location Left breast 18 (50%) 
 Right breast 18 (50%) 
 Medial  4 ( 11%) 
 Lateral  17 (47%) 
 Central 15 (42%) 
Lesion morphology Rounded 12 (33%) 
 Lobulated 6 (17%) 
 Irregular 18 (50%) 
 Ductal pattern - 
Lesion delineation Sharp 21 (58%) 
 Vague 12 (33%) 
 Spiculated 3 (8%) 
Internal morphology Homogeneous 18 (50%) 
 Inhomogeneous 18 (50%) 
 Rim enhancement/septations - 
Enhancement kinetics Type 1 3 (8%) 
 Type 2 12 (33%) 
 Type 3 21 (58%) 
BIRADS classification 3 6 (17%) 
 4 24 (67%) 
 5 6 (17%) 
 
In brackets: percentage within the subgroups 
 
 
results 
Thirty-five patients (median age 46 years, range 31 to 71 years) were included 
in the study. Nine patients had a personal history of either in situ or invasive 
breast cancer. Twenty-six patients had a family history positive for breast 
cancer. Previous surgery had been performed in 21 patients; five in case of 
benign lesions, 16 because of a malignant disease. Indications for MRI were 
as follows: 14 because of a family history of breast cancer (screening), seven 
as follow-up after breast cancer and 14 because of equivocal mammographies. 
In six cases mammography detected either a subtle architectural distortion, an 
increase of micro-calcifications or an increased density compared to the 
previous mammogram. All findings were reported to be inconclusive. In the 
remaining patients, the mammogram showed either (too) dense glandular 
tissue or no abnormalities. 
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In 25 patients pre-operative histological examination was carried out, which 
was obtained either by ultrasound-guided biopsy (n=14) or by MRI-guided 
biopsy (n=11). However, pathologic examination was described as 
‘inconclusive’ or ‘no atypia’ in all cases. After MRI-guided excisional biopsy 
seven, respectively one of these patients appeared to have malignant disease. 
 
MRI detected 36 suspicious lesions of which the characteristics can be found 
in table 1. Ultimately, 37 localisation procedures were performed: in two 
patients a second procedure was necessary to remove the same lesion and in 
one patient two separate lesions were detected. In this case only one wire was 
used because both were located in the same quadrant and only half a 
centimetre apart.  
 
The localisation wire was placed in the lesion itself in all but seven cases. In 
five patients the wire was placed between 2 and 6 mms from the lesion, in 
one 10 mms and in another one 20 mms from the lesion. The large distance 
in the latter cases was due to the localisation of the lesions: close to the chest 
wall, out of range of the localisation device. In two patients localisation was 
hampered by motion of the patient. However, adequate localisation was 
achieved in both cases. No other complications were reported. 
 
Overall, abnormalities as detected by MRI corresponded with 26 benign and 
10 malignant tumours. Table 2 shows a further specification of the 
histological findings.  
 
In four of 10 patients tumour-free resection margins were achieved by 
excisional biopsy. In one of them a mastectomy was performed in spite of the 
radical resection. Irradical resected tumours contained DCIS in five patients 
and invasive ductal cancer in four. Mean and median tumour sizes were 10 
mms (range 8 mm to 12 mm). Tumour resection margins were focally tumour-
positive in three cases. Of the patients with an irradically resected tumour, 
further surgery consisted of breast conserving surgery in two patients and 
mastectomy in six. No residual disease was encountered in three patients and 
multifocal disease in two. Tumour stages were found between in situ 
carcinoma and T2 invasive cancers. No nodal metastases were encountered.  
 
During follow-up, MRI-guided re-excision was performed in two patients 
because of an unchanged and still suspicious aspect on MRI as mentioned 
above. In one of them ductal hyperplasia was found in both procedures, in 
the other patient invasive ductal cancer was detected at re-excision in addition 
to the known DCIS. Moreover a prophylactic mastectomy was performed in 
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three patients in whom contralateral breast cancer was detected. In these cases 
no malignant disease was found. In four other patients surgical excision had, 
retrospectively, not been successful despite accurate wire localisation, since 
the lesion was still present on follow-up MRI. Because of unchanged 
characteristics on MRI further invasive procedures were omitted.  
 
Table 2: benign versus malignant lesions 
 
 Benign Malignant 
n=36 n=26 n=10 
BI-RADS classification    
  BI-RADS III 4 2 
  BI-RADS IV 16 8 
  BI-RADS V 6 0 
   
Histology  7 (ductal) hyperplasia 5 IDC 
 14 fibrosis/fibro adenoma 5 DCIS 
 2 lipomatous breast tissue*   
 3 LCIS  
 
IDC = Invasive Ductal Cancer; DCIS = Ductal Carcinoma In Situ; LCIS = Lobular In Situ Carcinoma 
*) in both cases where lipomatous breast tissue was found, no lesion was detected during follow-up 
 
 
discussion 
 
The data of this study indicate that MRI-guided wire localisation is technically 
feasible and can be performed safely and successfully. The added value of 
MRI in the detection of clinically and mammographically occult cancers was 
illustrated by the positive predictive value of 28% (10/36). Other studies 
report a yield of malignant lesions, ranging from 31% to 62%3,5,14,15, 
emphasising the need for an adequate method allowing histopathology work-
up of the detected lesions. The overall rate of benign to malignant biopsies 
among MRI-detected lesions ranges between 1:1 to 3:1 depending on the 
diagnostic criteria, indication (in case of a personal or family history of breast 
cancer, invasive procedures are probably more frequently indicated) and the 
desired sensitivity8, which is comparable with the range of 0% to 47% positive 
predictive values as reported for mammographically-guided needle 
localisation20. The histological diagnosis of benign ‘MRI only’ lesions was 
similar to those reported by others and did not show remarkable differences 
with those visible on mammography and/or ultrasound1,3,5,21. 
 
With respect to needle placement, no considerable technical difficulties or 
complications were encountered. In virtually all cases, needle placement was 
accomplished according to the generally accepted standards of no more than 
10 mms of the target8. A possible complication is breaking of the tip of the 
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wire during deployment or surgery as described by Morris in 2.9% of the 
patients15. Factors that challenge adequate needle placement are the following: 
difficult access to medial lesions, since needle placement is often only possible 
from the lateral side; compression of the lesion might cause the ‘accordion’ 
effect (i.e. the altering of spatial resolutions during either compression and 
release)15 and is also reported to prevent impairment of contrast 
enhancement1. However, since double hook wires were used in the present 
study, needle displacement was less likely to occur.  
 
Inadequate removal of the lesion despite correct needle positioning occurred 
in 16.2% (6/37) of the lesions. Moreover, nine out of 10 malignant tumours 
were irradically resected (90%). The introduction of this new technique in 
combination with the non palpability of the tumour will be responsible for a 
number of irradically resected tumours. Wire displacement either during 
surgery or because of the different position of the patient during both 
procedures could account for some of the inadequately excised lesions. 
Needle placement is performed with the patient in prone position, whereas 
the patient is lying on her back during surgery. In addition, the breast is 
compressed during positioning of the needle, which is not the case during 
excision, allowing guide wire displacement. Partly excised or missed lesions 
were reported in 0% to 12% cases of excisional biopsies after MRI-guided 
wire localisation1,3,5,14,15, whereas a review of literature found an average miss 
rate of 2.6% (range 0% to 17.9%) for mammographically-guided needle 
localisation20. A difference with mammographically detected abnormalities is 
the fact that the surgeon is able to visualise the lesion in relation to the needle 
on mammography, which is not possible with MRI. This could also account 
for an increased miss rate or relatively high number of incompletely excised 
tumours.  
 
Considering the described difficulties, a repeat MRI is recommended if any 
discrepancy exists between the histological results and the lesion based on 
imaging. The repeat MRI should be performed within 24 hours after surgery 
to avoid disturbing enhancement due to granulation tissue5,8,22. 
 
Although excisional biopsy after MRI-guided wire localisation has proven to 
be a successful method in obtaining adequate material for pathologic 
evaluation, the technique is associated with several disadvantages apart from 
the technical difficulties as described above. First of all, its use is currently 
restricted by its limited availability. Moreover, it is a time-consuming 
technique, a surgical procedure is required and no data are available 
concerning its cost effectiveness. It would therefore be desirable to increase 
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the number of minimally invasive percutaneous procedures. In the present 
study however, 25 of 37 lesions could not be successfully biopsied using other 
imaging modalities. From these lesions 32% turned out to be malignant. In 
MRI-guided needle biopsy several problems have been encountered such as 
needle artefacts, tissue shift during the intervention and fast equalisation of 
contrast enhancement in lesions with surrounding tissue. Therefore needle 
biopsy is not recommended for lesions smaller than 10 mms. MRI-guided 
vacuum biopsy is somewhat more invasive but promises to solve most of 
these problems and might be an alternative in these cases8. Compared to 
‘plain’ core biopsies, there is a technical advantage in that, due to the vacuum 
assistance, the demands concerning spatial accuracy of needle placement are 
much lower: due to the vacuum, tissues in a diameter of up to 20 mms around 
the core needle are dragged into the biopsy notch, thus compensating for a 
less-than-accurate needle placement12,13. 
 
It can be concluded, that excisional biopsy after MRI-guided wire localisation 
is a useful method to obtain an accurate diagnosis of clinically, 
mammographically and ultrasonographically occult lesions. The increasing 
quality and use of MRI in combination with its high sensitivity and moderate 
specificity will result in an increasing number of such occult lesions, leading to 
the more frequent need to use this technique, justifying further evaluation and 
development of the technique as well as a wider availability.  
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abstract 
 
INTRODUCTION - The value of frozen section in the diagnosis of a primary 
breast lesion has changed in the recent past due to the growing number of 
small non palpable lesions and the use of core needle biopsies. 
 
PATIENTS AND METHODS - In the present study we have critically evaluated the 
results of per-operative frozen section analysis in 216 patients with non 
palpable breast lesions. The results and the consistency of frozen section 
analysis were related to the pre-operative mammography and the final 
pathological outcome. 
 
RESULTS - The frozen section diagnoses benign (84 patients) and malignant 
(116 cases) were found to be highly reliable (100% for both), in contrast with 
the diagnosis ‘in situ’ carcinoma. A false negative rate of 2.3% and a 96.5% 
sensitivity were found. 43.5% of patients benefitted from this approach, 
because definitive surgical treatment could be performed immediately. 
 
CONCLUSION - Frozen section analysis may still be a valuable tool in the 
management of non palpable breast lesions, in cases in which pre-operative 
diagnostic methods were inconclusive. The use of frozen section analysis 
however, should obviously remain restricted to circumstances in which the 
diagnosis has an immediate impact on surgical treatment. In addition, there 
should be a gross lesion with a diameter of 5 mms or more. In case of 
microcalcifications only and if in situ carcinoma or atypical hyperplasia is 
detected by frozen section analysis, paraffin sections should be awaited. 
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introduction 
 
Since the introduction of breast cancer screening programmes the number of 
suspicious non palpable breast lesions has increased enormously. Before the 
era of the large core needle biopsy, no reliable method was available to obtain 
material for pathological examination, other than by excisional biopsy of 
suspicious lesions. In case of a malignancy not seldomly a second operation 
was indicated completing the treatment for the primary lesion in order to 
obtain tumour-free resection margins or to perform axillary treatment. Frozen 
section analysis has proven to be a highly reliable method for palpable 
lesions1,2. In non palpable lesions it may facilitate a more efficient approach as 
well3-6: a per-operative confirmation of malignancy enables axillary treatment 
during the same operation. However, in the past few years some critical 
studies have been published concerning the reliability of frozen section 
analysis especially in small non palpable lesions7-10. In the same period new 
strategies have been developed enabling a pre-operative diagnosis in the 
majority of non palpable breast lesions11-14. Using a large core needle biopsy 
procedure a 97% specificity rate could be reached14. Therefore the use of 
frozen section analysis has decreased in this group of patients anyway. 
Altogether the use of frozen section analysis in the management of non 
palpable breast lesions has become questionable. In 10% to 20% of the cases 
however, methods of pre-operative diagnostics still fail to provide a certain 
pre-operative diagnosis12. 
 
Although our strategy in diagnosing non palpable breast cancers has followed 
the trend including large core needle biopsies, the question remains whether 
frozen section analysis should remain contra-advised.  
 
 
patients and methods 
 
PATIENTS - Between January 1992 and January 2000, a total of 554 women 
with a mammographically suspicious non palpable breast lesion were referred 
to the Rijnstate Hospital Arnhem, the Netherlands. Four-hundred-and-ninety-
four of them underwent a diagnostic excisional biopsy. In 216 patients a per-
operative frozen section analysis was performed. Of the remaining 278 
patients either a pre-operative diagnosis had been obtained or patients 
refrained from frozen section analysis. All patients were treated before the 
implementation of the sentinel node procedure. 
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METHODS - Data of all 216 patients, subjected to frozen section analysis, were 
reviewed concerning aspect on mammography, results of frozen section 
analysis and consistency of frozen section analysis with definitive paraffin 
section diagnosis. Mammographic findings were divided into the following 
groups: densities, densities in combination with microcalcifications, 
microcalcifications only, stellate shaped masses and architectural distortions. 
Per group the malignancy rate was defined (table 1). 
 
Table 1: aspect on mammography 
 
Aspect on mammography Number of patients Percentage 
Density 99 45.8 
Density and microcalcifications 23 10.7 
Microcalcifications only 45 20.8 
Stellate shaped mass 47 21.8 
Architectural distortion 2 0.9 
Total 216 100 
 
Diagnoses obtained by frozen section analysis were classified into the 
following categories: invasive carcinomas, in situ carcinomas, benign lesions 
and lesions deferred to paraffin section analysis. To estimate the reliability of 
frozen section analysis, the diagnoses of paraffin section analysis were used as 
a golden standard. When only microcalcifications and/or no gross suspicious 
lesion were present at the cut surface, no frozen section analysis was 
performed. The diagnosis was deferred to the paraffin sections whenever any 
doubt existed. All lesions excluded by the pathologists were described as 
deferred, whether frozen section analysis was performed or not. 
 
The types of mammographic abnormalities and the presence of a gross lesion 
at histological examination were further analysed according to malignancy 
rate, whether the diagnosis was deferred or not and according to the 
consistency of the frozen section analysis with paraffin section diagnosis. 
Finally we reviewed the influence of frozen section analysis on the immediate 
surgical management and the reduction in the total number of operations per 
patient. 
 
 
results 
 
Two-hundred-and-sixteen patients underwent a wire-guided excisional biopsy 
and frozen section analysis (43.7% of the excisional biopsy group, 39% of the 
total group). Mammographic findings and corresponding histopathological 
diagnosis are shown in table 2. The majority of all lesions appeared to be 
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invasive cancers (116 of 216, 53.7%). A benign lesion was found in 84 
patients (38.9%) and in situ carcinoma occurred in 16 cases (7.4%).  
 
When comparing the separate mammographic abnormalities with the 
outcomes of paraffin sections, a stellate shaped mass showed the highest 
malignancy rate (80.9%). The lowest malignancy rate of 33.3% occurred in the 
group with microcalcifications only. Benign lesions were found in all groups. 
In situ carcinoma however, was solely found in groups with 
microcalcifications with or without a density. 
 
Table 2: Mammographic findings and corresponding paraffin section diagnoses 
 
Xm Paraffin section diagnosis  Total Malignancy rate 
 Benign In situ ca Invasive ca   
D 49 - 50 99 50.5% 
D+M 9 2 12 23 52.2% 
M 16 14 15 45 33.3% 
SSM 9 - 38 47 80.9% 
AD 1 - 1 2 50.0% 
Total 84 16 116 216 53.7% 
 
Xm = Mammography; D = Density; D+M = Density and Microcalcifications; M = Microcalcifications; SSM = Stellate Shaped Mass; AD = Architectural 
Distortion 
 
Comparison of frozen section analysis and paraffin section analysis (table 3) 
revealed a consistency of 76% (n=164). All lesions that were described as 
benign or invasive cancers by frozen section analysis were diagnosed correctly 
(n=155): none of the frozen section diagnoses benign or malignant was 
changed into another category when the lesion was examined using paraffin 
sections.  
 
Table 3: Results of frozen section analysis versus paraffin section results 
 
Frozen section Paraffin section diagnosis Correct diagnosis 
diagnosis Benign In situ cancer Invasive cancer  
Benign 55 0 0 100% 
In situ cancer 1 9 5 56% 
Invasive cancer 0 0 100 100% 
Deferred 28 7 11 n.a. 
Total 84 16 116  
 
n.a. = not applicable  
 
However, in case of ‘in situ carcinoma’ frozen section analysis appeared to be 
less reliable. Paraffin section analysis in these cases revealed six lesions that 
were wrongly interpreted in a total group of 16: five invasive cancers and one 
benign lesion. Subsequently, five invasive cancers and one benign lesion were 
missed by frozen sections, which results in an overall false-negative rate of 
2.3% and a false-positive rate of 0.05%. Corresponding aspects on 
mammography were two stellate shaped lesions (one benign and one invasive 
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cancer) and three abnormalities with microcalcifications (all invasive cancers). 
One of the invasive cancers contained micro-invasion, three others had a 
diameter smaller than 5 mms, and the last one a diameter of 9 mms. 
 
Diagnosis was deferred to paraffin section in 21% of the procedures (table 4). 
This group consisted primarily of patients with microcalcifications only on 
mammography (46%). In fact, in these cases the performance of frozen 
section analysis was restricted to the ones with a gross lesion in the specimen. 
Of all patients in whom the diagnosis was deferred 11 invasive cancers (24%), 
seven in situ carcinomas (15%) and 28 benign lesions (61%) were found at 
definitive pathological evaluation, evenly spread between all mammographic 
subgroups (table 4).  
 
Table 4: Results of deferred frozen section diagnosis 
 
Xm Frozen section Paraffin section diagnosis Invasive cancer 
 number Percentage* Benign In situ cancer  
D 10/99 10% 7 - 3 
D+M 6/23 26% 5 - 1 
M 21/45 47% 10 7 4 
SSM 9/47 19% 6 - 3 
AD 0/2 - - - - 
Total 46/216 21% 28 7 11 
 
Xm = Mammography; D = Density; D+M = Density and Microcalcifications; M = Microcalcifications; SSM = Stellate Shaped Mass; AD = Architectural 
Distortion; Percentage* = percentage of the corresponding aspect on mammography 
 
Table 5 provides data concerning additional surgical treatment. In 108 
patients (50%) additional surgery was performed in the same session as a 
result of frozen section analysis. Altogether 32 patients (14.8%) were 
subjected to a (separate) second surgical session (2nd operation total). 
Fourteen of these (stated as 2nd operation*) because of insufficient margins 
or because in situ carcinoma appeared to be invasive cancers after paraffin 
section analysis. In the remaining 18, histopathological diagnosis had been 
deferred during the first session.  
 
Table 5: Additional surgical therapy 
 
Frozen section diagnosis Immediate completion 
surgery 
2nd operation total 2nd operation* 
In situ cancer 10 5 2 
Invasive cancer 96 11 11 
Deferred 2 16 1 
Total 108 32 14 
 
Immediate completion surgery = immediate additional surgery, because of frozen section results; 2nd operation* = patients undergoing a second 
operation although direct adjuvant surgery had been performed 
 
From these data it can be calculated that 108 minus 14 patients were surgically 
treated in one session instead of two. Ultimately, 94 patients of the 216 
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(43.5%) in whom frozen section analysis was performed have benefitted from 
this approach. 
 
 
discussion 
 
The results of frozen section analysis appeared to have a 100% reliability in 
case of invasive cancers and benign lesions. A diagnosis of in situ carcinoma, 
however, seemed to be far less reliable, which could be explained by the fact 
that the areas of micro-invasion could be easily missed by frozen section 
especially in these small lesions (five of six lesions were smaller than 5 mms). 
It was obvious, that in cases in which no gross lesion was present the 
percentage of false-negative frozen section diagnoses was much higher, which 
was in nearly all cases due to sampling errors. In the current study 21% of the 
required frozen section analyses were deferred to paraffin section evaluation, 
mainly as a consequence of this set of criteria. In other reports the rate of 
deferred diagnoses varies between 3% and 33%9. 
 
Almost 39% of the specimen were benign, a rather high number, although 
decreasing with improved radiological methods. This is in line with other 
publications15. The introduction of the large core needle biopsies has reduced 
the use of per-operative frozen sections enormously. The large number of 
patients in this study (216 of 494, 43.7%) that were subjected to frozen 
section analysis is mainly due to the fact, that the majority was treated before 
the introduction of large core needle biopsies. By the end of this study only 
seven frozen section procedures were carried out annually.  
 
The increased use of breast conserving surgery has further reduced the 
frequency of frozen section analysis, as it requires careful pathologic 
examination to assess the adequacy of excision and histologic features that are 
of possible prognostic importance8. In case of small non palpable lesions, 
violation of the specimen may occur, precluding preparation of optimal 
permanent sections: interpretation of intraductal proliferations for example, 
may be challenging if the only available tissue was subjected to freezing7. 
Another drawback in performing frozen section analysis is the possibility that 
freezing may induce artefacts that may make subsequent diagnosis difficult5,7,8. 
The same applies for the evaluation of the radicality of surgery and the 
examination of receptor assays8,16. All factors can usually be avoided by 
restricting the use of frozen section analysis especially when 
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microcalcifications are present to cases with a gross lesion with a diameter of 
5 mms or more.  
 
In our series the 96.5% accuracy rate of frozen sections fell well within range 
of 82% to 97.7% as mentioned in other studies4-6. The discussion on the need 
to have an immediate diagnosis has been thwarted by the introduction of 
large core biopsy techniques. It is obviously preferable to acquire a pre-
operative diagnosis on an out-patient basis, of which large core needle 
biopsies have shown very good results14. However, a failure rate of 10% to 
20% has been described in acquiring such a diagnosis12. In a prospective 
study17 concerning stereotactic needle biopsies 13% of the planned 
procedures were cancelled. Extremely dense breasts, axillary location of the 
lesion, body mass index below 20, less than 15 mms distance to the chest wall 
or the presence of more than one non palpable lesion were identified as 
independent risk factors. In most of these cases, frozen section analysis 
should still be considered as a valuable tool to increase surgical efficiency. 
 
Restrictions in the use of frozen sections are the presence of 
microcalcifications only and abnormalities without a gross suspicious  
lesion4-7,10. In these cases it should be clearly discouraged. In addition, for all 
cases in which either in situ carcinoma or atypical hyperplasia is histologically 
detected on frozen section, final diagnosis should be deferred to paraffin 
sections6. 
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abstract 
 
INTRODUCTION - Since the introduction of the stereotactic large core needle 
biopsy (SLCNB) for suspicious mammographic lesions, non palpable breast 
cancer is diagnosed pre-operatively more often. Even though this has resulted 
in a lower total number of operations needed for definitive surgery, more 
than one operation is often required. Experience of the operating surgeon 
(registered surgeon versus surgical resident in training) could play an 
important role. We compared the results of the treatment of non palpable 
breast cancer between two teaching hospitals: the University Medical Centre 
Utrecht (UMCU) and the Rijnstate Hospital Arnhem (RHA). 
 
PATIENTS AND METHODS - A total of 240 patients from the UMCU (n=126) 
and the RHA (n=114) diagnosed with a malignancy at SLCNB from 1 
February 1997 until 31 May 2002 were included. The average age of the 
patients at the RHA was 61.3 years and at the UMCU 58.0 years. The total 
number of procedures was recorded as well as the type of operation and 
whether the first surgeon was a resident-in-training or registered as a surgeon.  
 
RESULTS - Of the 240 patients, biopsy results showed that 163 had an invasive 
carcinoma (IC) and 77 had a ductal carcinoma in situ (DCIS). In 74% of the 
cases one operation was sufficient (79% in the RHA versus 69% in the 
UMCU; p=0.08). In the RHA fewer operations per patient were carried out 
before radical resection was attained (1.25 versus 1.4; p=0.02). IC was more 
often treated by breast conserving surgery in the RHA than in the UMCU 
(74% versus 55%; p=0.01). The intention to treat DCIS by breast conserving 
surgery was more often seen in the UMCU than in the RHA (90% versus 
69%; p=0.02). Of all operations analysed in the RHA 48% were performed by 
a resident-in-training as first surgeon versus 87% in the UMCU (p<0.001). 
This had no influence on the percentage of primary radical resections if 
operated on by a resident-in-training: 78% in the RHA and 77% in the 
UMCU. 
 
CONCLUSION - Outcomes of surgical treatment were comparable in both types 
of teaching hospitals. Good results were achieved in non palpable breast 
cancer surgery that was carried out by residents-in-training.  
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introduction 
 
Since the introduction of stereotactic large core needle biopsy (SLCNB) for 
the diagnosis of non palpable breast lesions, the diagnosis of breast cancer has 
more frequently been made pre-operatively. As a result the total number of 
surgical interventions needed for adequate treatment of breast cancer has 
declined. Nevertheless, in a large number of cases more than one operation is 
required to obtain tumour-free resection margins. The fact that the resection 
margins are often not free of tumour after the first operation could be 
influenced by the experience of the performing surgeon. In teaching hospitals, 
a large proportion of breast surgery is performed by surgical residents. We 
compared the results of operative treatment of non palpable breast 
malignancies between two teaching hospitals: the University Medical Centre 
Utrecht (UMCU) and the Rijnstate Hospital Arnhem (RHA). We assumed 
(based on current practice in both hospitals) that in the UMCU breast cancer 
surgery is more often performed by surgical residents as the first operating 
surgeon than in the RHA, and that this may result in a higher number of 
surgical interventions needed for definite treatment of breast cancer. A 
secondary goal of this study was to identify other possible factors influencing 
the number of re-operations. 
 
 
patients and methods  
 
PATIENTS - All patients diagnosed with non palpable ductal carcinoma in situ 
(DCIS) or invasive cancer (IC) at SLCNB from 1 February 1997 until 31 May 
2002 were included (n=240). Of these patients, 114 were referred to the RHA 
(78 IC and 36 DCIS) and 126 to the UMCU (85 IC and 41 DCIS). Patients in 
the RHA were on average older (61.3 years versus 58.0 years; p=0.007), 
table 1. All patients in this study underwent the SLCNB in the UMCU. 
Patients originally referred to the RHA would return there for subsequent 
surgical treatment. All other patients would remain in the UMCU. In all 
patients, the aim was a primary therapeutic excision. The surgical procedure 
was considered to be radical when no malignancy was found at less than 1 
mm of the resection margins. Breast conserving surgery was performed as 
needle-guided wide local excision. 
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Table 1: Characteristics of patients and their non palpable lesions  
 
 RHA (n=114) UMCU (n=126) 
   
Age (mean) 61.3* 58.0* 
   
 n (%) n (%) 
   
History of breast cancer 11 (10) 18 (14) 
Ipsilateral breast cancer 1 (1) 5 (4) 
   
Mammographic lesion   
Density 63 (55) 58 (46) 
Calcifications 35 (31) 41 (33) 
Density with calcifications 16 (14) 24 (19) 
Distorted architecture - 3 (2) 
   
SLCNB diagnosis   
DCIS 36 (32) 41 (33) 
Invasive cancer 78 (68) 85 (67) 
 
*p=0.007 
 
BIOPSY PROCEDURE - Since 1997, the UMCU has used SLCNB for evaluating 
non palpable breast lesions suspicious for carcinoma. Biopsy procedures were 
performed according to a standard protocol as described earlier1. Radiologists 
performing the biopsies underwent special training: firstly, they attended ten 
biopsy procedures and subsequently they performed another ten biopsy 
procedures under the supervision of a radiologist with considerable 
experience in SLCNB.  
 
Biopsies were taken with a 14-gauge core needle, long throw (2.2 cms 
excursion) automated biopsy device with multiple passes (Bioptygun, C.R. 
Bard Inc., Covington, GA) with the patient on a prone table (Fisher Imaging, 
Denver, CO, of Lorad Stereoguide, Danbury, CT). Lesions were localised 
with digital mammography. It was advised to take a minimum of five biopsy 
specimens. In case of mammographic microcalcifications, at least eight 
specimens should be obtained and specimen radiography was carried out to 
identify the calcifications in the biopsy specimens. All SLCNB procedures 
were performed in the UMCU. The SLCNB patients originally referred by the 
RHA would return there for further treatment and follow-up. All other 
patients would remain in the UMCU.  
 
Histological evaluation of the SLCNB and surgical excision specimens were 
carried out as a routine by pathologists working in the referring hospitals. To 
arrive at an adequate histological diagnosis, the pathologists had access to 
clinical information and the mammographic images obtained during SLCNB. 
Prospective collection of data regarding the type of mammographic lesion, 
the biopsy procedure, the histological diagnosis and the management 
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following SLCNB was carried out in the UMCU. In both hospitals, 
pathological findings were compared to mammographic findings during the 
weekly multidisciplinary meeting that was attended by at least a radiologist 
performing SLCNB procedures, a pathologist and a surgeon.  
 
DATA-ANALYSIS - To compare the results of both hospitals, the total number 
of operations needed for definitive surgical treatment was registered, as well 
as the type of surgery performed. When analysing the total number of 
operations performed we studied both the total number of operations 
including a possible axillary lymph node dissection, and the total number of 
operations needed for radical resection of the tumour. We registered if the 
first operating surgeon was a registered surgeon or a surgical resident. An 
analysis of the experience per operating surgeon with breast surgery was not 
performed, because adequate information on this topic was lacking. 
Differences between the two groups were assessed using the Chi-square test 
or students’ t-test where appropriate. A p-value <0.05 was considered to be 
statistically significant. 
 
 
results 
 
In 177 of 240 patients (74%), clear resection margins were obtained during 
the first operative procedure (table 2). The difference between the RHA 
(79%) and the UMCU (69%) was not statistically significant. In the RHA the 
total number of operations needed to complete surgical treatment was 
signifcantly lower than in the UMCU. This difference remained when we took 
only into account the number of operations needed for radical tumour 
excision, excluding the axillary lymph node dissection as a second or third 
operative procedure. A total of 70 patients underwent two operations for 
complete surgical treatment: 27 in the RHA and 43 in the UMCU. In seven of 
them, the tumour had already been excised with clear margins during the first 
operation: two of these seven patients (one UMCU, one RHA) requested 
ablative surgery despite radical surgery. In the other five, axillary lymph node 
dissection was performed. In three cases (one UMCU, two RHA), a sentinel 
node biopsy had been performed as part of the first operation. The other two 
patients (UMCU) appeared not only to have DCIS (as diagnosed at SLCNB) 
but also invasive cancers (first diagnosed at excision), which were however 
radically excised during the first operative procedure. A third operation was 
performed in 12 patients (ten UMCU, two RHA).  
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Invasive carcinomas were more often treated with breast conserving surgery 
in the RHA when compared to the UMCU (table 2), but in the UMCU a 
larger diameter was found. Patients with DCIS were treated with breast 
conserving surgery more often in the UMCU; the tumours in this patient 
group were smaller in the UMCU compared to the ones in the RHA .  
 
Of all analysed operations, a surgical resident was the first operating surgeon 
in 48% of the cases in the RHA versus 87% in the UMCU (table 2). Among 
patients whose first operation was performed by a surgical resident, there was 
no difference in the percentage of radically excised tumours: 78% (43/55) in 
the RHA versus 77% (84/109) in the UMCU (p=0.87). In addition, when 
comparing only breast conserving surgery performed by a surgical resident, 
there were no significant differences in the percentage of initially radical 
resections between the UMCU and the RHA (64% versus 69%; p=0.57).  
 
Table 2. SLCNB diagnosis and type of surgery performed 
 
 RHA (n=114) UMCU (n=126) p-value 
 n (%) n (%)  
Type of 1st operation for DCIS lesions    p=0.02 
Mastectomy  11 (31) 4 (10)  
Breast-conserving surgery (BCS) 25 (69) 37 (90)  
Eventually treated with BCS 12 (33) 19 (46) p=0.25 
Mean tumour diameter DCIS (mm) 22.6 9.3 p=0.01 
# of operations needed to complete treatment 1.15 1.19 p=0.59 
Number of patients 36 41  
 
Type of 1st operation for IC lesions  
   
p=0.01 
Mastectomy  20 (26) 38 (44)  
Breast-conserving surgery (BCS) 58 (74) 47 (55)  
Eventually treated with BCS 49 (63) 38 (45) p=0.02 
Mean tumour diameter IC (mm) 13.9 18.5 p=0.03 
# of operations needed to complete treatment 1.2 1.2 P=0.59 
Number of patients 78 85  
    
1st operating surgeon    
Surgeon 59 (52) 17 (13)  
Surgical resident 55 (48) 109 (87) p<0.01 
1st operation radical 90 (79) 87 (69) p=0.08 
# of operations needed to complete treatment 1.25 1.41 p=0.02 
 
 
discussion 
 
The percentage of primary radical resections did not differ significantly 
between the UMCU and RHA. However, in the UMCU, more surgical 
procedures were needed per patient to complete surgical treatment. This 
could be explained partly by the surplus of patients in need of a third 
operation in the UMCU versus the RHA: ten versus two respectively. 
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Another explanation for these differences could be that invasive tumours 
were of a larger diameter in the UMCU group. Furthermore, until 2001 it was 
the standard procedure in the RHA to perform ablative surgery for grade I/II 
DCIS and for grade III DCIS a lumpectomy in combination with 
radiotherapy. In contrast, the primary treatment for all grades of DCIS in the 
UMCU has been breast conserving surgery since 2001, with radiotherapy for 
DCIS III.  
 
We presumed that the level of experience of the surgeon performing the 
primary resection would influence the final results of surgical treatment. It can 
be assumed that resection of non palpable breast lesions requires specific 
skills that improve with experience2. Recently, Moorthy et al.3 studied the 
surgical treatment of breast cancer performed by surgical residents and found, 
like we did, no differences in re-excision or recurrence rate when compared to 
patients operated on by consulting surgeons. They reported on both palpable 
(n=398) and non palpable lesions (n=107), whereas all lesions described in 
our study were non palpable. In addition, in their study a pre-operative 
diagnosis of cancer was available in 80% of cases3, whereas we only describe 
lesions with a pre-operative diagnosis of cancer. Blair et al.4 demonstrated that 
in the surgical treatment of breast cancer, better results are obtained by an 
oncologic surgeon than by a general surgeon. A similar result can be expected 
if treatment results of experienced surgeons are compared to those of surgical 
residents. However, this hypothesis could not be confirmed by the current 
study.  
 
Although a considerable difference was found in the total number of 
operations performed by surgical residents (87% UMCU versus 48% RHA), 
this did not seem to affect the percentage of primary radical resections. 
Because the study period extended over a few years, various surgical residents 
were involved in the surgical treatment of this patient group. It is therefore 
impossible to measure, in retrospect, the level of experience with the 
operative procedure of these residents. In addition, (almost) all resections 
were performed under supervision of a surgeon. We therefore conclude that 
non palpable breast cancer can be resected by surgical residents without 
imparing the radicality of the excision. 
 
In the RHA, breast conserving surgery was performed more often for 
invasive cancer. This may be explained, in part, by the fact that invasive 
cancers were larger in the UMCU. Likewise, lesions with DCIS were larger in 
the RHA and patients with DCIS in the UMCU were more often treated with 
breast conserving surgery. 
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This study shows that the results of surgical treatment of pre-operatively 
diagnosed non palpable breast cancer are comparable between the two 
hospitals. In addition, we found that surgical treatment of non palpable breast 
cancer, performed by surgical residents as the primary surgeon, had good 
results. This is important; surgical residents need proper training in breast 
procedures, since these are part of the core of the general surgeons’ work5. 
Obviously, supervision by a senior surgeon remains an essential part of the 
training of surgical residents in order to guarantee high quality of (oncologic) 
surgery.  
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abstract 
 
INTRODUCTION – A tumour-positive resection margin is a well-known 
prognostic factor for local recurrence. In these cases, a re-excision or 
mastectomy is usually performed in order to improve local control, although 
the re-excisional specimen is often free of tumour. It was the aim of this study 
to evaluate tumour characteristics that might be predictive for the presence of 
residual disease after excisional surgery. The ultimate goal was to define 
groups in which additional surgery could be restricted. 
 
PATIENTS AND METHODS - Data of 295 patients, subjected to wire-guided 
excisional breast biopsy were studied. Type and size of the primary tumour, 
the presence of DCIS and an extensive in situ component (EIC), multifocality 
of the tumour and nodal status were considered as possible indicators for 
residual disease. Univariate statistical evaluation was performed as well as a 
step-wise logistic regression analysis. 
 
RESULTS - Tumour-positive margins were found in 25% of the patients. 
Residual disease was found in 51% of the patients undergoing a re-operation. 
Altogether 80% of the patients with positive margins (ie 20% of all patients 
intentionally treated by breast conserving surgery) were treated by 
mastectomy. Nodal status and the presence of an extensive in situ component 
were the only two variables that were statistically significant. 
 
CONCLUSION - In case of tumour-positive margins, axillary involvement and 
the presence of an extensive in situ component in the primary tumour were 
predictive for residual disease. Consequently, no subgroups could be defined 
in whom additional surgery could be omitted. More ‘aggressive’ surgical 
therapy is, however, justified in patients belonging to the risk groups. 
 
 
 177 
introduction 
 
Breast conserving therapy (BCT) is generally accepted as an adequate 
alternative to mastectomy in the treatment of invasive breast cancer. Although 
prospective randomised trials have proven that no significant differences exist 
between mastectomy and BCT as to distant metastases, disease free or overall 
survival rates1, concerns remain about the continued risk of recurrence in the 
retained breast2. Several studies have been performed to detect prognostic 
factors for local recurrence2-11. The presence of tumour-positive resection 
margins is one of the most frequently mentioned. It is common practice to 
perform a re-excision or even a mastectomy in case of tumour-positive 
resection margins in order to obtain adequate local tumour control. In many 
cases, however, the re-excisional specimen appears to be free of tumour.  
 
Not much is known about these results in the treatment of non palpable 
breast tumours. It can be hypothesised that in these tumours-positive 
resection margins are encountered more often, because of the non-palpability 
of the tumour. This might decrease the percentage of conservatively treated 
patients, although these patients with small tumours are particularly good 
candidates for a breast saving procedure. It was the aim of this study to 
evaluate tumour characteristics of the primary tumour that might be 
predictive for residual disease after excisional surgery in case of tumour-
positive resection margins. Subsequently, (sub)groups might be defined in 
which additional surgery could be restricted. 
 
 
patients and methods 
 
PATIENTS - Data of 295 patients with non palpable invasive breast tumours 
were studied. These patients had been referred to the Rijnstate Hospital 
Arnhem between 1992 and 2002. All patients were subjected to a wire-guided 
excisional breast biopsy. In 259 of them (87.8%) this biopsy was meant to be 
the first step of a breast conserving procedure. In the other patients the 
biopsy was taken as a diagnostic procedure.  
 
SURGICAL TECHNIQUE - In case of an excisional biopsy, surgical excision was 
performed after wire-guided localisation of the tumour. The surgeon always 
intended to perform a radical excision, also in case of a diagnostic excisional 
biopsy. It was the aim to remove the tumour with a macroscopic margin of at 
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least 1 cm and a specimen X-ray was always performed during the operation. 
When needed and possible, an extra amount of tissue was removed from the 
breast. The specimen were marked with orienting sutures. Axillary lymph 
node dissection consisted of a level two lymph node dissection, which 
remained unchanged during the ten years of study, although sentinel lymph 
node biopsy was performed in 11 patients since 2000. 
 
PATHOLOGY - Margin assessment was standardised throughout the study 
period: the specimen was inked, laminated and in case of microcalcifications 
X-rayed. At least one lamella with tumour and selected blocks in the opposite 
directions were investigated. The distance in millimeters between the tumour 
and the excisional margin was reported. Margins were defined as tumour-
positive when either invasive cancer or in situ carcinoma was present at the 
surgical margin or within 1 mm from the inked edge. In case of tumour-
positive margins, a distinction was made and reported between a focal or 
completely irradical excision. A division was made between LCIS (Lobular 
Carcinoma In Situ) and DCIS (Ductal Carcinoma In Situ). For the grading of 
DCIS the same criteria were used as for the invasive counterparts, i.e. well (I), 
moderate (II) and poorly differentiated. In general, there is not much debate 
concerning the criteria for DCIS grade II and III. With respect to DCIS grade 
I there is no general consensus. Micropapillary and/or cibriform patterns with 
a monomorfic cubic or cylindrical cell type are obligatory as well as a certain 
size. EIC (extensive in situ component) was defined as more than 10 ducts in 
the tumour surroundings containing DCIS.  
 
Sampling and axillary clearance: pathological examination consisted of 
sampling of the lymph node situated at the medial axillary top. Thereafter all 
remaining lymph nodes were harvested. At least ten lymph nodes should be 
found. All nodes were embedded in total. Nodes larger than 0.5 cm were 
laminated. 
 
EVALUATION OF PATIENT DATA - Patient data were evaluated according to either 
the presence or absence of residual disease in the specimen of the re-
operation. In this paper these groups are described as residual (RTG) and no 
residual tumour groups (NRTG) respectively. An analysis was performed 
considering potentially predictive factors for the presence of residual tumour 
at re-excision. Of specific interest were considered the type and size of the 
tumour, presence of DCIS, EIC, multifocality of the tumour and nodal status. 
The standardised follow-up programme consisted of a yearly mammogram 
and a twice yearly physical examination during ten years. In this study the 
 179 
mean follow-up period was 3.9 years (range 0.1 to 9.9 years), a median follow-
up of 3.5 years was found. 
 
STATISTICAL METHODS - Regarding statistical evaluation, univariate proportions 
and means were calculated. Subsequently, a multivariate model was 
constructed with those variables that seemed to differ, to evaluate mutually 
corrected predictive quality. Furthermore, backward as well as forward step-
wise logistic regression analysis was carried out to identify those variables that 
best predicted the presence of residual tumour. 
 
 
results 
 
In 230 patients the excisional procedure led to adequate surgical margins. 
Tumour-positive margins were found in 65 (25%) of the specimen. Therefore 
either a re-excision (n=13) or mastectomy (n=52) was performed in these 
patients. Mean patient age was 60.2 years (range 35 to 83 years, median age 
61.3 years). Median tumour size was 11.0 mms (range 2 to 30 mms, mean size 
11.4 mms). Mammographic features are shown in table 1. 
 
A re-operation was performed in 65 patients because of tumour-positive 
margins; residual tumour was found in 33 cases (51%). Of the 32 patients of 
the group in which no residual tumour was found at re-operation (NRTG), 23 
patients were subjected to mastectomy. In the remaining nine patients, a 
(radical) re-excision was performed. In the 33 patients in the residual tumour 
group (RTG), the first re-operation consisted of 26 mastectomies and seven 
re-excisions. Of the seven re-excisions, three still had involved margins. These 
patients subsequently underwent a second re-operation, which consisted of a 
mastectomy in all cases. Altogether 52 patients were treated by mastectomy. 
This corresponds with 80% of the analysed subgroup and 20% of the total 
group intentionally treated with breast conserving therapy. Mastectomy was 
performed more often in the group in the RTG (88% versus 72%). Patients 
with residual tumour seemed more likely to develop recurrent disease (odds 
ratio 8.3; 95% confidence interval 1.0 to 72.3) and/or metastases (odds ratio 
6.9; 95% confidence interval 0.8 to 60.9). However, these findings were 
statistically non significant. 
 
Table 1 shows the factors that were considered as possibly predictive for the 
presence of residual disease. 47% of the cancers in the NRTG were smaller 
than 10 mms, as compared to 36% in the RTG. Corresponding mean tumour 
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sizes were 9.8 mms versus 11.8 mms. Solitary tumours appeared less likely to 
show residual disease (81% NRTG versus 67% RTG). In almost all cancers in 
which residual disease was present, the tumour contained DCIS (97% RTG 
versus 72% NRTG). In 55% EIC was found, compared to 41% in the 
NRTG.  
 
Residual tumour was found more often in patients with positive axillary nodes 
(52% versus 12.5%), especially when extranodal tumour growth was present. 
Mean tumour size of patients with positive axillary nodes was 13.1 mms as 
opposed to 10 mms when no axillary metastases were found. Ultimately a 
higher percentage of local recurrences and metastases was found in the RTG.  
 
Table 1: Tumour characteristics and univariate analysis 
 
n=65 
 
NRTG 
n=32 
RTG 
n=33 
Odds Ratio 95% CI 
Tumour diameter < 10 mms 15 (47%) 12 (36%) 0.7 0.6 – 0.8 
Mean tumour diameter 10.0 mms  
(2-22) 
12.0 mms  
(2-30) 
2.0 0.7 – 5.3 
Solitary/Multifocal      
Solitary  26 (81%) 22 (67%) 1  
Multifocal 6 9 1.8 0.5 – 5.8 
Arbitrary 0 2   
Aspect on mammography     
Microcalcifications  10 11 1.2 0.4 – 4.1 
Microcalcifications and density 6 5 0.9 0.2 – 4.0 
Density  16 17 1  
Histology primary tumour     
Ductal 23 27   
Lobular 5 4   
Tubular  4 2   
DCIS in primary tumour     
DCIS present 23 (72%) 32 (97%) 1.5 0.5 – 4.2 
DCIS absent 9 1 1  
EIC      
EIC present 13 (41%) 18 (55%) 1.8 0.7 – 4.7 
EIC absent 19 15 1  
Nodal status      
Positive 4 (12.5%) 17 (52%) 6.4 1.8 – 22.2 
Negative 28 16 1  
Extranodal growth     
Present 2 6 3.3 0.6 – 17.9 
Absent 30 27 1  
 
NRTG = No Residual Tumour Group; RTG = Residual Tumour Group; CI = Confidence Interval; DCIS = Ductal Carcinoma In Situ; EIC = Extensive In 
Situ Component 
 
Using univariate analysis a tumour diameter of more than 10 mms, 
multifocality of the tumour, the presence of either DCIS or EIC, nodal status 
and extra-nodal growth seemed somewhat predictive for residual tumour. 
These variables were therefore included in the multivariate model (table 2). 
The forward entry included nodal status and EIC in the model and was able 
to correctly identify 87.1% of those without residual tumour, but only 48.4% 
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of those with residual tumour. This was similar if only nodal status was 
included. The backward model retained the same variables. If all variables 
were included in the model, the majority of the cases with residual tumour 
was identified, but at the cost of specificity, leading to a lower overall 
predictive value of the model. Overall, nodal status and EIC were the only 
two variables that had odds ratios that were statistically significant (table 2). 
Tumour-positive axillary nodes with an odds ratio of 11 increase the 
likelihood of residual cancer more than 10 times, and EIC four times 
respectively. 
 
Table 2: Multivariate analysis 
 
 Odds Ratio 95% CI 
Nodal status 11.3 1.7 - 70.7 
Extracapsular growth 0.5 0.05 - 5.5 
DCIS 1.1 0.3 - 4.0 
EIC 4.2 1.0 - 16.9 
Diameter 1.9 0.5 - 7.2 
 
CI = Confidence Interval; DCIS = Ductal Carcinoma In Situ; EIC = Extensive In Situ Component 
 
 
discussion 
 
Several tumour characteristics were found, predictive for the presence of 
residual disease after re-excision. Especially nodal status and the presence of 
EIC within the primary tumour were prone for residual disease. It seemed 
also obvious, although not statistically significant, that in the RTG local 
recurrences were encountered more often as well as distant metastases.  
 
Available studies comparing similar data all address a mix of palpable and non 
palpable breast cancers. It can be assumed, that biological and tumour 
characteristics are similar in both palpable and non palpable invasive cancers 
when other tumour characteristics such as size are comparable. Consequently, 
a similar margin of resection should also be achieved in non palpable cancers. 
However, this is more difficult to achieve due to the specific surgical technical 
problems associated with its non-palpability. The dilemma of how to handle 
in case of tumour-positive resection margins therefore probably occurs more 
often in non palpable tumours, which forms the background of the choice for 
this group of patients in the present study. In the existing literature, residual 
tumour was associated with large tumour size, young age, axillary node-
positive status, presence of lymphovascular invasion and the presence of 
EIC12. These factors are often also associated with an increased local 
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recurrence rate. In most of these studies, however, the evaluation was 
restricted to univariate analysis. Because of a wide range of confounding 
factors, it is still not clear whether obtaining a radical margin during breast 
conserving surgery will decrease the rate of local recurrence12.  
 
Swanson et al.13 correlated the initial margin status with the amount of 
residual disease found on re-excision and the effect on local failure. It was 
found that the status of the initial excision biopsy margin did not greatly 
predict the frequency of finding residual cancer in the breast on re-excision. 
They therefore questioned the initial margin status as an accurate indicator of 
the amount of disease left in the breast. In other series however, there does 
seem to be a trend towards an increased frequency of residual disease at re-
excision as related to the amount of initial margin involvement. However, 
even if margins were negative, residual disease was found in 0% to 33% of the 
cases13. Differences are partially due to the absence of a uniform definition of 
a tumour-free resection margin, because of different methods used for the 
examination of excisional margins, which vary in literature from cavity 
biopsies14,15 to examinations of the (tumour free distance to the) inked 
resection margins of the excised tissue4,14,16.  
 
One could therefore question the additional value of re-excision, depending 
on the amount of residual disease left. Swanson13 advocates the use of an 
additional radiation boost to the site of the primary tumour in case of a 
tumour-free resection margin of 3 mms or less. The (positive) effect on local 
control is, however, contradictory. In the current study, margins were defined 
as tumour-free if no tumour was found within 1 mm of the cut edge. Patients 
with positive margins are consequently more likely to show residual disease at 
re-excision. This, in combination with a positive resection margin as a known 
prognostic factor for local recurrence and the contradictory effect of a 
radiation boost, leads to the conclusion, that a re-excision should be 
performed in case of positive margins, even if it is compromising the 
cosmetic result. Especially the presence of EIC and nodal involvement are 
tumour characteristics prone for residual disease as well as for increased local 
recurrence rates and therefore justify more ‘aggressive’ additional surgery.  
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abstract 
 
INTRODUCTION - Staging of breast cancer is routinely performed by 
ultrasonography of the liver, chest X-ray and bone scintigraphy. FDG-PET 
has proven to be a valuable tool in the staging and follow-up of a wide variety 
of malignancies. However, literature of the added value of FDG-PET in 
breast cancer is limited. The aim of the present prospective study was to 
evaluate the role of FDG-PET in the staging of high risk patients with a 
primary or recurrent breast cancer. 
 
PATIENTS AND METHODS – Forty-two FDG-PET scans were performed in 
patients with a high risk of distant metastases or with a suspected loco-
regional recurrence. All patients were subjected to chest X-ray, 
ultrasonography of the abdomen, bone scintigraphy, FDG-PET and, if 
applicable, mammography and/or ultrasonography of the breast. In case of 
abnormalities on FDG-PET, confirmation was always attempted. If 
confirmation could not be achieved, FDG-PET was considered to be false-
positive. 
 
RESULTS - In primary cancers increased FDG uptake was found in five of 17 
patients. In the 25 patients with a suspected relapse FDG-PET showed 
increased uptake in 43 areas, 22 correctly confirming the area of suspected 
relapse and 21 indicating other sites of metastases. Compared to conventional 
imaging FDG-PET revealed unexpected, but confirmed lesions in two 
primary cancers and three relapses. Patient management was changed in five 
patients. 
 
CONCLUSION - FGD-PET is a useful diagnostic method for the detection of 
(distant) metastatic disease and loco-regional recurrences. Especially the high 
sensitivity and negative predictive value could be helpful in clinical practice, 
because the number of false-negative findings with conventional methods is 
relatively high. Since conventional methods revealed no additional lesions, it 
should be the objective of further studies whether it is useful to perform 
FDG-PET earlier in the diagnostic work-up of patients with a high risk of 
metastatic disease.  
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introduction 
 
The presence of distant metastases is the most important prognostic factor in 
patients with breast cancer and changes the intention of therapy from curative 
to palliative. Consequently, accurate staging in both primary and recurrent 
breast cancers has a major impact on the choice of treatment in these patients. 
Staging of breast cancer is routinely performed by ultrasonography of the 
liver, chest X-ray and bone scintigraphy. FDG-PET, an imaging modality 
utilising the increased uptake of glucose by tumour cells, has proven to be a 
valuable tool in the staging and follow-up of a wide variety of malignancies1-3. 
However, literature addressing the added value of FDG-PET in breast cancer 
patients is limited4-7. The aim of the present prospective study is to evaluate 
the role of FDG-PET in the staging of high-risk breast cancer patients with a 
primary or recurrent breast cancer. 
 
 
patients and methods 
 
PATIENTS - From 2001 until 2003 42 patients (age 29 to 80 years, mean 58.1 
years) were prospectively evaluated. Patients with resected primary breast 
cancer with unfavourable histology of the lymph nodes (defined as tumour-
positive top axillary lymph nodes or any tumour-positive axillary nodes with a 
high mitotic activity index (MAI > 10)) and patients with a suspected relapse 
of disease were eligible. Seventeen patients were evaluated shortly after 
surgery for a primary cancer, 25 patients were suspected of relapse. A relapse 
of disease was defined as a clinically suspected loco-regional recurrence 
and/or suspected distant metastases. All patients underwent chest X-ray, 
ultrasonography of the abdomen, bone scintigraphy and FDG-PET. In case 
of suspected local recurrence, mammography and/or ultrasonography of the 
breast were also performed. The mean period of follow-up was 11 months 
(range 0 to 26 months). 
 
FDG-PET - A dedicated PET-scanner (ECAT-EXACT, Siemens/CTI, 
Knoxville, TN, USA) was used for data acquisition. Prior to FDG-injection, 
patients were fasting for at least 6 hours. Intake of sugar-free liquids was 
permitted. Immediately prior to the procedure, the patients were hydrated 
with 500 ml of water. One hour after intravenous injection of 200-220 MBq 
FDG (Mallinckrodt Medical, Petten, The Netherlands) and 12 mg 
furosemide, emission and transmission images of the area between proximal 
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femora and the base of the skull were acquired (10 minutes per bed position). 
The images were corrected for attenuation and reconstructed using the 
ordered-subsets expectation maximisation (OSEM) algorithm. The 
reconstructed images were displayed in coronal, transverse and sagittal planes. 
 
EVALUATION OF DIAGNOSTIC PROCEDURES - For this study the results of all 
diagnostic procedures were prospectively evaluated without knowledge of the 
results of corresponding evaluations and subsequently integrated to determine 
patient management. In case of suspected abnormalities on FDG-PET, 
confirmation was always attempted, either by pathological examination or by 
additional radiological evaluation: in most cases by magnetic resonance 
imaging (MRI) and/or computed tomography (CT). If multiple distant 
metastases were suspected on FDG-PET, the results were considered as true-
positive if one or more of these lesions were confirmed. If no final 
confirmatory diagnosis of FDG-PET abnormalities could be achieved, FDG-
PET was considered to be false-positive for the clinical management of 
patients. However, when metastases were subsequently confirmed at follow-
up, the final assessment of FDG-PET was changed to true-positive.  
 
 
results 
 
Chest X-ray, ultrasound of the liver and bone scintigraphy were suggestive for 
distant metastases in four of 17 patients with a primary breast cancer and in 
ten of 25 patients with a suspected relapse (table 1). As expected, the bone 
scan resulted in a significant number of false-positive findings due to non-
malignant causes. 
 
Table 1: Results of conventional imaging for the identification of metastases 
 
 Primary tumour Suspected relapse Total 
Chest X-ray  0 2TP 2TP 
Liver US 0 1TP 1TP 
Bone scanning 1TP, 3FP 4TP, 3FP 5TP, 6FP 
Total 1TP, 3FP 7TP, 3FP 8TP, 6FP 
 
US = Ultrasonography; TP = True-Positive, FP = False-Positive 
 
As shown in table 2, FDG-PET was negative in 12 of 17 patients with 
primary breast cancer. Increased FDG uptake was observed in six tumour 
sites in five patients. Three (in lung, liver and bone) were true-positive. The 
other three lesions remained unconfirmed (liver, bone and cervical lymph 
node) and were regarded false-positive on FDG-PET. Thus in two of 17 
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patients FDG-PET identified additional sites of disease (liver and lung), 
which became evident not earlier than after two and nine months of follow-
up respectively. The bone metastasis was also positive on bone scintigraphy. 
No additional FDG-PET-negative metastases became apparent during 
follow-up in this patient group. 
 
Table 2: Sites of increased FDG-uptake in primary cancers and results of further 
analysis 
 
n=17  FDG-PET Confirmed directly Confirmed during 
follow-up 
No confirmation 
Negative 12 - - - 
Lung 1 - 1 - 
Liver 2 - 1 1 
Bone 2 1 - 1 
LN elsewhere 1 - - 1 
 
LN = Lymph Node 
 
In table 3 the results of FDG-PET are presented for the 25 patients with 
suspected relapse of disease. Seventeen patients were diagnosed with a loco-
regional recurrence, four with a lesion in the contralateral breast or axilla and 
four other patients showed possible distant metastases (three bone, one 
cutaneous metastases). Loco-regional recurrences were divided into 
recurrences confined to the ipsilateral breast or chest wall, referred to as local 
recurrences (n=13) and regional recurrences occuring in regional lymph nodes 
(n=4). In 24 of 25 patients FDG-PET showed increased uptake. FDG-PET 
confirmed the site of suspected relapse in 22 patients, but missed two local 
recurrences on the chest wall (after mastectomy) and one cutaneous distant 
metastasis. Conventional staging methods revealed possible distant metastases 
in ten patients: true-positive in seven and false-positive in three (table 1). 
FDG-PET was suggestive for disease other than the known recurrences in 21 
areas in 14 patients including all seven conventionally diagnosed metastases. 
Of the 21 lesions, nine were confirmed, whereas 12 lesions were not 
confirmed: seven lymph nodes, three lung, one liver, one bone. In the 
majority of these cases confirmation was not attempted since at least one 
distant metastasis had already been proven otherwise. In these circumstances 
additional information would have had no clinical implications. 
 
Comparing conventional imaging with FDG-PET in patients with a suspected 
relapse of disease, three additional lesions (liver, lung and contralateral breast) 
were detected by FDG-PET. The liver lesion could only be confirmed by CT 
after a follow-up of 6 weeks. The lesion in the contralateral breast was not 
further analysed at the time of a clinical local recurrence, but resulted in a 
pT4N2 tumour less than one year after it was visualised on FDG-PET. 
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Table 3: Lesion based analysis of increased FDG-uptake in suspected recurrences 
and results of further analysis and follow-up  
 
Indication n=25 FDG-PET Confirmed 
directly 
Confirmed during 
follow-up 
No confirmation 
LR ipsilateral 13 11 11* - - 
RR ipsilateral 4 5 4 - 1 
LR contralat 3 4 3 1 - 
RR contralat 1 4 3 - 1 
Lung - 6 3 - 3 
Liver - 3 1 1 1 
Bone 3 5 4 - 1 
LN elsewhere - 5 - - 5 
Other 1 - -** - - 
 
* = two local recurrences missed by FDG-PET; ** = missed by FDG-PET; LR = Local Recurrence; RR = Regional Recurrence; n.a. = not applicable; LN = 
Lymph Node 
 
Thus unexpected and later confirmed malignant lesions were found in two 
patients with primary cancers and three patients with suspected relapses by 
FDG-PET. Patient management was changed in five patients. Additional 
radiotherapy was applied in two cases with increased uptake in regional lymph 
nodes. Radiotherapy was replaced by systemic treatment in one because of the 
presence of lung metastases. In the remaining two patients liver metastases as 
indicated by FDG-PET became obvious by either CT or MRI only after six 
and eight weeks respectively, while the patients were already subjected to 
radiotherapy. In a sixth patient, evaluation of a contralateral breast lesion was 
erroneously not performed.  
 
Table 4: Patient based analysis sensitivity, specificity, positive and negative 
predictive value of FDG-PET 
 
 Primary tumour Suspected relapse Total 
Sensitivity 100% 95% 95% 
Specificity 75% 20% 62% 
Positive predictive value 20% 83% 71% 
Negative predictive value 100% 50% 93% 
 
 
 
discussion 
 
Compared to conventional diagnostic screening modalities FDG-PET 
identified all known malignancies and metastases in all but three cases. In 
addition previously unknown malignant lesions were found in 19 of 42 
patients (45%). The subsequent sensitivity of 95% and negative predictive 
value of 93% are in line with data in literature varying from 89% to 94%4,8-12.  
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FDG-PET showed a high negative predictive value for detection of clinical 
loco-regional recurrences, which is in accordance with the results of other 
studies6,10. This might be helpful in case of indeterminate mammography and 
ultrasonography, which frequently occurs after breast conserving therapy12. 
However, limited sensitivity does exist for the detection of lesions smaller 
than 1 cm8,13.  
 
FDG-PET was especially useful for the detection of additional metastases in 
lymph nodes, the lung and liver. Lymph nodes suggestive for metastatic 
disease are frequently detected by FDG-PET. However, they are often not 
identified on CT-scanning or - being smaller than 1 cm - described as non-
pathologic. Because of the small diameter of lesions and their anatomical 
position, it is usually difficult to provide a pathological diagnosis. Eubank et 
al. also analysed this dilemma in patients with possible mediastinal and 
internal mammary lymh node metastases14. In 33 of 73 patients amenable to 
follow up, FDG-PET showed a superior detection rate of 85% compared 
with CT of 54% when prospectively interpreted14,15.  
 
FDG-PET revealed several additional pulmonary lesions. In contrast, two 
rapidly progressive and chemotherapy-resistant patients developed pulmonary 
metastases within six to 12 months after FDG-PET, which at the time of 
staging showed no lung abnormalities. Literature comparing FDG-PET and 
chest X-ray is scarce, although FGD-PET is described to be more 
sensitive4,11. However, studies comparing FDG-PET with CT of the thorax 
are in favour of FDG-PET13,15-17. Moreover, it is known that CT of the thorax 
is superior to chest X-rays in the detection of distant metastases18, whereas 
chest X-ray is considered to be sufficient in the staging of breast cancer in the 
detection of pulmonary metastases19.  
 
Few data are available addressing the value of FDG-PET with respect to the 
presence of liver metastases. In the present study, FDG-PET was superior to 
abdominal ultrasonography. Van der Hoeven5 also observed superior results 
with FDG-PET, whereas Dose4 found no significant differences between 
FDG-PET and abdominal ultrasonography in 50 patients. Gallowitsch20, 
Rostom6 and Bender17 also concluded that there were no differences between 
FDG-PET and conventional imaging modalities, but compared FDG-PET 
with a mix of ultrasonography, MRI or CT. 
 
Concerning bone metastases the use of FDG-PET is advocated although 
bone scintigraphy is considered to be complementary4,8,10,12,21. Moreover, 
FDG-PET has proven to be able to detect skeletal metastases at an early stage 
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when the disease is still confined to the bone marrow8. Currently the 
preferred method remains a matter of debate4-6,20. Differences in detection 
rates between these techniques are generally attributed to differences in 
metabolic activity between osteolytic and osteoblastic metastases22. Osteolytic 
lesions show a higher metabolic activity resulting in a higher detection rate 
and earlier detection on FDG-PET, whereas osteoblastic metastases are 
frequently undetectable by FDG-PET8,20,22. In the present study all bone 
metastases were detected by both FDG-PET and bone scintigraphy, although 
the number of false-positive lesions was higher with bone scintigraphy. 
Similar findings were published by Schirrmeister11.  
 
FDG-PET also showed lesions that could not be confirmed by other 
modalities. Since these were considered as false-positive, specificity (62%) and 
positive predictive value (71%) were negatively influenced. Other studies 
reported specificity rates varying from 75% to 90%4,8-12. False positive uptake 
in lymph nodes in the axilla, neck and mediastinum may be misclassified 
because of increased muscle uptake mimicking lymph node lesions12,23. Both 
muscle activity during scanning, but also physical activity before and 
immediately after injection of FDG have been suggested to increase muscle 
uptake23.  
 
Although additional lesions were found in 45% of the patients, this resulted in 
a change in treatment in 12% of the patients. Additional lesions do not 
necessarily lead to a different treatment modality since additional distant 
metastases at a different site have no impact on the choice of treatment. The 
possible influence of positive findings of FDG-PET on therapeutic strategies 
strongly emphasises the need for confirmation of lesions detected by FDG-
PET. In some cases, however, metastatic disease as suggested by FDG-PET, 
only becomes apparent by other diagnostic methods after a certain period of 
time. FDG-PET might thus be more sensitive than other diagnostic methods. 
Illustrative in this respect is the additional value of FDG-PET in the analysis 
of asymptomatic breast cancer patients with raised tumour marker levels 
during follow-up24-26. Of specific interest is the study performed by Pecking 
where 14 of 92 scans were found to be false-positive, ten of which became 
true positive within one year26. 
 
False-positive bone lesions have been described more often and are 
subscribed to both physiological and artifactual FDG uptake12,23. Follow-up 
and repeated FDG-PET and/or additional radiological evaluation might be 
helpful for further analysis of false-positive lesions. However, since patients in 
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this study were subjected to chemotherapy for other reasons, it was 
impossible to further evaluate the unconfirmed lesions. 
 
In conclusion, FDG-PET appears a useful diagnostic method for the 
detection of (distant) metastatic disease and loco-regional recurrences. 
Especially the high sensitivity and negative predictive value could be helpful 
in clinical practice, because the number of false-negative findings with 
conventional methods is relatively high. However, false-positive FDG-PET 
scans do occur. Therefore confirmation of FDG-PET findings is always 
indicated when a change of management is considered. However, especially 
the initiation of systemic treatment makes unconfirmed FDG-PET lesions a 
difficult issue if not impossible to verify. Claims that some unconfirmed 
positives can be considered (very) early ‘markers’ of disease and thus truly-
positive findings are not easy to substantiate. Since conventional methods 
revealed no lesions which were FDG-PET-negative, it should be the objective 
of further studies whether it is useful to perform FDG-PET earlier in the 
diagnostic work-up of patients with a high risk of metastatic disease. 
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discussion 
 
A review of the literature covering variation in local recurrence and survival 
rates provides increasing evidence for the hypothesis that the quality of 
surgical oncology is, at least in part, responsible for the existence of 
differences in outcome in the treatment of solid tumours. Not only has the 
number of publications grown, but also the level of evidence contained 
therein has become stronger, chapters 2 and 3. The greater attention to this 
topic reflects a general tendency towards requiring quality assurance for all 
aspects of care (i.e. the growing demand for evidence based medicine). It 
might also be interpreted as a change in attitude allowing a more open 
discussion of differences in quality. In this respect it is remarkable that the 
majority of publications addressing this topic originate from ‘northern’ 
Europe (Scandinavia, the Netherlands, Germany and the UK) and North 
America. 
 
With regard to the technical aspects of surgery in the treatment of solid 
tumours, it can be stated that the worst step during the surgical procedure 
determines outcome, especially in terms of local control: if the surgeon 
accidentally cuts into the tumour, this will negatively influence the patients’ 
prognosis. Moreover with regard to radiotherapy it has become clear that, 
although it is of additional value in local control, it cannot make up for the 
effect of inadequate surgery.  
 
It has become apparent that the quality of surgical technique is determined by 
the level and quality of training, experience and the number of patients treated 
per year by the individual surgeon. Results are also linked to the quality of the 
hospital in which the patient is treated. Factors contributing to better 
outcome with regard to the characteristics of the hospital are related to the 
level of peri-operative care, determined by the presence and quality of 
facilities, the volume of patients, the annual number of specific procedures 
and the quality of care provided by related specialties.  
 
The quality of surgical resection also depends on the quality and use of pre-
operative diagnostic imaging, the quality of pathological examination of the 
resected specimen and feedback to the surgeon regarding the adequacy of 
resection and inversely with respect to the quality of pathological 
examination. The presence of a multidisciplinary treatment team is of 
importance in allowing feedback and discussion pertaining to the quality of 
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treatment and is of additional value in indicating and providing (neo-) 
adjuvant treatment. 
 
Based on the findings in the first part of the manuscript it seems that quality 
improvement and/or control of surgery is best performed prospectively and 
in a multi centre setting, especially if a ‘new’ surgical technique is to be 
implemented. Primarily because surgeons will then be most amenable towards 
feedback concerning their technical performance. Moreover, the required 
infrastructure and funding are easier to arrange under these circumstances, 
although it will remain challenging to convince sponsors that the funding of 
quality improving procedures in surgery is worthwhile. Until now surgical 
quality assurance programmes have, usually, been restricted to multi centre 
randomised clinical trials (MCRCTs) in which a sponsor (the industry) is 
present, expecting benefits from the use of standardised procedures. In other 
circumstances the occupational group itself is expected to provide guidelines 
and/or quality control of surgery. This is usually restricted to a written 
guideline consisting of a varying amount of text, since the implementation 
and evaluation of a standardised surgical technique itself is complicated, very 
time-consuming, requiring a specific infrastructure and therefore expensive to 
perform. 
 
Probably the most important obstacle, however, is the attitude of the surgeon. 
The enthusiasm among surgeons to participate in MCRCTs in general is 
limited, because of the associated amount of paperwork without a (financial) 
reward. The number of MCRCTs addressing surgical technique is still limited 
and surgeons are restraint in taking initiatives to change this. These factors 
hamper quality assurance of the surgical procedure in MCRCTs: strict criteria 
aiming at quality control of the surgical procedure might even discourage the 
surgeon from participation.  
 
Since the results of MCRCTs are determining future treatment strategies it is 
important to eliminate the known obstacles. Participation of surgeons in 
MCRCTs might be stimulated by increasing the prestige of involvement in 
such trials. This is obviously more easily achieved when implementing a ‘new’ 
and promising surgical technique, but participation rates could be increased 
simply by reducing the administrative burden.  
 
In single centres, the approach to improve and assure the quality of surgical 
oncology will be different from the one necessary in MCRCTs, although the 
general recommendations will remain unchanged. Therefore, the clinical value 
of the technical and organisatorial recommendations as described above will 
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be discussed on the basis of the single centre studies concerning diagnosis and 
treatment of primarily non palpable breast lesions. In addition evidence-based 
practice guidelines concerning diagnosis and treatment of breast cancer, 
published in the Netherlands in 20021, will also be used in this discussion.  
 
Although there are limitations in the current study, the results might 
contribute to an improvement in the quality of surgical oncology. Main 
weaknesses are that virtually all analyses were performed retrospectively, three 
different hospitals were evaluated, only limited attention was paid to surgical 
technique itself and some studies have become outdated in the mean time.  
 
Opportunities that could contribute to improvements in diagnostic imaging in 
order to optimise surgical care were found in the comparison between 
scintimammography (SSM) and magnetic resonance imaging (MRI), although 
MRI was performed in a limited number of patients. Both SSM and MRI are 
of additional value in differentiating benign from malignant disease in patients 
in whom the combination of clinical examination and conventional imaging 
techniques are indeterminate. This facilitates early detection of breast cancer 
in a selected group of patients, positively influencing prognosis. Since the 
quality of MRI is still improving in contrast to SSM, it is expected that MRI 
will replace SSM in the long term. Another argument for the choice for MRI 
is that it provides more detailed images, allowing exact anatomical localisation 
of a lesion. This feature is useful in otherwise occult lesions in particular, 
because it enables the localisation and therefore excision of the lesion. It will 
have become clear from the evaluation of the MRI-guided needle localisation 
that this is a promising technique, making further investments in its 
development seem worthwhile. A disadvantage is the relatively high 
percentage of benign lesions resulting from the high sensitivity and low 
specificity of MRI. It would therefore be preferable to use less invasive 
techniques for the differentiation between benign and malignant lesions. 
Moreover, it is expected, that with the increasing use and quality of MRI, 
knowledge concerning the interpretation of MRI-only lesions will increase, 
leading to a higher specificity. Furthermore, the current status emphasises the 
importance of a multidisciplinary team: decisions on further diagnosis and/or 
treatment are based on all available data of the individual patient and the 
combined interpretation of experts in stead of on the basis of written reports 
of the separate examinations. With the optimal use of multidisciplinary 
consultation in this particular example between surgeon and radiologist, one 
could reduce the number of operations.  
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In the study evaluating MRI-localised excisional biopsies, the number of 
‘missed’ lesions was rather high, indicating the complexity of the excision of 
non palpable lesions, although one would expect that there are no differences 
in surgical technique when compared to conventional needle localisations. 
Unfortunately data concerning the experience and results of the surgeons 
operating the MRI and conventionally localised non palpable breast lesions 
are not available from that particular hospital. However, a comparison of the 
results of surgical treatment between a university hospital and a regional 
teaching hospital revealed no clear differences, even though the percentage of 
operations performed by a resident was much higher in one of the hospitals. 
Returning to the MRI-guided needle localised excisional biopsies, it is 
recommended to restrict the availability of the technique to a limited number 
of hospitals, because of the limited number of patients depending on it, which 
will necessitate the concentration of expertise. Another argument to do so is 
the fact that data concerning the cost effectiveness of the technique have not 
yet been evaluated.  
 
Imaging modalities used for staging of the disease and for the evaluation of a 
relapse of disease also belong to the diagnostic procedures. A comparison 
between FDG-PET and conventional imaging modalities revealed a higher 
sensitivity for FDG-PET in the detection of metastases. In spite of 
disadvantages such as the limited availability and experience, the high costs 
and the high number of false-positives, it might be advantageous for the 
patient, since only one examination will be sufficient to detect metastatic or 
recurrent disease. The potential of FDG-PET to detect metastatic disease at 
an earlier stage than conventional imaging techniques could enable earlier 
treatment. However, the additional value of this potential should not be 
overrated, since a positive effect on the overall prognosis of the breast cancer 
patient in case of earlier treatment of metastatic disease has not yet been 
proven.  
 
Besides the improvements in diagnosis and surgical treatment, the proper 
evaluation of the resected specimen by the pathologist is of utmost 
importance. Practice guidelines with regard to the evaluation of breast cancer 
specimen are widely available. It is the aim not only to evaluate the complete 
removal of the tumour, but also in which way this has been performed and to 
analyse prognostic factors. Although it seems to be generally accepted to 
perform a re-operation in case of an irradical resection, it would be beneficial 
to decide on the extent of resection on the basis of prognostic factors. An 
analysis in this field provided some indications, but because of the limited 
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number of patients and the retrospective character of the study, no definitive 
conclusions could be drawn.  
 
The benefit of multidisciplinary treatment is clear, although no criteria have 
been defined to monitor the quality of care as provided by such a team. It is 
generally accepted that treatment protocols are defined in each hospital 
separately, although these will obviously usually be based on evidence-based 
guidelines if available. The investment in and use of national or preferably 
international evidence-based treatment guidelines should be encouraged. 
Criteria for the evaluation of the quality of multidisciplinary treatment teams 
should be defined. In this respect the before mentioned database, chapter 2, 
would also be of use in which the type of treatment would be one of the 
endpoints.  
 
Concentration of care (volume, experience and training) and subspecialisation 
(within medical specialties of the different hospitals) will probably contribute 
mostly to the improvements of overall treatment results. Recommendations 
regarding minimum numbers are arbitrary. A disadvantage is that the effect is 
still only evaluable after a certain amount of time, since local recurrence and 
overall survival rates as well as morbidity and mortality will remain the best 
indicators of the quality of surgical care. This emphasises the need for 
adequate and prospective databases collecting this information and enabling 
the monitoring of results and facilitating feedback to the providers of care.  
 
An international tendency towards centralisation of oncologic care is 
encountered and is also advocated in the Netherlands2. Causes for this Dutch 
plea include the increasing number of cancer patients, indications of relative 
decline in Dutch oncological care compared to other European countries3,4, a 
change in attitude of patients and increasing evidence of hospital factors as 
indicators of treatment outcome2. An earlier, but similar, initiative in the 
United Kingdom resulted in the Calman-Hine report aiming at the 
improvement of oncological care by setting benchmarks for (providers of) the 
treatment of different tumour types5. 
 
In the Netherlands it is assumed that patients with rare tumours are usually 
referred to specialised treatment centres, as was advised by the Dutch Health 
Council in 1993, although several reports indicate that this concentration still 
has not been fully effected2. It is suggested that only the implementation of an 
accreditation system per tumour type and/or stage and/or treatment modality 
could structurally change this situation. However, it is expected that the 
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accompanying administrative burden and costs will hamper the adoption of 
such an accreditation system2.  
 
The current debate concerning centralised treatment concentrates not only on 
the care for patients with rare tumours, but also on the treatment of patients 
with common malignancies. That these patients might also benefit from more 
specialised care will have become apparent in the first chapters of this thesis. 
The developments and improvements in the quality of surgical treatment in 
frequently occurring cancers will have a particularly large impact on the 
prognosis of cancer patients, given the high numbers concerned.  
 
Besides the concentration of care, initiatives to improve the quality of surgery 
are essential to provide better care. In this respect it should be emphasised 
that the initiative for surgical quality improving procedures should be 
expected from the occupational group itself. First of all, this enables the 
correct interpretation of available parameters. For example high morbidity 
and mortality rates might be caused by the selection of patients referred to a 
particular hospital, rather than by a low quality of care. Secondly, tools and 
ideas to improve the quality of surgical technique are or should be particularly 
available in the professional group itself: the implementation of a better 
training programme for surgical residents and the continued audit of the 
quality of performance of fully qualified surgeons should be the 
responsibilities of the scientific societies, although conflicts of interest are 
present. Considering the increasing attention to the quality of care in general, 
in addition to the changing attitude of the patient, it is self-evident, that if 
professionals themselves will not take the initiative to evaluate the quality of 
care, others will. Patients’ associations are particularly eager to do so, but 
might rank the quality of care on the basis of inadequate criteria. Examples of 
patients’ evaluations are available concerning coronary surgery in the US and 
UK. Similarly, the Dutch Association of Breast Cancer Patients (BVN) has 
recently defined ‘quality criteria from the patients’ perspective’6,7.  
 
Funding of quality assurance programmes is to be expected from either the 
government or insurance companies, since improvements in the quality of 
surgery will be of benefit not only for the cancer patient in particular, but also 
for the population in general, because of an associated reduction in costs for 
care. Surgery is still the only option for cure in most solid tumours. Better 
surgery is expected to result in a higher number of curatively treated patients 
in combination with lower morbidity and mortality rates. Moreover 
radiotherapy might be omitted in certain cases, provided that surgery has been 
adequately performed.  
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Two publications are illustrative when one compares the costs associated with 
different treatment strategies: the publications by Schrag8 and Quirke9. The 
first addresses the financial aspects of the chemotherapeutic treatment of 
patients with metastatic colorectal cancer. Without chemotherapy, the median 
duration of survival among patients with metastatic colorectal cancer was 
eight months. With fluoroacil, it increased to 12 months. In the past decade 
developments of combination therapy extended median survival to 21 
months. However, the near doubling of the median survival has been 
accompanied by a 340-fold increase in drug costs just for the initial eight 
weeks of treatment (63 US$ to 21.033 US$). The most recent combination 
therapy (irinotecan and cetuximab) for second- and third-line treatment of 
metastatic colorectal cancer, as described by Cunningham10, further increases 
the median survival by 1.7 months at a cost of 30.790 US$ for an eight-week 
course. It should be remarked that the mentioned treatment regimens remain 
palliative and there is not yet evidence that the new therapies increase cure 
rates8.  
 
In contrast, Quirke9 published an evidence-based overview of the benefits of 
total mesorectal excision as introduced by Heald some 20 years ago. Studies 
involving more than 4.000 patients show that large reductions in local 
recurrences and a 20% increase in survival can be achieved with high-quality 
surgical and pathological training in this technique. In the United Kingdom 
this was achieved, with funding from the National Cancer Plan, through 
establishing a two-day training programme, which was offered to all 
multidisciplinary teams treating patients with colorectal cancer. It was 
estimated that the individual costs per patient would be less than £200 in the 
UK. If there is the expected 20% reduction in cancer deaths then each will 
have been bought at a cost of £10009. If one compares the differences in 
costs and implications between the implementation of quality assurance 
programmes in surgical oncology with the increase in costs for an only limited 
survival advantage by chemotherapy, it is surprising, that it is so difficult to 
convince both the government and insurance companies to finance such 
projects. 
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samenvatting 
 
HOOFDSTUK 1 bevat een uitgebreide bespreking van de achtergronden van dit 
onderzoek. Het toenemende aantal kankerpatiënten is binnen Europa 
aanleiding geweest voor een analyse van eventuele verschillen in 
behandelresultaten. Voor de hypothese dat er een grote variatie bestond in de 
behandelresultaten werd een bevestiging gevonden. Dit proefschrift 
concentreert zich rond de vraag of en in hoeverre dergelijke verschillen 
kunnen worden toegeschreven aan de kwaliteit van chirurgisch handelen. 
Daaruit voortvloeiend rijst de vraag of en op welke wijze hierin een 
verbetering kan worden bewerkstelligd. Er wordt daarbij een onderscheid 
gemaakt tussen multicentre gerandomiseerde klinische studies (MCRCTs) en 
afzonderlijke ziekenhuizen. Onderzoeken aangaande de MCRCTs werden 
uitgevoerd vanuit de European Organisation for Research and Treatment of 
Cancer (EORTC) te Brussel, Belgiё. De overige onderzoeken werden 
gebaseerd op data van het Rijnstate Ziekenhuis te Arnhem (RZA), het 
Universitair Medisch Centrum Nijmegen St Radboud (UMCN) en het 
Universitair Medisch Centrum Utrecht (UMCU) en betreffen diverse aspecten 
van de chirurgische behandeling van mammacarcinoom, met de nadruk op 
niet-palpabele afwijkingen. 
 
In HOOFDSTUK 2 wordt onderzocht wat er bekend is over bestaande 
methoden ten aanzien van kwaliteitscontroles of verbeter- c.q. 
waarborgmethoden op het gebied van de chirurgische oncologie. Aangezien 
hierover vrijwel geen publicaties werden gevonden werd er ook gezocht naar 
aanwijzingen voor een relatie tussen verschillen in behandelresultaten en aan 
de chirurg en het ziekenhuis gerelateerde factoren, zoals opleiding, ervaring en 
het aantal ingrepen per jaar. Voor vrijwel alle solide tumoren werden grote 
verschillen gevonden in behandelresultaten. De kwaliteit van de chirurgische 
behandeling lijkt hierbij vooral invloed te hebben op de lokale controle. Ook 
zijn er aanwijzingen dat een verbetering in de kwaliteit van de chirurgie en het 
ziekenhuis hierop van grote invloed kan zijn, evenals op de morbiditeit en 
mortaliteit.  
 
In het volgende hoofdstuk, HOOFDSTUK 3, wordt dieper in gegaan op de 
invloed van chirurgisch handelen op de resultaten van behandeling specifiek 
voor de colorectale carcinomen. Doel van de studie was om bestaande 
verschillen aan te tonen en om maatstaven te definiëren voor het bij voorkeur 
prospectief beoordelen van de kwaliteit van de chirurgie. Vooral op het 
gebied van de rectumcarcinomen is de positieve en sterke invloed van een 
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meer verfijnde chirurgische techniek duidelijk aangetoond. Het lokale recidief 
percentage blijkt sterk teruggebracht te kunnen worden. Bovendien wordt 
ook de kwaliteit van leven verbeterd door het terugbrengen van de operatie-
gerelateerde morbiditeit. Belangrijkste maatregelen om dit te bereiken zijn het 
beperken van het aantal operateurs (dus specialisatie) en adequate training in 
de juiste operatietechniek, meer nog dan het stellen van een minimum aantal 
operaties per jaar.  
 
In HOOFDSTUK 4 worden de resultaten beschreven van een inventarisatie 
binnen de onderzoeksgroepen van het EORTC van bestaande methoden en 
toekomstige plannen voor het waarborgen van de kwaliteit van de 
chirurgische oncologie in het kader van de MCRCTs. Het EORTC heeft in 
het verleden veel gedaan aan de ontwikkeling van methoden ter beoordeling 
en waarborging van de kwaliteit van behandeling met name op het gebied van 
chemo- en radiotherapie. Het waarborgen van de kwaliteit van de chirurgische 
oncologie wordt geacht een stuk ingewikkelder te zijn, aangezien het 
uitvoeren van een operatie uit talloze kleine stappen bestaat afhankelijk van de 
individuele chirurg, die moeilijker te controleren zijn. 
 
Dataverzameling binnen het EORTC geschiedde voornamelijk door middel 
van interviews. Ook werden alle protocollen en bijbehorende formulieren en 
publicaties van de diverse groepen beoordeeld. Er blijken diverse methoden 
in gebruik dan wel in ontwikkeling te zijn, met wisselend succes. Voorbeelden 
zijn de controle van geleverde gegevens, het standaardiseren van operatie- en 
pathologieverslagen, trainingen en bezoeken op locatie. Vooralsnog is er 
tussen de onderzoeksgroepen geen gezamenlijke strategie ontwikkeld. 
 
Op grond van de bevindingen van bovenstaande hoofdstukken blijkt, dat er 
lange tijd verondersteld werd, dat de chirurgie geen of slechts een beperkte 
invloed zou hebben op de lokale controle (en overleving). Het gebrek aan 
criteria voor het beoordelen van de kwaliteit van de chirurgie is dan ook 
opvallend en in groot contrast met bestaande richtlijnen op het gebied van 
chemotherapie en radiotherapie. Voor een deel kan dit verklaard worden door 
de complexiteit van het monitoren van chirurgisch technisch handelen, maar 
de belangrijkste redenen lijken wel de onderschatting te zijn van de invloed 
van de kwaliteit van de chirurgie op de behandelresultaten en een gebrek aan 
financiering om controles uit te kunnen voeren. In toenemende mate is er nu 
aandacht voor het ontwikkelen van methoden voor het waarborgen dan wel 
controleren van de kwaliteit van de chirurgische oncologie. Niet alleen het 
beoordelen van de chirurgische techniek is hierbij van belang, maar ook het 
optimaliseren van de kwaliteit van de preoperatieve diagnostiek, adequate 
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beoordeling van het gereseceeerde preparaat door de patholoog en feedback 
over de kwaliteit van resectie naar de chirurg evenals de aanwezigheid van 
multidisciplinaire behandeling. 
 
In de volgende hoofdstukken wordt bezien hoe deze aspecten kunnen 
worden ingezet om in een afzonderlijk ziekenhuis de kwaliteit van chirurgisch 
handelen te optimaliseren. Dit geschiedt aan de hand van onderzoeken op het 
gebied van vooral niet-palpabele mamma-afwijkingen.  
 
HOOFDSTUK 5 bevat een vergelijking tussen de waarde van Tc-99m-sestamibi 
scintimammografie (SSM) en magnetic resonance imaging (MRI) als 
aanvullende diagnostische methoden bij patiënten bij wie de combinatie van 
lichamelijk onderzoek en conventionele diagnostiek niet-conclusief is. In 161 
patiënten werden 175 scintimammografiëen vervaardigd. Bij 32 patiënten 
werd eveneens een MRI gemaakt. Verificatie van de bevindingen geschiedde 
met behulp van pathologisch onderzoek (n=106) of door middel van follow-
up (n=69). Maligne afwijkingen werden gevonden in 19% van alle gevallen. 
Sensitiviteit, specifiteit, positief en negatief voorspellende waarden voor 
mammografie waren 50%, 92%, 61% en 88%; 71%, 85%, 53% en 92% voor 
SSM en 90%, 73%, 60% en 94% voor MRI. In combinatie met mammografie 
zijn zowel SSM als MRI van aanvullende waarde in het onderscheid tussen 
benigne en maligne afwijkingen bij patiënten bij wie mammografie 
onvoldoende uitsluitsel geeft, hoewel er in toenemende mate gebruik wordt 
gemaakt van MRI in plaats van SSM. De hoogste sensitiviteit werd gevonden 
voor MRI (90% versus 71%), terwijl SSM een hogere specificiteit gaf (85% 
versus 73%). Gezien deze bevindingen zou het interessant zijn om de 
aanvullende waarde van SSM te beoordelen voor patiënten met een verdachte 
afwijking op de MRI, aangezien SSM een niet-invasieve, beter beschikbare en 
goedkopere methode is dan de MRI-geleide biopsie.  
 
De resultaten van de MRI-geleide naaldgelokaliseerde excisiebiopsie van 
dergelijke op MRI verdachte mamma-afwijkingen worden onderzocht in 
HOOFDSTUK 6. Hierin komen duidelijk de voor- en nadelen van de MRI als 
diagnosticum naar voren, waarbij vooral gedoeld wordt op de al genoemde 
hoge sensitiviteit, maar lage specificiteit. Met het toenemende gebruik van de 
MRI wordt de behandelende arts dan ook frequenter geconfronteerd met 
voor maligniteit verdachte afwijkingen die alleen te visualiseren zijn met 
behulp van MRI. Het is in die gevallen lastig om materiaal te verkrijgen voor 
evaluatie door de patholoog. Over de waarde van MRI-geleide 
naaldgelokaliseerde chirurgische excisiebiopsie is nog weinig bekend. Ook is 
de methode slechts zeer beperkt beschikbaar in Nederland. Reden voor een 
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retrospectieve evaluatie van de resultaten van de 35 patiënten bij wie de 
techniek werd uitgevoerd in het Universitair Medisch Centrum St Radboud. 
In totaal werden 37 procedures uitgevoerd, waarbij 24 benigne en 13 maligne 
afwijkingen werden gevonden. Tijdens de lokalisatieprocedures traden geen 
complicaties op. Echter bij controle bleek 13.5% van de laesies niet 
verwijderd te zijn en 69% van de maligne afwijkingen was irradicaal 
gereseceerd. Overigens was bij 25 patiënten preoperatieve pathologische 
evaluatie verricht, waarvan de resultaten waren beschreven als ‘niet-conclusief’ 
of ‘geen atypie’. Uiteindelijk bleek 24% van deze afwijkingen een maligne 
oorsprong te hebben. Ondanks deze tekortkomingen is het toch een 
veelbelovende methode in de analyse van op MRI verdachte en anderszins 
occulte laesies. Het toenemende aantal van dergelijke afwijkingen 
rechtvaardigt verdere ontwikkeling. 
 
Een ander aspect van het verbeteren van chirurgische zorg is het 
minimaliseren van het aantal operaties waarmee een hogere efficiency wordt 
nagestreefd. Een middel daartoe is het verrichten van vriescoupe-onderzoek 
naar de aard van de laesie; benigne dan wel maligne. In HOOFDSTUK 7 wordt 
de toegevoegde waarde hiervan beoordeeld op basis van de resultaten van 216 
patiënten met niet-palpabele mamma tumoren. Honderd procent zekerheid 
boden de vriescoupe-diagnosen benigne (n=84) en maligne (n=116). Wanneer 
echter de diagnose ‘in situ’ werd gegeven was voorzichtigheid geboden. In die 
patiënten bleek de diagnose fout-negatief te zijn in 2.3% van de gevallen en 
werd een sensitiviteit gevonden van 96.5%. In het kader van de efficiency 
bleek 43.5% van de patiënten voordeel te hebben gehad van vriescoupe-
onderzoek, aangezien in dezelfde sessie ook definitieve chirurgische 
behandeling plaatsvond. Ondanks de goede resultaten wordt vriescoupe-
onderzoek voor dit doel tegenwoordig nog maar zelden uitgevoerd onder 
meer omdat het vrijwel altijd mogelijk is ook van niet-palpabele mamma-
afwijkingen een betrouwbare pre-operatieve (histologische) diagnose te 
verkrijgen. Onder bepaalde voorwaarden zou de techniek echter nog van 
aanvullende waarde kunnen zijn. 
 
In HOOFDSTUK 8 staat de vraag centraal of er verschillen zijn in de 
chirurgische behandeling tussen twee typen opleidingsklinieken: het 
Universitair Medisch Centrum Utrecht (UMCU) en het Rijnstate Ziekenhuis 
Arnhem (RZA). Uitgangspunt voor de analyse vormden 240 patiënten bij wie 
een maligniteit werd gevonden op basis van de in het Universitair Medisch 
Centrum Utrecht (UMCU) uitgevoerde stereotactische histologische 
naaldbiopsie. Chirurgische behandeling vond plaats in het ziekenhuis 
waarvandaan de patiënte verwezen was: 126 in het UMCU en 114 in het 
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RZA. Biopsie resultaten toonden een invasief carcinoom bij 163 patiënten en 
een ductaal carcinoma in situ (DCIS) bij 77 patiënten. Bij 74% van de 
patiënten was één operatie voldoende (79% RZA versus 69% UMCU; 
p=0.08). In het RZA was een kleiner aantal operaties per patiënt nodig voor 
het bereiken van een radicale resectie (1.25 versus 1.4; p=0.02). Invasief 
carcinoom werd in het RZA vaker sparend behandeld dan in het UMCU 
(74% versus 55%; p=0.01). DCIS daarentegen werd in het UMCU vaker 
sparend behandeld (90% versus 69%; p=0.02). In het RZA werd 48% van de 
operaties uitgevoerd door een chirurg in opleiding als eerste operateur versus 
87% in het UMCU (p<0.001). Dit had echter geen invloed op het percentage 
primaire radicale resecties: 78% in het RZA en 77% in het UMCU indien de 
operatie was uitgevoerd door een chirurg in opleiding als eerste operateur. 
Resultaten van chirurgische behandeling waren vergelijkbaar in beide 
ziekenhuizen en goede resultaten werden bereikt in de chirurgische 
behandeling van niet-palpabele mammacarcinomen, ook wanneer de operatie 
werd uitgevoerd door chirurgen in opleiding.  
 
Tumor-positieve resectiemarges en de aanwezigheid van resttumor bij re-
excisie zijn onderwerp van studie in HOOFDSTUK 9. Een tumor-positieve 
resectiemarge is één van de bekende prognostische factoren voor een lokaal 
recidief. Indien hiervan sprake is, wordt in het algemeen dan ook een re-
operatie uitgevoerd, hoewel er vaak geen resttumor wordt aangetroffen in het 
re-excisie preparaat. In dit onderzoek worden tumorkarakteristieken 
onderzocht die voorspellend zouden kunnen zijn voor de aanwezigheid van 
resttumor in deze gevallen. Het uiteindelijke doel was om patiëntengroepen te 
definiëren waarbij de omvang van aanvullende chirurgie kan worden beperkt. 
Geanalyseerde tumorkarakteristieken waren het type en de omvang van de 
primaire tumor, de aanwezigheid van DCIS en een uitgebreide in situ 
component (EIC), multifocaliteit van de tumor en lymfeklierstatus. In een 
groep van 295 patiënten bij wie een naaldgelokaliseerde excisiebiopsie werd 
verricht, werden tumor-positieve marges aangetroffen in 25% van de 
patiënten. Resttumor werd gevonden in 51% van de patiënten bij wie een re-
operatie werd uitgevoerd. Uiteindelijk werd bij 80% van de patiënten met 
tumor-positieve marges een mamma-amputatie uitgevoerd. Dit komt overeen 
met 20% van de totale groep die in opzet sparend geopereerd werd. 
Lymfeklierstatus en de aanwezigheid van EIC waren de enige twee statistisch 
significante variabelen. In deze groepen is ‘agressievere’ chirurgie op zijn 
plaats. 
 
In HOOFDSTUK 10 wordt de aanvullende waarde van [18F]-FDG-PET in de 
stadiёring van mammacarcinoom en in het ontdekken van een recidief dan 
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wel metastasen beoordeeld. Normaal gesproken bestaat het 
disseminatieonderzoek bij mammacarcinoom uit echografie van de lever, een 
X-thorax en een botscan. FDG-PET is voor een groot aantal tumoren van 
aanvullende waarde gebleken in de stadiёring en follow-up. Op het gebied van 
mammacarcinoom is de literatuur echter beperkt. In dit prospectieve 
onderzoek wordt de rol van FDG-PET geëvalueerd in de stadiёring van 42 
patiënten met een primair mammacarcinoom dan wel een recidief met een 
grote kans op afstandsmetastasen. Resultaten van de conventionele 
onderzoeken worden vergeleken met die van FDG-PET. Indien afwijkingen 
aanwezig waren op FDG-PET werd er altijd naar gestreefd een bevestiging te 
krijgen. Indien een bevestiging niet verkregen (kon) worden dan werden deze 
bevindingen beoordeeld als fout-positief. In primaire carcinomen werd 
postoperatief verhoogde FDG-opname gevonden in vijf van de 17 patiënten. 
In de 25 patiënten met de verdenking op een recidief toonde FDG-PET 
verhoogde opname op 43 plaatsen; 22 daarvan waren een correcte bevestiging 
van het verdachte recidief en 21 vormden aanwijzingen voor mogelijke 
additionele metastasen. Vergeleken met conventionele diagnostiek, toonde 
FDG-PET onverwachte, maar uiteindelijk bevestigde laesies in twee primaire 
carcinomen en drie recidieven. Bij vijf patiënten werd het beleid veranderd. 
Op basis van deze gegevens lijkt FGD-PET een waardevol diagnosticum voor 
het ontdekken van metastasen op afstand en lokale recidieven. De hoge 
sensitiviteit (95%) en negatief voorspellende waarde (93%) kunnen nuttig zijn 
in de praktijk, gezien het relatief hoge aantal fout-negatieve bevindingen met 
de conventionele beeldvormende technieken. 
  
HOOFDSTUK 11 bevat de discussie omtrent de bevindingen van de 
afzonderlijke hoofdstukken. De onderzoeksvragen zoals geformuleerd in 
hoofdstuk 1 worden beantwoord en aan de hand hiervan worden 
aanbevelingen gegeven ter verbetering van de kwaliteit van de chirurgische 
oncologie. 
 214 samenvatting/summary 
summary 
 
CHAPTER 1 is an extensive introduction and background for this study. The 
increasing number of cancer patients has been the motivation for an analysis 
of possible differences in treatment results within Europe. The hypothesis 
that wide differences in treatment outcomes do exist was confirmed. This 
thesis concentrates on the question whether and to what extent such 
differences could be attributed to the quality of surgical care. In addition it is 
of interest to analyse methods to improve and assure the quality of surgical 
oncology. In this respect a distinction will be made between multi centre 
randomised clinical trials (MCRCTs) and single centres. Studies concerning 
MCRCTs were performed within the European Organisation for Research 
and Treatment of Cancer (EORTC) in Brussels, Belgium. The remaining 
studies were based on data of the Dutch Rijnstate Hospital Arnhem (RHA), 
the University Medical Centre Nijmegen (UMCN) and the University Medical 
Centre Utrecht (UMCU) and address several aspects of the surgical treatment 
of breast cancer with an emphasis on non palpable lesions. 
 
In CHAPTER 2 methods of quality assurance in surgical oncology are reviewed, 
and the relationship between surgery-related factors and the variety in 
outcomes in the treatment of solid cancers is determined. Wide variations 
were encountered in virtually all tumour types. Clear evidence was found that 
an improvement in the quality of the surgical procedure could have major 
implications on the prognosis and quality of life of cancer patients.  
 
The next chapter, CHAPTER 3, nalyses the impact of surgical treatment on 
outcomes in colorectal cancers in order to give an insight in the causal factors 
for the observed differences between hospitals and surgeons. The final goal 
of the review was to identify quality indicators in surgical oncology which 
could be relevant for the (prospective) evaluation of the quality of surgical 
oncology. In the field of rectal cancers in particular, the positive and strong 
influence of a more refined surgical technique has been proven clearly. The 
use of a standardised surgical technique results in a significantly reduced local 
recurrence rate, an increase in survival and an improved quality of life by a 
reduction in operation-related morbidity. The most important measures to 
accomplish this are specialisation and adequate training, as opposed to the 
requirement of a minimum number of annually performed operations.  
  
CHAPTER 4 reports the results of an inventory within the clinical research 
groups of the EORTC concerning the existing methods and future prospects 
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in quality assurance in surgical oncology within MCRCTs. The EORTC has a 
long history in the development of quality assurance, in particular in radio- 
and chemotherapy. Quality assurance in surgical oncology is considered to be 
more complicated, because it is a multi-step procedure depending on the 
individual. Data were collected with interviews and the analysis of clinical trial 
protocols, case report forms and publications in this field by the EORTC 
groups. Several methods have been used or are currently under investigation 
to ensure the quality of surgery within clinical trials. These include the review 
of reported data, standardisation of surgery and pathology forms, training 
sessions and site-visits. However, there has been no attempt to harmonise 
these initiatives across the different medical specialties.  
 
Based on the findings of the previous chapters it has become clear that the 
influence of the quality of surgery on treatment outcomes was, for a long 
period, assumed to be limited. The lack of criteria for the audit of surgical 
care is remarkable and in contrast with existing guidelines in the fields of 
chemo- and radiotherapy. In part this is due to the complexity of monitoring 
the quality of surgical technique. However, the underestimation of the 
influence of surgery and the lack funding to implement quality assurance 
programmes seem to be more important. With the growing evidence of the 
impact of surgical technique on outcomes, increasing attention is paid to the 
development of quality assurance programmes. Not only is surgical technique 
itself to be evaluated but also the optimising of pre-operative diagnostics, 
adequate examination of the resected specimen by the pathologist and 
feedback concerning the quality of resection to the surgeon as well as the 
presence of multidisciplinary treatment.  
 
Focus of the subsequent chapters is to identify ways and means to apply the 
knowledge gained from the previous theoretical assessment to the day-to-day 
practice of hospitals in order to optimise the quality of surgery. This part of 
the thesis particularly addresses non palpable breast cancer. 
 
CHAPTER 5 contains a comparison between Tc-99m-sestamibi 
scintimammography (SSM) and magnetic resonance imaging (MRI) in the 
evaluation of breast lesions in case of indeterminate mammographies. One-
hundred-and-seventy-five SSMs were performed in 161 patients. Thirty-two 
patients also underwent MRI. Imaging results were either confirmed by 
pathological examination (n=106) or patients were subjected to a follow-up 
programme (n=69). Malignant lesions were found in 19% of all cases. 
Sensitivity, specificity, positive predictive value and negative predictive value 
for all patients were 50%, 92%, 61% and 88% for mammography; 71%, 85%, 
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53% and 92% for SSM and 90%, 73%, 60% and 94% for MRI. In 
combination with mammography both SSM and MRI are helpful adjuncts in 
distinguishing benign from malignant disease in patients with indeterminate 
mammographies. Most favourable sensitivity is found for MRI (90% versus 
71%) whereas SSM shows better specificity rates (85% versus 73%). Currently 
a tendency is found towards the more frequent use of MRI instead of SSM. 
However, it would be interesting to investigate the role of SSM as an 
additional clinical tool in patients with a positive MRI because of the high 
sensitivity and relatively low specificity of MRI since SSM is a non-invasive, 
cheaper investigation and is more readily available than an invasive MRI-
guided biopsy to investigate the found lesion. 
 
The results of MRI-guided pre-operative wire localisation of breast lesions 
only visible on MRI are examined in CHAPTER 6. With the increasing use of 
MRI in combination with its high sensitivity but lower specificity, the treating 
physician is more frequently confronted with non palpable breast lesions that 
are only visible on MRI. In these cases it is often difficult to obtain adequate 
material for pathological examination. One of the methods to do so is 
excisional biopsy after MRI-guided wire localisation. However, literature 
concerning the additional value of this technique is limited. It was the aim of 
this study to examine the feasibility and added value of this method in the 
analysis of otherwise occult breast lesions. Data of all 35 patients, referred to 
the University Medical Centre Nijmegen, subjected to this technique were 
retrospectively reviewed. A total of 37 procedures were performed. In all 
cases, the localisation procedure was successfully completed and no 
complications were reported. Of the excised lesions, 24 appeared to be benign 
and 13 were malignant. In 25 patients pre-operative pathological examination 
had been carried out, of which the results were described as ‘inconclusive’ or 
‘no atypia’ in all cases. After MRI-guided excisional biopsy, nine of these 
patients appeared to have malignant disease (24%). In five patients (13.5%), 
the lesion was missed during surgical excision in spite of accurate wire 
localisation, requiring MRI-guided re-excision in one patient. Irradical 
resection was reported in 69% of the malignant lesions. Despite these 
shortcomings it is a promising tool in the evaluation of suspicious breast 
lesions that are only visible on MRI. The expected increase of otherwise 
occult lesions justifies the further evaluation and development of the 
technique as well as a wider availability.  
 
Another aspect of improving surgical care is the reduction in the number of 
surgical procedures in order to achieve definitive surgical treatment. Frozen 
section analysis evaluating the benign or malignant origin of the lesion is such 
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a procedure. In CHAPTER 7 the added value of this procedure is evaluated on 
the basis of 216 patients with non palpable breast lesions. The frozen section 
diagnoses benign (84 patients) and malignant (116 cases) were found to be 
highly reliable (100% for both), in contrast with the diagnosis ‘in situ’ 
carcinoma. A false-negative rate of 2.3% and a 96.5% sensitivity were found. 
43.5% of patients benefitted from this approach, because definitive surgical 
treatment could be performed immediately. However, frozen section analysis 
for this purpose is currently considered to be obsolete. In particular the 
development of stereotactic large core needle biopsies in recent years has 
enabled the provision of a reliable pre-operative diagnosis in most cases, 
making per-operative examinations with the accompanying disadvantages 
superfluous. If this is not possible, frozen section analysis might still be of 
additional value.  
  
CHAPTER 8 compares possible differences in the surgical treatment of non 
palpable breast cancer between two surgical training hospitals: the University 
Medical Centre Utrecht (UMCU) and the Rijnstate Hospital Arnhem (RHA). 
A total of 240 patients from the UMCU (n=126) and the RHA (n=114) 
diagnosed with a malignancy at stereotactic large core needle biopsy were 
included. Biopsy results showed that 163 had an invasive cancer and 77 had a 
ductal carcinoma in situ (DCIS). In 74% of the cases one operation was 
sufficient (79% in the RHA versus 69% in the UMCU; p=0.08). In the RHA 
fewer operations per patient were carried out before radical resection was 
attained (1.25 versus 1.4; p=0.02). Invasive cancers were more often treated 
by breast conserving treatment in the RHA than in the UMCU (74% versus 
55%; p=0.01). The intention to treat DCIS by breast conserving therapy was 
more often seen in the UMCU than in the RHA (90% versus 69%; p=0.02). 
Of all operations analysed in the RHA 48% were performed by a resident-in-
training as first surgeon versus 87% in the UMCU (p<0.001). This had no 
influence on the percentage of primary radical resections: 78% in the RHA 
and 77% in the UMCU. It can be concluded that outcomes of surgical 
treatment were comparable in both types of teaching hospitals. Good results 
were achieved in non palpable breast cancer surgery that was carried out by 
residents-in-training.  
 
Tumour-positive resection margins and the presence of residual tumour in the 
re-excisional specimen are studied in CHAPTER 9. A tumour-positive resection 
margin is a well-known prognostic factor for local recurrence. In these cases, 
a re-excision or mastectomy is usually performed in order to improve local 
control, although the re-excisional specimen is often free of tumour. It was 
the aim of this study to evaluate tumour characteristics that might be 
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predictive for the presence of residual disease after excisional surgery. The 
ultimate goal was to define groups in which additional surgery could be 
restricted. Data of 295 patients, subjected to wire-guided excisional breast 
biopsy were studied. Type and size of the primary tumour, the presence of 
DCIS and an extensive in situ component (EIC), multifocality of the tumour 
and nodal status were considered as possible indicators for residual disease. 
Tumour-positive margins were found in 25% of the patients. Residual disease 
was found in 51% of the patients undergoing a re-operation. Altogether 80% 
of the patients with positive margins (i.e. 20% of all patients intentionally 
treated by breast conserving therapy) were treated by mastectomy. Nodal 
status and the presence of an extensive in situ component were the only two 
variables that were statistically significant. No subgroups could be defined in 
whom additional surgery could be omitted. More ‘aggressive’ surgical therapy 
is, however, justified in patients belonging to the risk groups. 
 
In CHAPTER 10 the added value of [18F]-FDG-PET in staging breast cancer 
and detection of relapse is evaluated. Staging of breast cancer is routinely 
performed by ultrasonography of the liver, chest X-ray and bone scintigraphy. 
FDG-PET has proven to be a valuable tool in the staging and follow-up of a 
wide variety of malignancies. However, literature of the added value of FDG-
PET in breast cancer is limited. The aim of the present prospective study was 
to evaluate the role of FDG-PET in the staging of 42 patients with a primary 
or recurrent breast cancer and a high risk of distant metastases. Results of 
conventional imaging procedures were compared with those of FDG-PET. In 
case of abnormalities on FDG-PET, confirmation was always attempted. If 
confirmation could not be achieved, FDG-PET was considered to be false-
positive. In primary cancers, increased FDG uptake was found post-
operatively in five of 17 patients. In the 25 patients with a suspected relapse 
FDG-PET showed increased uptake in 43 areas, 22 correctly confirming the 
area of suspected relapse and 21 indicating other sites of metastases. 
Compared to conventional imaging, FDG-PET revealed unexpected, but 
confirmed lesions in two primary cancers and three relapses. Patient 
management was changed in five patients. It is concluded that FDG-PET is a 
useful diagnostic method for the detection of (distant) metastatic disease and 
loco-regional recurrences. Especially the high sensitivity (95%) and negative 
predictive value (93%) could be helpful in clinical practice, because the 
number of false-negative findings with conventional methods is relatively 
high.  
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CHAPTER 11 contains the discussion concerning the findings of the separate 
chapters. The research questions as formulated in chapter 1 are answered and 
recommendations are provided to improve the quality of surgical oncology. 
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met mijn onderzoek aan de slag was, heb ik er vaak met plezier aan gewerkt. 
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Prof. van de Velde, ik ben u zeer dankbaar voor de begeleiding tijdens mijn 
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manier van nakijken en feedback waren bijzonder prettig.  
 
Prof. Wobbes, eveneens veel dank voor de plezierige begeleiding en snelle 
respons. Ons meningsverschil in februari 2003 was behoorlijk, maar is onze 
samenwerking en de totstandkoming van dit manuscript zeker ten goede 
gekomen. Uw uitstekende bereikbaarheid en bereidheid tot commentaar in de 
slotfase waren zeer welkom; ook daarvoor dank. 
 
Door financiering van de KWF Kankerbestrijding heb ik de mogelijkheid 
gekregen een jaar voor het EORTC te Brussel te werken. Na een jaar rennen 
in de kliniek was het weliswaar een grote overgang plotseling hele dagen 
achter een bureau te zitten, maar ik ben erg blij dat ik deze kans heb gekregen. 
Buiten het feit dat dit project heeft geleid tot een aantal interessante artikelen, 
essentieel als basis voor dit proefschrift, was het boeiend om eens achter de 
schermen te kunnen kijken van een zó grote onderzoeksorganisatie. 
 
Op wetenschapsgebied dank ik de vele verschillende mede-auteurs voor hun 
enthousiasme en kritische commentaren. 
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deelnemers voor de verschillende onderzoeken te recruiteren. Niet alleen voor 
de PET-scan maar ook voor onderzoeken buiten de scope van dit 
proefschrift wisten jullie steeds weer deelnemers te enthousiasmeren. Het was 
fijn hierin altijd op jullie te kunnen rekenen. 
 
Jolijn Betlem en Kirsten Hek-Bresser, dank voor jullie vriendschap en 
luisterende oor. Ook heel bijzonder en enorm leuk dat we tegelijkertijd een 
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Alle families, vrienden en vriendinnen…ook jullie veel dank voor jullie 
interesse en hulp. De Betlem-kinderen in het bijzonder voor het weekend 
waarin jullie me hielpen met het schiften van (1000!) statussen, een 
gedenkwaardig weekendje. 
 
Lieve Femke, jouw komst heeft het einde van deze periode toch wel 
bespoedigd. Je uitgerekende dag van komst was een harde deadline, maar we 
waren ook heel blij dat je eerder kwam. Wat een verrassing en wat een timing.  
 
De weergoden, het klinkt raar in een dankwoord. Ik denk echter dat ik één 
van de weinigen was die blij was met het slechte weer in de zomer van 2004.  
 
En natuurlijk…mijn allerliefste Gert-Jan. Hoe kan ik jou bedanken voor alles? 
Je steun was in alle opzichten geweldig en onmisbaar. En de rest…dat blijft 
tussen ons. Ik hoop dat we altijd zo blij en gelukkig met elkaar zullen blijven! 
Zo, kunnen we nu weer leuke dingen gaan doen. 
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